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A B S T R A C T
Background
The Seven Countries study in the 1960s showed that populations in theMediterranean region experienced lower coronary heart disease
(CHD) mortality probably as a result of different dietary patterns. Later observational studies have confirmed the benefits of adherence
to a Mediterranean dietary pattern on cardiovascular disease (CVD) risk factors but clinical trial evidence is more limited.
Objectives
To determine the effectiveness of a Mediterranean-style diet for the primary and secondary prevention of CVD.
Search methods
We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 9);
MEDLINE (Ovid, 1946 to 25 September 2018); Embase (Ovid, 1980 to 2018 week 39); Web of Science Core Collection (Thomson
Reuters, 1900 to 26 September 2018); DARE Issue 2 of 4, 2015 (Cochrane Library); HTA Issue 4 of 4, 2016 (Cochrane Library); NHS
EED Issue 2 of 4, 2015 (Cochrane Library). We searched trial registers and applied no language restrictions.
Selection criteria
We selected randomised controlled trials (RCTs) in healthy adults and adults at high risk of CVD (primary prevention) and those
with established CVD (secondary prevention). Both of the following key components were required to reach our definition of a
Mediterranean-style diet: high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consumption
of other traditional foods high in monounsaturated fats such as tree nuts) and a high intake of plant-based foods, including fruits,
vegetables and legumes. Additional components included: low to moderate red wine consumption; high consumption of whole grains
and cereals; low consumption of meat and meat products and increased consumption of fish; moderate consumption of milk and dairy
products. The intervention could be dietary advice, provision of relevant foods, or both. The comparison group received either no
intervention, minimal intervention, usual care or another dietary intervention. Outcomes included clinical events and CVD risk factors.
We included only studies with follow-up periods of three months or more defined as the intervention period plus post intervention
follow-up.
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Data collection and analysis
Two review authors independently assessed studies for inclusion, extracted data and assessed risk of bias. We conducted four main
comparisons:
1. Mediterranean dietary intervention versus no intervention or minimal intervention for primary prevention;
2. Mediterranean dietary intervention versus another dietary intervention for primary prevention;
3. Mediterranean dietary intervention versus usual care for secondary prevention;
4. Mediterranean dietary intervention versus another dietary intervention for secondary prevention.
Main results
In this substantive review update, 30 RCTs (49 papers) (12,461 participants randomised) and seven ongoing trials met our inclusion
criteria. The majority of trials contributed to primary prevention: comparisons 1 (nine trials) and 2 (13 trials). Secondary prevention
trials were included for comparison 3 (two trials) and comparison 4 (four trials plus an additional two trials that were excluded from
the main analyses due to published concerns regarding the reliability of the data).
Two trials reported on adverse events where these were absent or minor (low- to moderate-quality evidence). No trials reported on costs
or health-related quality of life.
Primary prevention
The included studies for comparison 1 did not report on clinical endpoints (CVDmortality, total mortality or non-fatal endpoints such
as myocardial infarction or stroke). The PREDIMED trial (included in comparison 2) was retracted and re-analysed following concerns
regarding randomisation at two of 11 sites. Low-quality evidence shows little or no effect of the PREDIMED (7747 randomised)
intervention (advice to follow a Mediterranean diet plus supplemental extra-virgin olive oil or tree nuts) compared to a low-fat diet on
CVDmortality (hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.50 to 1.32) or total mortality (HR 1.0, 95% CI 0.81 to 1.24)
over 4.8 years. There was, however, a reduction in the number of strokes with the PREDIMED intervention (HR 0.60, 95% CI 0.45
to 0.80), a decrease from 24/1000 to 14/1000 (95% CI 11 to 19), moderate-quality evidence). For CVD risk factors for comparison 1
there was low-quality evidence for a possible small reduction in total cholesterol (-0.16 mmol/L, 95% CI -0.32 to 0.00) and moderate-
quality evidence for a reduction in systolic (-2.99 mmHg (95% CI -3.45 to -2.53) and diastolic blood pressure (-2.0 mmHg, 95% CI -
2.29 to -1.71), with low or very low-quality evidence of little or no effect on LDL or HDL cholesterol or triglycerides. For comparison
2 there was moderate-quality evidence of a possible small reduction in LDL cholesterol (-0.15 mmol/L, 95% CI -0.27 to -0.02) and
triglycerides (-0.09 mmol/L, 95% CI -0.16 to -0.01) with moderate or low-quality evidence of little or no effect on total or HDL
cholesterol or blood pressure.
Secondary prevention
For secondary prevention, the Lyon Diet Heart Study (comparison 3) examined the effect of advice to follow a Mediterranean diet and
supplemental canola margarine compared to usual care in 605 CHD patients over 46 months and there was low-quality evidence of a
reduction in adjusted estimates for CVD mortality (HR 0.35, 95% CI 0.15 to 0.82) and total mortality (HR 0.44, 95% CI 0.21 to
0.92) with the intervention. Only one small trial (101 participants) provided unadjusted estimates for composite clinical endpoints for
comparison 4 (very low-quality evidence of uncertain effect). For comparison 3 there was low-quality evidence of little or no effect of a
Mediterranean-style diet on lipid levels and very low-quality evidence for blood pressure. Similarly, for comparison 4 where only two
trials contributed to the analyses there was low or very low-quality evidence of little or no effect of the intervention on lipid levels or
blood pressure.
Authors’ conclusions
Despite the relatively large number of studies included in this review, there is still some uncertainty regarding the effects of a Mediter-
ranean-style diet on clinical endpoints and CVD risk factors for both primary and secondary prevention. The quality of evidence for
the modest benefits on CVD risk factors in primary prevention is low or moderate, with a small number of studies reporting minimal
harms. There is a paucity of evidence for secondary prevention. The ongoing studies may provide more certainty in the future.
P L A I N L A N G U A G E S U M M A R Y
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Mediterranean-style diet for the prevention of cardiovascular disease
It is well established that diet plays a major role in cardiovascular disease risk. The traditional Mediterranean dietary pattern is of
particular interest because of observations from the 1960s that populations in countries of the Mediterranean region, such as Greece
and Italy, had lower mortality from cardiovascular disease compared with northern European populations or the US, probably as a
result of different eating habits.
This review assessed the effects of providing dietary advice to follow a Mediterranean-style diet or provision of foods relevant to the diet
(or both) to healthy adults, people at increased risk of cardiovascular disease and those with cardiovascular disease, in order to prevent
the occurrence or recurrence of cardiovascular disease and reduce the risk factors associated with it. Definitions of a Mediterranean
dietary pattern vary and we included only randomised controlled trials (RCTs) of interventions that reported both of the following
key components: a high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consumption of other
traditional foods high in monounsaturated fats such as tree nuts) and a high intake of plant-based foods, including fruits, vegetables
and legumes. Additional components included: low to moderate red wine consumption; high consumption of whole grains and cereals;
low consumption of meat and meat products and increased consumption of fish; moderate consumption of milk and dairy products.
The control group was no intervention or minimal intervention, usual care or another dietary intervention. We found 30 RCTs (49
papers) that met these criteria. The trials varied enormously in the participants recruited and the different dietary interventions. We
grouped studies to look at the effects of following a Mediterranean-style diet into the following four categories to help us with our
interpretation of the results:
1. Mediterranean dietary intervention compared to no intervention or a minimal intervention to prevent the onset of cardiovascular
disease;
2. Mediterranean dietary intervention compared to another dietary intervention to prevent the onset of cardiovascular disease;
3. Mediterranean dietary intervention compared to usual care for people with cardiovascular disease to prevent recurrence;
4. Mediterranean dietary intervention compared to another dietary intervention for people with cardiovascular disease to prevent
recurrence.
Few trials reported on the occurrence of cardiovascular disease either in those with or without disease to begin with. A large trial in
people at high risk of cardiovascular disease found a benefit of theMediterranean dietary intervention compared to a low-fat diet on the
risk of having a stroke, but not on heart attacks, death from heart disease or other causes. A further study in people with cardiovascular
disease found a benefit of theMediterranean dietary intervention on death from heart disease or other causes. We rated these two studies
as providing low to moderate-quality evidence. We had to exclude two studies from our analyses as concerns had been raised that the
data were unreliable. The other trials in the review measured risk factors for cardiovascular disease. There was low to moderate-quality
evidence for some beneficial changes in lipid levels and blood pressure with a Mediterranean-style diet in people without disease. In
people with cardiovascular disease already there was very low to low-quality evidence that there was no effect of a Mediterranean-style
diet on risk factors. Two trials reported side effects of the diet that were either absent or minor.
The review concludes that, despite the large number of included trials, there is still uncertainty regarding the effects of a Mediterranean-
style diet on cardiovascular disease occurrence and risk factors in people both with and without cardiovascular disease already. We did
find seven studies that are still ongoing and when we have the results from these we will incorporate them into the review to help reduce
the uncertainty.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Mediterranean dietary intervention compared to no intervention or minimal intervention for the primary prevention of cardiovascular disease
Patient or population: adults without cardiovascular disease
Setting: community
Intervention: Mediterranean dietary intervent ion
Comparison: no intervent ion or minimal intervent ion
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with no interven-
tion or minimal inter-
vention
Risk with Mediter-
ranean dietary inter-
vention
CVD mortality - - - - - Not reported
Total mortality - - - - - Not reported
Total cholesterol
(mmol/ L), change f rom
baseline
Follow-up: range 3
months to 24 months
The mean total choles-
terol change f rom base-
line ranged f rom -0.003
to -0.2 mmol/ L
MD 0.16 mmol/ L lower
(0.32 lower to 0.00)
- 569
(5 RCTs)
⊕⊕©©
LOW 12
-
LDL cholesterol (mmol/
L), change f rom base-
line
Follow-up: range 3
months to 6 months
The mean LDL choles-
terol change f rom base-
line ranged f rom -0.2 to
0.05 mmol/ L
MD 0.08 mmol/ L lower
(0.26 lower to 0.09
higher)
- 389
(4 RCTs)
⊕©©©
VERY LOW 123
-
HDL cholesterol
(mmol/ L), change f rom
baseline
Follow-up: range 3
months to 24 months
The mean HDL choles-
terol change f rom base-
line ranged f rom -0.07
to 0.03 mmol/ L
MD 0.02 mmol/ L higher
(0.04 lower to 0.08
higher)
- 569
(5 RCTs)
⊕⊕©©
LOW 124
-
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Triglycerides (mmol/ L),
change f rom baseline
See comment See comment - 480
(4 RCTs)
⊕⊕©©
LOW 12
Studies were not
pooled stat ist ically due
to substant ial hetero-
geneity (I2 = 92%)
Systolic blood pressure
(mmHg), change f rom
baseline
Follow-up: range 3
months to 24 months
The mean systolic
blood pressure change
f rom baseline ranged
f rom -1 to 1.4 mmHg
MD 2.99 mmHg lower
(3.45 lower to 2.53
lower)
- 269
(2 RCTs)
⊕⊕⊕©
MODERATE 3
-
Diastolic blood pres-
sure (mmHg), change
f rom baseline
Follow-up: range 3
months to 24 months
The mean diastolic
blood pressure change
f rom baseline ranged
f rom -1 to 1.7 mmHg
MD 2.00 mmHg lower
(2.29 lower to 1.71
lower)
- 269
(2 RCTs)
⊕⊕⊕©
MODERATE 3
-
Adverse events - - - - - Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; CVD: cardiovascular disease; HDL: high-density lipoprotein; LDL: low-density lipoprotein; MD: mean dif ference; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by one level for risk of bias. Majority of studies were at unclear risk of select ion bias or attrit ion bias, or both.
2Downgraded by one level for inconsistency. Forest plot shows dif ferent direct ions of ef fect and I2 value is very high.
3Downgraded by one level for imprecision due to small number of part icipants (< 400).
4Downgraded one level for inconsistency. Studies could not be pooled due to very high heterogeneity, and forest plots show
dif ferent direct ions of ef fect.
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B A C K G R O U N D
Description of the condition
Cardiovascular disease (CVD) is currently the leading cause of
mortality worldwide, causing one-third of deaths globally (Roth
2017). In 2015, there were more than 400 million individuals
living with CVD and nearly 18 million CVD deaths worldwide,
based on the most recent estimates from the Global Burden of
Disease (GBD) consortium (Roth 2017). Importantly, data sug-
gest that CVD mortality trends are no longer declining in high-
income regions, whereas low- andmiddle-income countries are ex-
periencing an increasing burden from CVD-related deaths (Roth
2017). According to World Health Organization’s estimates, over
80% of CVD deaths occur in low- and middle-income countries
and the number of CVD deaths is expected to increase to 23.3
million by 2030, with CVD remaining the single leading cause of
mortality globally (Mathers 2006; WHO 2011).
In Europe, more than 85 million people currently (2015) live with
CVD, which causes nearly 4 million deaths annually, account-
ing for 45% of the overall mortality burden. Death rates from
both ischaemic heart disease (IHD) and stroke are generally higher
in Central and Eastern Europe than in Northern, Southern and
Western Europe (European Heart Network 2017).
The societal burden of CVD is substantial, in terms of both direct
health care costs and indirect costs, such as productivity losses and
informal care of people living with CVD. For example, it is esti-
mated that CVD costs the European Union economy EURO210
billion a year (European Heart Network 2017).
In addition to the role of genetic, demographic and socioeconomic
characteristics, modifiable risk factors for CVD, such as high blood
pressure, high cholesterol, tobacco smoking, obesity and poor diet
are now widespread throughout the world, accounting for a large
proportion of the overall CVD burden (Roth 2017). This calls for
cost-effective preventive strategies to address these risk factors in
the first place.
Specifically, there is a longstanding recognition that diet plays a
major role in the aetiology of many chronic diseases, thereby con-
tributing to significant geographic variations in morbidity and
mortality rates from chronic disease across different countries and
populations worldwide (WHO2003). For example, it is estimated
that dietary factors are responsible for the largest contribution,
among all behavioural risk factors, to the risk of CVD mortality
at the population level across Europe (European Heart Network
2017).
In particular, the Mediterranean dietary pattern has been long in-
vestigated for its potential beneficial effects on a range of chronic
disease outcomes, starting from ecological data in the context of
the Seven Countries study in the 1960s (Keys 1986). Several ob-
servational studies have shown greater longevity and quality of
life, as well as reduced mortality and morbidity from CVD, can-
cer and other nutrition-related diseases with greater adherence to
a Mediterranean dietary pattern (Benetou 2008; Buckland 2009;
Feart 2009; Fung 2009;Knoops 2004; Lagiou 2006;Mitrou 2007;
Trichopoulou 1995; Trichopoulou 2003; Trichopoulou 2007).
Systematic reviews of observational prospective studies have con-
firmed that greater adherence to aMediterranean diet is associated
with a significant improvement in health status and a significant
reduction in overall mortality, as well as in morbidity and mor-
tality from CVD and other major chronic diseases (Dinu 2018;
Grosso 2017; Rosato 2017; Sofi 2008; Sofi 2010; Sofi 2014).
For example, in a comprehensive meta-analysis of observational
prospective studies including 4,172,412 participants, a two-point
increase in adherence score to the Mediterranean diet was asso-
ciated with an 8% reduction in overall mortality and a 10% re-
duced risk of CVD (Sofi 2014). These results were further cor-
roborated by a recent overview of the evidence from meta-anal-
yses of both observational studies and randomised clinical trials
(Dinu 2018). This latest review provides robust evidence support-
ing beneficial effects of a greater adherence to the Mediterranean
diet on a range of health outcomes, including overall mortality,
CVD, coronary heart disease and myocardial infarction (Dinu
2018). Furthermore, the Mediterranean diet has been associated
with favourable effects on major CVD risk factors. For example,
studies have documented a decreased incidence of hypertension,
diabetesmellitus andmetabolic syndrome as awhole with a greater
adherence to aMediterranean dietary pattern (Martinez-Gonzalez
2008;Nunez-Cordoba 2009; Psaltopoulou 2004; Rumawas 2009;
Sánchez-Taínta 2008). These findings have been corroborated by
systematic reviews supporting beneficial effects of the Mediter-
ranean diet on the metabolic syndrome and its individual compo-
nents (Buckland 2008; Kastorini 2011).
Against the large body of epidemiological observational studies,
there is less evidence from well-conducted and adequately pow-
ered randomised controlled trials (RCTs), especially with regard
to the potential efficacy of the Mediterranean diet in the primary
prevention of CVD (Serra-Majem 2006). Most of the RCTs have
addressed the effect of a Mediterranean type of diet on the occur-
rence of complications and recurrent events in people with existing
CVD, showing favourable effects in CVD secondary prevention
(Barzi 2003; de Lorgeril 1994; de Lorgeril 1996; de Lorgeril 1999;
de Lorgeril 2011; Panagiotakos 2016). There is also considerable
variability in the definition of, and duration of, the interventions
evaluated.
Recent evidence from the PREDIMED (Prevención con Dieta
Mediterránea) study, a large primary prevention trial (N = 7447)
among high-risk individuals in Spain, showed that a modified
Mediterranean diet supplemented with extra-virgin olive oil or
nuts was associated with major cardiovascular benefits (Estruch
2013). Specifically, both interventions groups experienced an ap-
proximately 30% reduction in the rate of major cardiovascular
events (myocardial infarction, stroke or death from cardiovascu-
lar causes) compared to the control diet group (advice to reduce
dietary fat), after a median follow-up of 4.8 years (Estruch 2013).
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This trial has recently been retracted and re-analysed as method-
ological issues concerning randomisation came to light for 2 of the
11 sites, and the inclusion of non-randomised second household
members. The new publication controlled for these in the analyses
and has conducted a series of sensitivity analyses excluding these
sites where they have found similar results for clinical endpoints
(Estruch 2018).
Description of the intervention
The original Mediterranean type of diet reflects the common di-
etary pattern of communities in countries of the Mediterranean
region in the early 1960s (Keys 1986), which was an expression of
common cultural and historical roots, and a shared set of lifestyle
and eating habits rather than a mere assortment of specific micro-
and macro-nutrients (Trichopoulou 1997). The Mediterranean
diet has been defined (Helsing 1989; Nestle 1995; Serra-Majem
1993; Willett 1995), and includes the following dietary factors:
a high intake of plant foods comprising mainly fruits and vegeta-
bles, cereals and whole-grain breads, beans, nuts and seeds; locally
grown, fresh and seasonal, unprocessed foods; large quantities of
fresh fruit consumed daily whereas concentrated sugars or honey
are consumed a few times per week in smaller quantities; olive oil
as a main cooking ingredient and source of fat; low to moderate
amounts of cheese and yogurt; low quantities of red meat and
higher quantities of fish; and low tomoderate amounts of red wine
often accompanying main meals.
The intervention under investigation for the current review was
dietary advice to follow a Mediterranean-style diet or provision of
foods relevant to the Mediterranean diet or both. At least two key
components were required to reach our definition of a Mediter-
ranean-style diet (Helsing 1989; Nestle 1995; Serra-Majem 1993;
Willett 1995).
These are the following:
1. high monounsaturated/saturated fat ratio (use of olive oil as
main cooking ingredient and/or consumption of other traditional
foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables
and legumes.
The rationale for this definition is based on recent work (Grosso
2017;Martínez-González 2017), which emphasises that protective
effects of the diet appear to be most attributable to olive oil, fruits,
vegetables and legumes. We chose at least two of the key active
components as our definition of a Mediterranean-style diet as one
component does not constitute a dietary pattern.
Additional components include:
3. low to moderate red wine consumption;
4. high consumption of whole grains and cereals;
5. low consumption of meat and meat products and increased
consumption of fish;
6. moderate consumption of milk and dairy products.
The traditional Mediterranean diet is not low in fat but is charac-
terised by a relative increase in monounsaturated fats in the form
of olive oil and tree nuts compared to saturated fats.
How the intervention might work
There is a large quantity of observational and experimental ev-
idence supporting potential mechanisms to explain the benefi-
cial effect of the Mediterranean diet on cardiovascular health
(Serra-Majem 2006). For example, there is evidence of favourable
effects of the Mediterranean diet on insulin resistance and en-
dothelium-dependent vasoreactivity, as well as of the antioxidant
and anti-inflammatory effects of the Mediterranean diet and its
individual components such as fruits and vegetables, olive oil,
nuts, whole grains, fish and red wine (Chrysohoou 2004; Dai
2008; Estruch 2010; Pitsavos 2005; Ryan 2000). In addition, the
Mediterranean dietary pattern has been associated with benefi-
cial effects on many cardiovascular risk factors, including lipopro-
teins, obesity, diabetesmellitus and hypertension (Buckland 2008;
Kastorini 2011; Martinez-Gonzalez 2008; Nunez-Cordoba 2009;
Psaltopoulou 2004; Rumawas 2009; Sánchez-Taínta 2008). There
is additionally a large body of consistent epidemiological evidence
supporting the notion that light to moderate red wine intake (one
or two drinks/day), andmoderate alcohol consumption in general,
is associated with reduced all-cause and cardiovascular mortality
and morbidity, and has beneficial effects on cardiovascular risk
factors, when compared with both abstention and heavy drinking
(Brien 2011; Corrao 2000; Di Castelnuovo 2002; Di Castelnuovo
2006; Ronksley 2011). In contrast, excess alcohol consumption is
associated with an increased risk of cardiovascular mortality and
morbidity, primarily through an increased risk of hypertension
and stroke (Stranges 2004; Taylor 2009).
Recent trial evidence also suggests anti-inflammatory effects of the
Mediterranean diet, with potential benefits on endothelial func-
tion as well (Estruch 2010; Schwingshackl 2014). Overall, the
protective effects of the Mediterranean diet on health outcomes
are likely derived from synergistic interactions among different
components as a whole dietary pattern rather than from relative
effects of specific food groups (Grosso 2017).
Why it is important to do this review
Modification of dietary factors forms an integral part of the pri-
mary prevention of cardiovascular diseases, as well as of their clin-
ical management (secondary prevention). A Mediterranean-style
dietary pattern is likely to produce a beneficial effect on the occur-
rence of several chronic diseases, primarily CVD, which are closely
linked to lifestyle and eating habits. This notion is corroborated
by the dietary recommendations of several scientific associations
for the prevention of major chronic disease (AHA 2006; WHO
2003). We aim to update and expand our previous systematic re-
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view (New Reference), to examine the effectiveness of a Mediter-
ranean-style diet in both the primary and secondary prevention
of CVD, so that the findings are of use to a broader audience,
and to explore heterogeneity further with an increased number
of included studies. We will include participants at risk as well as
those with established CVD to inform guidelines for both preven-
tion and management of CVD. We will also consider any control
group and stratify results based on this.
O B J E C T I V E S
To determine the effectiveness of a Mediterranean-style diet for
the primary and secondary prevention of CVD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Adults of all ages (18 years or more) without established CVD
to examine the effects of a Mediterranean-style diet on the pri-
mary prevention of CVD, and those with established CVD to de-
termine the effects of the intervention on secondary prevention.
Established CVD was defined as people who had experienced a
previous myocardial infarction (MI), stroke, revascularisation pro-
cedure (coronary artery bypass grafting (CABG) or percutaneous
transluminal coronary angioplasty (PTCA)), people with angina,
or angiographically defined CHD, cerebrovascular disease (stroke)
andperipheral arterial disease. For participantswithout established
CVD we included both those from the general population and
those at increased risk of CVD. We excluded studies that were
conducted exclusively in patients with type 2 diabetes (T2DM)
as whilst having T2DM is a major risk factor for CVD, patients
with T2DM form a specific group and interventions for diabetes
are covered specifically by the Cochrane Metabolic and Endocrine
Disorders review group. We performed stratified analyses to ex-
amine the effects of a Mediterranean-style diet on those with and
without established CVD.
Types of interventions
The intervention under investigation for the current review was
dietary advice to follow aMediterranean-style diet or a provision of
foods relevant to the Mediterranean diet, or both. At least two key
components were required to reach our definition of a Mediter-
ranean-style diet (Helsing 1989; Nestle 1995; Serra-Majem 1993;
Willett 1995).
These are the following:
1. high monounsaturated/saturated fat ratio (use of olive oil as
main cooking ingredient and/or consumption of other traditional
foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables
and legumes.
The rationale for this definition is based on recent work (Grosso
2017;Martínez-González 2017), which emphasises that protective
effects of the diet appear to be most attributable to olive oil, fruits,
vegetables and legumes. We chose at least two of the key active
components as our definition of a Mediterranean-style diet as one
component does not constitute a dietary pattern.
Additional components include:
3. low to moderate red wine consumption;
4. high consumption of whole grains and cereals;
5. low consumption of meat and meat products and increased
consumption of fish;
6. moderate consumption of milk and dairy products.
The traditional Mediterranean diet is not low in fat but is charac-
terised by a relative increase in monounsaturated fats in the form
of olive oil and tree nuts compared to saturated fats.
We were interested in studying the effects of aMediterranean-style
diet and so excluded studies with multi component interventions
including other dietary interventions or lifestyle interventions such
as exercise unless the effects of the Mediterranean-style diet were
reported separately.
We included only studies with follow-up periods of three months
or more defined as the intervention period plus post intervention
follow-up. We considered trials where the comparison group was
no intervention or minimal intervention (e.g. leaflet to follow a di-
etary pattern with no person-to-person intervention or reinforce-
ment) and also other dietary interventions.
In the main analysis we did not combine primary and secondary
prevention studies and different comparator groups as this would
havemade interpretation of the results difficult due to heterogene-
ity; instead we conducted four main analyses:
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention;
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention;
3. Mediterranean dietary intervention versus usual care for
secondary prevention;
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention.
Types of outcome measures
Endpoints were measured using validated measures.
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Primary outcomes
1. Cardiovascular mortality.
2. All-cause mortality.
3. Non-fatal endpoints such as MI, CABG, PTCA, angina or
angiographically defined CHD, stroke, carotid endarterectomy
or peripheral arterial disease (PAD).
Secondary outcomes
1. Changes in blood lipids (total cholesterol, high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, triglycerides) and blood pressure (systolic and
diastolic blood pressure).
2. Occurrence of type 2 diabetes as a major CVD risk factor.
3. Health-related quality of life.
4. Adverse effects (as defined by the authors of the included
trials).
5. Costs.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 9) in theCochrane Library (searched 26
September 2018);
• MEDLINE Daily and MEDLINE Epub Ahead of Print,
In-Process & Other Non-Indexed Citations (Ovid, 1946 to 25
September 2018) (searched 26 September 2018);
• Embase (Ovid, 1980 to 2018 week 39) (searched 26
September 2018);
• Web of Science Core Collection (Thomson Reuters, 1900
to 26 September 2018) (searched 26 September 2018);
• DARE Issue 2 of 4, 2015 (Cochrane Library) - no longer
updated (searched 26 June 2017);
• HTA Issue 4 of 4, 2016 (Cochrane Library) - no longer
updated (searched 26 June 2017);
• NHS EED Issue 2 of 4, 2015 (Cochrane Library) - no
longer updated (searched 26 June 2017).
We used medical subject headings (MeSH) or equivalent and text
word terms and the Cochrane sensitivity-maximising RCT filter
for MEDLINE (Lefebvre 2011), and adaptations of it for Embase
and Web of Science. We applied no language restrictions. We
tailored searches to individual databases (Appendix 1).
Searching other resources
In addition, we checked reference lists of reviews for additional
studies.
We searched ClinicalTrials.gov (www.clinicaltrials.gov) and the
World Health Organization (WHO) International Clinical Trials
Registry Platform ( ICTRP) ( apps.who.int/trialsearch/) for on-
going trials. The the metaRegister of controlled trials ( mRCT)
( www.controlled-trials.com/mrct) is no longer available and was
searched last for the previous review publication (Rees 2013).
We contacted authors where necessary for additional information.
We will continue to monitor retraction statements for included
studies.
Data collection and analysis
Selection of studies
Two review authors (of KR, NM, AT, LE, DW, AV, AD) indepen-
dently screened titles and abstracts for inclusion of all the potential
studies identified as a result of the searches and coded them as ’re-
trieve’ (eligible or potentially eligible/unclear) or ’do not retrieve’.
We combined the responses from each of the two review authors
and retrieved the full-text study reports/publication. Two review
authors (of KR, NM, AT, LE, DW, AV, AD, LH) independently
screened the full text and identified studies for inclusion and ex-
clusion using the pre-specified inclusion criteria. In the case of
any disagreements, a third author arbitrated (KR). We identified
and excluded duplicates and collated multiple reports of the same
study so that each study rather than each report was the unit of
interest in the review. We recorded the selection process in suffi-
cient detail to complete a PRISMA flow diagram.
Data extraction and management
We used a data collection form for study characteristics and out-
come data, which we had piloted. Two review authors (of KR, LE,
DW, AV, AD, LH) extracted the following characteristics from
included studies:
1. Methods: study design, total duration of study, number of
study centres and location, study setting and date of study.
2. Participants: N randomised, N lost to follow-up/
withdrawn, N analysed, mean age, age range, gender, primary or
secondary prevention (at increased risk of CVD, or established
CVD), inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
treatments/medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Additional notes, e.g. conflicts of interest of trial authors.
Disagreements were resolved by consensus or by involving a third
person (KR). One review author (KR) transferred data into the
ReviewManager (RevMan 2014) file (RevMan 2014).We double-
checked that data were entered correctly by comparing the data
presented in the systematic review with the data extraction form.
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Assessment of risk of bias in included studies
Two review authors (of KR, LE, DW, AV, AD, LH) independently
assessed risk of bias for each study using the criteria outlined in
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011). We resolved any disagreements by discussion or
by involving another author (KR). We assessed the risk of bias
according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low or unclear
and provided a quote from the study report together with a jus-
tification for our judgement in the ’Risk of bias’ table. We sum-
marised the risk of bias judgements across different studies for
each of the domains listed. We expected blinding of participants
and personnel to be difficult to achieve and unlikely for trials of
dietary interventions and so we have not recorded this as high risk
but unclear.
For cluster-randomised trials we intended to follow the guidance
in section 16.3.2 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), and to explore the following: re-
cruitment bias, baseline imbalance, loss of clusters, incorrect anal-
ysis and comparability with individually randomised trials. How-
ever, no cluster-randomised trials met our inclusion criteria.
When considering treatment effects, we took into account the risk
of bias for the studies that contribute to that outcome.
Measures of treatment effect
We processed data in accordance with the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We expressed
dichotomous outcomes as risk ratios (RR) with 95% confidence
intervals (CI). Where available we have used adjusted estimates
of treatment effect as hazard ratios, and used the inverse vari-
ance method to pool these statistically. For continuous variables,
we compared net changes (i.e. intervention group minus control
groupdifferences) and calculatedmeandifferences (MD) and95%
CIs for each study. We intended to use standardised mean differ-
ence (SMD) where different scales had been used to measure the
same outcome (e.g. quality of life) and to test the robustness of
using this and MD using sensitivity analyses. However, none of
the included studies reported these outcomes. We narratively de-
scribed skewed data reported as medians and interquartile ranges.
Unit of analysis issues
We intended to analyse cluster-randomised trials in accordance
with guidance in section 16.3.2 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), however no
cluster-RCTs met the inclusion criteria. For trials with multiple
arms we divided the control group N by the number of arms to
avoid double-counting in meta-analyses. We analysed outcomes
at the longest period of follow-up where multiple measurements
had been taken unless there was significant (> 30%) attrition.
Dealing with missing data
Where standard deviations (SD) for outcomes were not reported,
other variance measures such as standard errors and confidence
intervals were not available to derive SDs from and we were un-
able to obtain information from study authors, we imputed these
following the methods presented in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). Where studies
did not report results as change from baseline for continuous out-
comes, we calculated these and the SD differences following the
methods presented in the Cochrane Handbook for Systematic Re-
views of Interventions for imputing these (Section 16.1.3.2 Imput-
ing standard deviations for changes from baseline; Higgins 2011),
and assumed a correlation of 0.5 between baseline and follow-up
measures as suggested by Follman 1992.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the tri-
als in each analysis. When we identified substantial heterogene-
ity (50% to 90%) we reported it and explored possible causes by
prespecified subgroup analysis. Where heterogeneity was consid-
erable (75% to 100%), we did not pool studies statistically but
presented them in forest plots and suppressed the summary effect
estimate.
Assessment of reporting biases
For outcomes where we were able to pool more than 10 trials, we
created and examined a funnel plot to explore possible publication
bias and these fed into the GRADE assessment (see below).
Data synthesis
We undertook meta-analyses only where this was meaningful, i.e.
if the treatments, participants and the underlying clinical question
were similar enough for pooling tomake sense.We used a random-
effects model as we cannot assume that all studies in the meta-
analysis are estimating the same intervention effect, but rather are
estimating intervention effects that follow a distribution across
studies.
’Summary of findings’ table
We created a ’Summary of findings’ tables using the following
outcomes:
1. Cardiovascular mortality.
2. All-cause mortality.
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3. Non-fatal endpoints such as MI, CABG, PTCA, angina or
angiographically defined CHD, stroke, carotid endarterectomy
or peripheral arterial disease (PAD).
4. Changes in blood lipids (total cholesterol, high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, triglycerides) and blood pressure (systolic and
diastolic blood pressure).
5. Adverse events.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness and publication bias)
to assess the quality of a body of evidence as it relates to the stud-
ies that contribute data to the meta-analyses for the prespecified
outcomes. We used methods and recommendations described in
Section 8.5 and Chapter 12 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011), using GRADEpro
software ( https://gradepro.org/). We created a separate ’Summary
of findings’ table for each comparison:
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention;
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention;
3. Mediterranean dietary intervention versus usual care for
secondary prevention;
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention.
We justified all decisions to downgrade the quality of studies using
footnotes and made comments to aid the reader’s understanding
of the review where necessary.
Two review authors (AT, NM) working independently made
judgements about evidence quality, with disagreements resolved
by discussion or involving a third author (KR).We justified, docu-
mented and incorporated the judgements into reporting of results
for each outcome.
Subgroup analysis and investigation of heterogeneity
Wehave stratified themain analyses for the following comparisons,
to address heterogeneity and aid interpretation of findings:
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention;
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention;
3. Mediterranean dietary intervention versus usual care for
secondary prevention;
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention.
We have also performed subgroup analyses to examine the effect
of interventions described as the Mediterranean diet or style of
diet or those including both of the core components of increased
fruit and vegetable consumption and exchange of saturated fat for
monounsaturated fat, compared with other interventions meeting
our criteria.
Sensitivity analysis
We excluded two studies from themain analysis in sensitivity anal-
yses where concerns have been publicly made as to the reliability
of the data (Singh 1992; Singh 2002).
We intended to conduct sensitivity analyses including only studies
at low risk of bias in the domains of random sequence generation,
allocation concealment and incomplete outcome data, but for the
majority of studies these domains were rated as unclear.
Reaching conclusions
We based our conclusions only on findings from the quantita-
tive and narrative synthesis of included studies for this review. We
avoided making recommendations for practice and our implica-
tions for research suggest priorities for future research and outline
what the remaining uncertainties are in the area.
R E S U L T S
Description of studies
Results of the search
The original review explored the effects of a Mediterranean-style
diet compared to no intervention or minimal intervention for
the primary prevention of CVD and included 11 RCTs (New
Reference). The current review represents a substantive update
and expansion in scope to include also secondary prevention in
those with established CVD and other dietary interventions as
comparison groups.
The previous review, New Reference, identified 11 RCTs and one
ongoing trial and six of these RCTs are included in the current
review. Five studies in the previous review were excluded from this
update as the definition of a Mediterranean-style diet has been re-
fined further following expert review and recent evidence suggest-
ing themost likely active components (see Types of interventions).
Searching to September 2018 identified a further 12,133 refer-
ences, which reduced to 9483 after de-duplication. We also re-
screened the database from the original review given the expansion
in scope in terms of both participants and comparison groups.
From the updated searching we shortlisted 187 studies and these
went forward for formal inclusion and exclusion. From re-screen-
ing the original database we shortlisted 77 studies and these went
forward for formal inclusion and exclusion. Following full-text
review and collation of multiple papers for individual studies 30
RCTs (49 papers) and seven ongoing trials met the inclusion cri-
teria. The flow of studies throughout the review is presented in
the PRISMA diagram in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Details of the methods, participants, intervention, comparison
group andoutcomemeasures for each of the studies included in the
review are shown in the Characteristics of included studies table. A
summary of the description of included studies is presented below
for each comparison group for clarity.
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
Nine trials (11 papers) were included with 1337 participants ran-
domised.
The health status of participants varied between studies. The
majority of participants were classified as healthy and were re-
cruited by three of the trials (Castagnetta 2002; Djuric 2009;
Konstantinidou 2010), with two further trials recruiting elderly
people (Clements 2017; Davis 2017). The remaining four tri-
als recruited previously untreated hypercholesteraemic partici-
pants (Wardle 2000), elderly participants with long-standing
hypercholesterolaemia (Lindman 2004), and sedentary people
with metabolic syndrome (Esposito 2004) or metabolic disease
(Chasapidou 2014). Two trials recruited only women: one re-
cruited only postmenopausal women (Castagnetta 2002), and the
other trial recruited women aged 25 to 65 years (Djuric 2009). In
contrast, one trial recruited only men (Lindman 2004), and the
remaining six recruited both men and women (Chasapidou 2014;
Clements 2017; Davis 2017; Esposito 2004; Konstantinidou
2010; Wardle 2000). The trials were conducted in the US
(Djuric 2009), Italy (Castagnetta 2002; Esposito 2004), Spain
(Konstantinidou 2010), Greece (Chasapidou 2014), Norway
(Lindman 2004), Australia (Davis 2017) and the UK (Clements
2017;Wardle 2000). The duration of the intervention and follow-
up periods varied: three months (Konstantinidou 2010; Wardle
2000), six months (Castagnetta 2002; Chasapidou 2014; Davis
2017; Djuric 2009; Lindman 2004), one year (Clements 2017),
and two years (Esposito 2004).
We identified four ongoing trials
(Hardman 2015; NCT03053843; NCT03129048; Sotos-Prieto
2017) (see Characteristics of ongoing studies table). All describe
the intervention as a Mediterranean diet. Three will report CVD
risk factors in an elderly Australian population (Hardman 2015),
older obese adults from the US (NCT03129048), and firefighters
from the US (Sotos-Prieto 2017), and one will report quality of
life in patients with atrial fibrillation (NCT03053843).
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
Thirteen trials (25 papers) were included with 8687 participants
randomised. The majority of participants were enrolled in one
large multicentre trial (7747 participants, PREDIMED).
The health status of participants varied between studies. The
majority of participants were described as at increased risk of
CVD (Dinu 2017; PREDIMED; Sofi 2018; Vincent-Baudry
2005), with specific diagnoses of hypertension (Lapetra 2018),
central obesity (Bajerska 2018), hypercholesterolaemia (Athyros
2011), non-alcoholic fatty liver disease (NAFLD) (Misciagna
2017; Properzi 2018), HIV (Ng 2011; Stradling 2018), and heart
or lung transplant recipients (Entwistle 2018).One study recruited
women with breast cancer (Skouroliakou 2017). Two trials re-
cruited only women (Bajerska 2018; Skouroliakou 2017), the re-
mainder recruiting both men and women. The trials were con-
ducted in Spain (Lapetra 2018; PREDIMED), Italy (Dinu 2017;
Misciagna 2017; Sofi 2018), Greece (Athyros 2011; Skouroliakou
2017), France (Vincent-Baudry 2005), the UK (Entwistle 2018;
Stradling 2018), Poland (Bajerska 2018), Australia (Properzi
2018), and China (Ng 2011). The duration of the intervention
and follow-up periods varied: three months (Dinu 2017; Properzi
2018; Sofi 2018; Vincent-Baudry 2005), four months (Athyros
2011; Bajerska 2018), six months (Misciagna 2017; Skouroliakou
2017), one year (Entwistle 2018; Ng 2011; Stradling 2018), two
years (Lapetra 2018), and up to five years (PREDIMED).
The dietary interventions in the comparison group varied, in-
cluding low-fat (Athyros 2011; Entwistle 2018; Lapetra 2018;
Ng 2011; PREDIMED; Properzi 2018; Stradling 2018; Vincent-
Baudry 2005), the traditional diet of that country (Bajerska 2018),
national recommendations/disease-specific guidance (Misciagna
2017; Skouroliakou 2017), and vegetarian (Dinu 2017; Sofi
2018).
We identified one ongoing trial (Papamiltiadous 2016) (see
Characteristics of ongoing studies table) looking at the effects of a
Mediterranean diet compared to a low-fat moderate carbohydrate
diet on CVD risk factors in NAFLD.
3. Mediterranean dietary intervention versus usual care for
secondary prevention
Two trials (four papers) were included with 706 participants ran-
domised.
Both trials recruited patients with CVD, one in men and women
with CHD (Michalsen 2006), and the other in men and women
who had experienced a myocardial infarction within six months
(The Lyon Diet Heart Study). Participants were recruited from
Germany (Michalsen 2006) and France (The Lyon Diet Heart
Study). The duration of the intervention and follow-up periods
varied from 12 months (Michalsen 2006) to 24 and 46 months
(The Lyon Diet Heart Study).
No ongoing trials have been identified to date for this comparison
group.
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
Six trials (10 papers) were included with 1731 participants ran-
domised. An expression of concern has been published about the
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reliability of two of the studies in this comparison group (Singh
1992; Singh 2002), and we have conducted sensitivity analyses
excluding these studies from all analyses. These were also the trials
with the majority of participants (1406 participants, Singh 1992;
Singh 2002).
All trials recruited patients with CVD. Three trials recruited men
and women with CHD (Colquhoun 2000; Mayr 2018; Weber
2012), one after a firstmyocardial infarction (Tuttle 2008) and one
with acute myocardial infarction or unstable angina (Singh 1992).
One trial recruited patients with establishedCHD or those at high
risk of CHD, although themajority of participants had established
disease (58% in the intervention group and59% in the comparison
group) so this study has been analysed as a secondary prevention
study (Singh 2002). Participants were recruited from Australia
(Colquhoun 2000; Mayr 2018), the US (Tuttle 2008), Brazil (
Weber 2012), and India (Singh 1992; Singh 2002). The duration
of the intervention and follow-up periods varied: three months
(Colquhoun 2000; Weber 2012), six months (Mayr 2018), and
two years (Singh 1992; Singh 2002; Tuttle 2008).
In a pilot trial, the comparison group comprised foods typical
of the Mediterranean diet and the intervention was a Brazilian
cardioprotective diet following the principles of theMediterranean
dietary pattern but with local foods to enhance adherence (Weber
2012). We have used the Mediterranean diet as the intervention
group in our analyses.
The dietary interventions in the comparison group varied, includ-
ing low-fat (Colquhoun 2000; Mayr 2018; Tuttle 2008) and na-
tional recommendations/disease-specific guidance (Singh 1992;
Singh 2002; Weber 2012).
We identified two ongoing trials (Delgado-Lista 2016; Itsiopoulos
2018) (see Characteristics of ongoing studies table) in patients
with CHD and all will report on clinical endpoints.
Excluded studies
Details and reasons for exclusion for the studies that most closely
missed the inclusion criteria are presented in the Characteristics of
excluded studies table. The majority of studies were excluded on
the basis of the intervention not meeting the two core criteria of
a Mediterranean-style diet (see Types of interventions) or studies
were short-term (less than 12 weeks).
Risk of bias in included studies
Details are provided for each of the included studies in the ’Risk
of bias’ section of the Characteristics of included studies table and
summaries are presented in Figure 2 and Figure 3.We assessed risk
of bias as ’low’, ’high’ or ’unclear’. A summary of the risk of bias
of the included studies is presented below for each comparison
group for clarity.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
The methods of random sequence generation were unclear in six
of the nine included studies (Castagnetta 2002; Chasapidou 2014;
Clements 2017; Djuric 2009; Lindman 2004; Wardle 2000).
In the three studies where this was clear, we judged the meth-
ods used to be at low risk of bias (Davis 2017; Esposito 2004;
Konstantinidou 2010). The methods of allocation concealment
were unclear in seven of the nine included studies. Where this
was clear, we judged the methods used to be at low risk of bias
(Esposito 2004; Wardle 2000).
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
Themethods of random sequence generationwere unclear in six of
the 13 included studies (Athyros 2011; Lapetra 2018; Dinu 2017;
Properzi 2018; Skouroliakou 2017; Vincent-Baudry 2005). In the
seven studies where this was clear, we judged the methods used to
be at low risk of bias (Bajerska 2018; Entwistle 2018; Misciagna
2017; Ng 2011; PREDIMED; Sofi 2018; Stradling 2018). The
methods of allocation concealment were unclear in 10 of the 13
included studies. Where this was clear, we judged the methods
used to be at low risk of bias (Entwistle 2018; Sofi 2018; Stradling
2018).
3. Mediterranean dietary intervention versus usual care for
secondary prevention
The methods of random sequence generation were unclear in one
of the two included studies (The Lyon Diet Heart Study), and in
the other we judged the methods used to be at low risk of bias
(Michalsen 2006). The methods of allocation concealment were
unclear in one study (Michalsen 2006) and in the other we judged
the methods used to be at low risk of bias (The Lyon Diet Heart
Study).
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
The methods of random sequence generation were unclear in five
of the six included studies (Colquhoun 2000; Singh 1992; Singh
2002; Tuttle 2008; Weber 2012), and in the one study where
this was clear, we judged the methods used to be at low risk of
bias (Mayr 2018). The methods of allocation concealment were
unclear in four of the six included studies. Where this was clear,
we judged the methods used to be at low risk of bias (Tuttle 2008;
Weber 2012).
Blinding
The blinding of participants and personnel for behavioural inter-
ventions is difficult, if not impossible, in most cases and so we
have not judged this as a high risk of bias. We rated this domain
as unclear for all trials in all four comparison groups.
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
The blinding of participants and personnel was unclear in all nine
trials. Blinding of outcome assessment was unclear in eight of the
nine trials (Castagnetta 2002; Chasapidou 2014; Clements 2017;
Davis 2017; Djuric 2009; Konstantinidou 2010; Lindman 2004;
Wardle 2000). In the remaining trial, outcome assessments were
made blind to the group assignment and we judged this to be at
low risk of bias (Esposito 2004).
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
The blinding of participants andpersonnel was unclear in all 13 tri-
als. Blinding of outcome assessment was unclear in 10 of the 13 tri-
als (Athyros 2011; Entwistle 2018; Lapetra 2018; Dinu 2017; Ng
2011; PREDIMED; Properzi 2018; Skouroliakou 2017; Stradling
2018; Vincent-Baudry 2005). In the remaining three trials, out-
come assessments were made blind to the group assignment and
we judged this to be at low risk of bias (Bajerska 2018; Misciagna
2017; Sofi 2018).
3. Mediterranean dietary intervention versus usual care for
secondary prevention
The blinding of participants and personnel was unclear in both
trials. Blinding of outcome assessment was unclear in one trial
(Michalsen 2006). In the remaining trial, outcome assessments
were made blind to the group assignment and we judged this to
be at low risk of bias (The Lyon Diet Heart Study).
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
The blinding of participants and personnel was unclear in all six
trials. Blinding of outcome assessment was unclear in five of the
six trials (Colquhoun 2000;Mayr 2018; Singh 1992; Tuttle 2008;
Weber 2012). In the remaining trial, outcome assessments were
made blind to the group assignment and we judged this to be at
low risk of bias (Singh 2002).
Incomplete outcome data
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
We judged three of the nine trials to be at low risk of bias as
loss to follow-up was low and reasons provided or intention-to-
treat (ITT) analyses were performed, or both (Esposito 2004;
Konstantinidou 2010; Wardle 2000). We judged one study to be
at high risk of bias as there was differential loss to follow-up that
exceeded 20% in the intervention group (Djuric 2009). For the
remaining trials, we judged the risk of bias as unclear.
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
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We judged six of the 13 trials to be at low risk of bias as loss to
follow-up was absent or low and reasons provided or ITT analyses
were performed, or both (Athyros 2011; Bajerska 2018; Entwistle
2018; Misciagna 2017; PREDIMED; Sofi 2018). We judged one
study to be at high risk of bias for attrition due to differential
loss to follow-up between the intervention and comparison groups
with loss to follow-up at 36% in the comparison diet (Vincent-
Baudry 2005). For the remaining trials, we judged the risk of bias
as unclear.
3. Mediterranean dietary intervention versus usual care for
secondary prevention
We judged both trials to be at low risk of bias as loss to follow-
up was low and reasons provided or ITT analyses were performed
(Michalsen 2006; The Lyon Diet Heart Study).
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
For all six trials (Colquhoun 2000;Mayr 2018; Singh 1992; Singh
2002; Tuttle 2008; Weber 2012), we judged the risk of attrition
bias as unclear.
Selective reporting
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
For four studies we judged the risk of bias associated with selec-
tive reporting as unclear (Castagnetta 2002; Chasapidou 2014;
Clements 2017; Lindman 2004). The remaining five studies
clearly stated the primary and secondary outcomes and reported
the results for these and were therefore judged to be of low risk
of bias in this domain (Davis 2017; Djuric 2009; Esposito 2004;
Konstantinidou 2010; Wardle 2000).
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
For four studies we judged the risk of bias associated with selective
reporting as unclear (Dinu 2017; Lapetra 2018; Properzi 2018;
Stradling 2018). The remaining nine studies clearly stated the
primary and secondary outcomes and reported the results for these
and were therefore judged to be of low risk of bias in this domain
(Athyros 2011; Bajerska 2018; Entwistle 2018; Misciagna 2017;
Ng 2011; PREDIMED; Skouroliakou 2017; Sofi 2018; Vincent-
Baudry 2005).
3. Mediterranean dietary intervention versus usual care for
secondary prevention
Both studies clearly stated the primary and secondary outcomes
and reported the results for these and were therefore judged to be
of low risk of bias (Michalsen 2006; The Lyon Diet Heart Study).
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
For three studies we judged the risk of bias associated with se-
lective reporting as unclear (Colquhoun 2000; Mayr 2018; Singh
1992). The remaining three studies clearly stated the primary and
secondary outcomes and reported the results for these and were
therefore judged to be of low risk of bias in this domain (Singh
2002; Tuttle 2008; Weber 2012).
Other potential sources of bias
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
There was insufficient information to judge the risk of other
sources of bias and we categorised all nine studies as unclear (
Castagnetta 2002;Chasapidou 2014;Clements 2017;Davis 2017;
Djuric 2009; Esposito 2004; Konstantinidou 2010; Lindman
2004; Wardle 2000).
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
There was insufficient information to judge the risk of other
sources of bias and we categorised all 13 studies as unclear (
Athyros 2011; Bajerska 2018;Dinu 2017; Entwistle 2018; Lapetra
2018; Misciagna 2017; Ng 2011; PREDIMED; Properzi 2018;
Skouroliakou 2017; Sofi 2018; Stradling 2018; Vincent-Baudry
2005).
3. Mediterranean dietary intervention versus usual care for
secondary prevention
There was insufficient information to judge the risk of other
sources of bias and we categorised both studies as unclear
(Michalsen 2006; The Lyon Diet Heart Study).
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
An expression of concern has been published about the reliability
of two of the studies in this comparison group (Singh 1992;
Singh 2002). We have conducted sensitivity analyses excluding
these studies from all analyses. We regarded these two studies as
at high risk of other bias. We judged the remaining four studies
as at unclear risk of other sources of bias as there was insufficient
information to make a judgement (Colquhoun 2000; Mayr 2018;
Tuttle 2008; Weber 2012).
Effects of interventions
See: Summary of findings for the main comparison
Mediterranean dietary intervention compared to no intervention
or minimal intervention for the primary prevention of
cardiovascular disease; Summary of findings 2 Mediterranean
dietary intervention compared to another dietary intervention
for the primary of cardiovascular disease; Summary of findings
3 Mediterranean dietary intervention compared to usual care
for secondary prevention of cardiovascular disease; Summary
of findings 4 Mediterranean dietary intervention compared to
another dietary intervention for the secondary prevention of
cardiovascular disease
See: Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3; Summary of findings 4.
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Data are presented in the analyses by primary and secondary pre-
vention of CVD and by comparison group - no intervention/usual
care/minimal intervention versus another dietary intervention.
As an expression of concern has been published about the relia-
bility of the studies Singh 1992 and Singh 2002, we conducted
sensitivity analyses excluding these studies. This affects the follow-
ing outcomes in theMediterranean dietary intervention versus an-
other dietary intervention for secondary prevention comparisons:
non-fatal MI, fatal MI, sudden cardiac death, total cardiac end-
points, lipid levels and blood pressure.
Clinical events (primary outcomes: cardiovascular
mortality, all-cause mortality and other non-fatal
endpoints)
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
None of the nine included studies reported on clinical events.
Trials were relatively small (numbers randomised ranged from 60
to 384) and short-term (three months to two years).
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
The PREDIMED trial was the only trial reporting clinical events
for this comparison. PREDIMED comprised two dietary inter-
ventions: the PREDIMED intervention plus supplementation
with extra-virgin olive oil and the PREDIMED intervention plus
supplementation with tree nuts, and compared these to a low-fat
diet. The trial included 7447 men and women from 11 sites in
Spain at increased risk of CVD. The trial was stopped early as clear
benefits of the Mediterranean diet over the low-fat diet were seen
for the primary outcome at 4.8 years. The original trial, Estruch
2013, was retracted and re-analysed when methodological issues
concerning randomisation came to light for two sites, and the in-
clusion of non-randomised second household members. The new
publication controlled for these in the analyses and conducted a
series of sensitivity analyses excluding these sites (Estruch 2018).
The new publication reports on the composite clinical outcome,
CVD and total mortality, MI and stroke where an effect of the
PREDIMED intervention compared to a low-fat diet on compos-
ite clinical endpoints was found (hazard ratio (HR) 0.70, 95%
confidence interval (CI) 0.58 to 0.85) (Analysis 2.1). In sensitivity
analyses, the hazard ratio for this outcome in 6405 participants
compared to control was 0.65 (95% CI 0.50 to 0.85) when ex-
cluding participants from site D and second household members,
and 0.69 (95% CI 0.53 to 0.92) in 5859 participants when ex-
cluding participants also from site B.
The re-analysed paper also reports clinical endpoints separately
where there was little or no effect of the PREDIMED intervention
compared to a low-fat diet on total mortality (HR 1.0, 95% CI
0.81 to 1.24, low-quality evidence) (Analysis 2.3), CVDmortality
(HR 0.81, 95% CI 0.50 to 1.32, low-quality evidence) (Analysis
2.2) ormyocardial infarction (HR0.79, 95%CI 0.57 to 1.10, low-
quality evidence) (Analysis 2.4), but moderate-quality evidence
for a reduction in the number of strokes with the intervention
(HR 0.60, 95%CI 0.45 to 0.80) (Analysis 2.5). Reductions in the
numbers of participants experiencing peripheral arterial disease
were also observed with the PREDIMED intervention (HR 0.42,
95% CI 0.28 to 0.61, moderate-quality evidence) (Analysis 2.6),
but these data are less certain as they were not re-analysed in the
recent paper (Estruch 2018), but come from earlier reports of the
trial.
One small trial (N = 180) comparing the Mediterranean diet to a
low-fat diet in hypertensive patients reported unadjusted estimates
for stroke of risk ratio (RR) 0.33, 95% CI 0.04 to 3.14) over two
years of follow-up (Analysis 2.8) (Lapetra 2018).
3. Mediterranean dietary intervention versus usual care for
secondary prevention
One study reports clinical endpoints for this comparison group
(The Lyon Diet Heart Study). This study recruited 605 patients
within six months of a myocardial infarction, aged less than 70
years, the majority of whom were men (90%) from secondary care
in France (The Lyon Diet Heart Study).
The LyonDietHeart Study examined the effect of aMediterranean
diet compared to usual care over 46 months and found reductions
in adjusted estimates for a composite endpoint of CVD deaths
and non-fatal myocardial infarction (HR 0.28, 95% CI 0.15 to
0.52) (Analysis 3.3), CVD mortality (HR 0.35, 95% CI 0.15 to
0.82, low-quality evidence) (Analysis 3.2) and total mortality (HR
0.44, 95% CI 0.21 to 0.92, moderate-quality evidence) (Analysis
3.1) with the intervention (The Lyon Diet Heart Study).
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
Three studies report clinical endpoints for this comparison group
(Singh 1992; Singh 2002; Tuttle 2008), and two of these have
been excluded in sensitivity analyses from all main analyses due
to published concerns regarding the reliability of the data (Singh
1992; Singh 2002). For all analyses for comparison 4, forest plots
are provided including and excluding these two studies, and we
report in the text the results of sensitivity analyses excluding these
studies. For the adjusted outcomes non-fatal myocardial infarc-
tion, fatal myocardial infarction, sudden cardiac death, total car-
diac endpoints, total mortality and CVDmortality, no other stud-
ies were identified after removing the Singh 1992 and Singh 2002
studies so these forest plots are empty and could not be shown.
One small study from theUS in 101 patients randomised sixweeks
post myocardial infarction, following aMediterranean diet or low-
fat diet, provided unadjusted estimates for total cardiac endpoints
(all-cause and cardiac deaths, myocardial infarction, hospital ad-
missions for heart failure, unstable angina or stroke (RR 0.98,
95% CI 0.40 to 2.41, very low-quality evidence) (Analysis 4.13),
showing considerable uncertainty in the effect size (Tuttle 2008).
Two further ongoing trials will report clinical endpoints in CHD
patients randomised to the Mediterranean dietary intervention
compared to other dietary interventions (Delgado-Lista 2016;
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Itsiopoulos 2018). One is conducted in Spain and randomising
1002 patients with an estimated completion date of September
2019 (Delgado-Lista 2016). The other is conducted in Australia
and randomising 1032 patients with anticipated last enrolment in
October 2018 (Itsiopoulos 2018).
Cardiovascular risk factors (secondary outcomes:
changes in blood lipids and blood pressure, and
occurrence of type 2 diabetes)
Lipid levels
Total cholesterol
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
Five trials (569 participants randomised) measured total choles-
terol levels and reported data that could be used in meta-analyses
(Davis 2017; Djuric 2009; Esposito 2004; Konstantinidou 2010;
Wardle 2000). We assessed the overall quality of evidence as low
and it showed a possible reduction in total cholesterol of -0.16
mmol/L (95% CI -0.32 to 0.00, 5 trials, 569 participants, I² =
73%) (Analysis 1.1).
Two trials measured total cholesterol but did not provide data in
a useable format for meta-analyses (Castagnetta 2002; Clements
2017). One trial reported a significant reduction in total choles-
terol levels with the dietary intervention (Castagnetta 2002), and
the other reported that total cholesterol was unaffected by both the
Mediterranean diet and minimal dietary intervention (Clements
2017).
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
Seven trials (939 participants randomised) measured total choles-
terol and provided data that could be pooled in a meta-anal-
ysis (Athyros 2011; Bajerska 2018; Ng 2011; PREDIMED;
Skouroliakou 2017; Sofi 2018; Vincent-Baudry 2005). For the
PREDIMED trial data on lipids were reported for two study sites
rather than all 11 sites, but these were not the two sites where
methodological issues arose. There was low-quality evidence that
the Mediterranean diet produced a possible small reduction in to-
tal cholesterol (mean difference (MD) -0.13 mmol/L, 95% CI -
0.30 to 0.04, I² = 70%) (Analysis 2.9).
Two further trials measured total cholesterol but did not provide
data in a useable format formeta-analyses. Preliminary results from
theCARDIOVEG study showed that the vegetarian diet wasmore
effective in reducing total cholesterol (-2.9%) with no significant
change in theMediterranean group (Dinu 2017). In a preliminary
report of a trial comparing the Mediterranean diet and a low-
fat diet in patients with NAFLD to reduce CVD risk, significant
within-group improvements were seen for total cholesterol in the
Mediterranean diet group but not the low-fat diet group (P < 0.05)
(Properzi 2018).
3. Mediterranean dietary intervention versus usual care for
secondary prevention
Two trials (441 participants randomised) measured total choles-
terol and provided data that could be pooled in a meta-analysis
(Michalsen 2006; The Lyon Diet Heart Study). There was low-
quality evidence that the Mediterranean diet produced little or no
effect on total cholesterol levels (MD 0.07 mmol/L, 95%CI -0.19
to 0.33, I² = 19%) (Analysis 3.4).
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
Two studies with a published expression of concern report total
cholesterol for this comparison groupwith data in a useable format
for meta-analyses (Singh 1992; Singh 2002). Both of these studies
have published concerns regarding the reliability of the data and
have been excluded in sensitivity analyses from all main analyses
(Singh 1992; Singh 2002). No other studies were identified after
removing the Singh 1992 and Singh 2002 studies so these forest
plots are empty and could not be shown.
Two further studies reported on lipid levels overall. One study re-
ported as a conference proceeding compared effects of theMediter-
ranean diet with a low-fat diet on lipid levels in CHD patients on
statin therapy (Colquhoun 2000). We were unable to pool these
data statistically as no measures of variance were available. The au-
thors found no differences between the two diets at three months
follow-up. In a preliminary analysis of the AUSMED trial the au-
thors report that compared to the low-fat diet, the MedDiet did
not change the lipid profile (P > 0.05) (Mayr 2018). The variables
were not measured in a later analysis of the full cohort.
Low-density lipoprotein cholesterol
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
Four trials (389 participants randomised) measured LDL choles-
terol and provided data that could be pooled in a meta-analysis
(Davis 2017; Djuric 2009; Konstantinidou 2010; Wardle 2000).
There was very low-quality evidence that the Mediterranean diet
produced little or no effect on levels of LDL cholesterol (MD -
0.08 mmol/L, 95% CI -0.26 to 0.09, I² = 54%) (Analysis 1.2).
Two trials measured LDL cholesterol but did not provide data
in a useable format for meta-analyses. Preliminary analysis of an
ongoing study reported a change in LDL cholesterol levels of 0.39
mmol/L between baseline and follow-up of six months in 181
patients with metabolic disease following Mediterranean dietary
advice, with a difference between the intervention and control
group who received no advice of -7.9% (P = 0.05) (Chasapidou
2014). Another trial reported that LDL cholesterol was unaffected
by both the Mediterranean diet and minimal dietary intervention
(Clements 2017).
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2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
Seven trials (947 participants randomised) measured LDL choles-
terol and provided data that could be pooled in a meta-analysis
(Athyros 2011; Bajerska 2018; PREDIMED; Skouroliakou 2017;
Sofi 2018; Stradling 2018; Vincent-Baudry 2005). For the PRED-
IMED trial data on lipids were reported for two study sites rather
than all 11 sites, but these were not the two sites where method-
ological issues arose. There was moderate-quality evidence that the
Mediterranean diet produced a small reduction in LDL cholesterol
(MD -0.15 mmol/L, 95% CI -0.27 to -0.02, I² = 46%) (Analysis
2.10).
One further trial measured LDL cholesterol but did not provide
data in a useable format formeta-analyses. Preliminary results from
the CARDIOVEG study show that the vegetarian diet was more
effective in reducing LDL cholesterol (-5.1%) with no significant
change in the Mediterranean diet group (Dinu 2017).
3. Mediterranean dietary intervention versus usual care for
secondary prevention
Two trials (441 participants randomised) measured LDL choles-
terol and provided data that could be pooled in a meta-analysis
(Michalsen 2006; The Lyon Diet Heart Study). There was low-
quality evidence that the Mediterranean diet produced little or no
effect on LDL cholesterol levels (MD 0.11 mmol/L, 95% CI -
0.09 to 0.31, I² = 0%) (Analysis 3.5).
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
Three studies report LDL cholesterol for this comparison group
with data in a useable format for meta-analyses (Singh 1992;
Singh 2002; Tuttle 2008). Two of the studies have been excluded
in sensitivity analyses from all main analyses due to published
concerns regarding the reliability of the data (Singh 1992; Singh
2002). For all analyses for comparison 4, forest plots are provided
including and excluding these two studies, andwe report in the text
the results of the sensitivity analyses excluding these studies. In the
remaining study, Tuttle 2008, there was very low-quality evidence
of little or no effect of the Mediterranean diet on LDL cholesterol
levels (MD 0.08 mmol/L, 95% CI -0.26 to 0.42) (Analysis 4.17).
High-density lipoprotein cholesterol
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
Five trials (569 participants randomised) measured HDL choles-
terol levels and reported data that could be used in meta-analyses
(Davis 2017; Djuric 2009; Esposito 2004; Konstantinidou 2010;
Wardle 2000). There was low-quality evidence of little or no effect
of the intervention on HDL levels (MD 0.02 mmol/L, 95% CI -
0.04 to 0.08, I² = 70%) (Analysis 1.3).
One trial measured HDL cholesterol but did not provide data in
a useable format for meta-analyses (Clements 2017). This trial re-
ported that HDL cholesterol was unaffected by both the Mediter-
ranean diet and minimal dietary intervention (Clements 2017).
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
Six trials (891 participants randomised) measured HDL choles-
terol and provided data that could be pooled in a meta-analysis
(Athyros 2011; Bajerska 2018; PREDIMED; Skouroliakou 2017;
Sofi 2018; Vincent-Baudry 2005). For the PREDIMED trial data
on lipids were reported for two study sites rather than all 11 sites,
but these were not the two sites where methodological issues arose.
There was moderate-quality evidence showing little or no effect
of the Mediterranean diet on HDL cholesterol levels (MD 0.02
mmol/L, 95% CI -0.01 to 0.04), I² = 0%) (Analysis 2.11).
One study in patients withNAFLD reported lipid levels at baseline
and follow-up as normal or altered rather than actual values and
variance. They found that lower levels of HDL cholesterol were
observed only in the low glycaemicMediterranean diet group after
six months (Misciagna 2017).
3. Mediterranean dietary intervention versus usual care for
secondary prevention
Two trials (441 participants randomised) measured HDL choles-
terol and provided data that could be pooled in a meta-analysis
(Michalsen 2006; The Lyon Diet Heart Study). There was low-
quality evidence that the Mediterranean diet produced little or no
effect on HDL cholesterol levels (MD -0.01 mmol/L, 95% CI -
0.08 to 0.07, I² = 13%) (Analysis 3.6).
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
Three studies report HDL cholesterol for this comparison group
with data in a useable format for meta-analyses (Singh 1992;
Singh 2002; Tuttle 2008). Two of the studies have been excluded
in sensitivity analyses from all main analyses due to published
concerns regarding the reliability of the data (Singh 1992; Singh
2002). For all analyses for comparison 4, forest plots are provided
including and excluding these two studies, and we report in the
text the results of the sensitivity analyses excluding these studies. In
the remaining study, Tuttle 2008, there was low-quality evidence
of little or no effect of theMediterranean diet on HDL cholesterol
levels (MD -0.05 mmol/L, 95%CI -0.17 to 0.06) (Analysis 4.19).
Triglycerides
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
Four trials (480 participants randomised) measured triglyceride
levels and reported data that could be used in meta-analyses (
Davis 2017; Djuric 2009; Esposito 2004; Wardle 2000). There
was considerable heterogeneity between trials (I² = 92%) and so
we did not pool the studies statistically (Analysis 1.4). Two trials
reported beneficial effects of the Mediterranean diet (Davis 2017;
Esposito 2004), one reported no effect (Djuric 2009), and the
other favoured the control (Wardle 2000).
Three trialsmeasured triglyceride levels but did not provide data in
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a useable format for meta-analyses (Clements 2017), or provided
data as medians (with 25th and 75th percentiles) (Konstantinidou
2010; Lindman 2004). One trial reported that triglyceride levels
were unaffected by both the Mediterranean diet and minimal di-
etary intervention (Clements 2017). In the two trials reporting
medians, no effect of the diet on triglyceride levels was observed
(Konstantinidou 2010; Lindman 2004).
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
Seven trials (939 participants randomised) measured triglyceride
levels and provided data that could be pooled in a meta-anal-
ysis (Athyros 2011; Bajerska 2018; Ng 2011; PREDIMED;
Skouroliakou 2017; Sofi 2018; Vincent-Baudry 2005). For the
PREDIMED trial data on lipids were reported for two study sites
rather than all 11 sites, but these were not the two sites where
methodological issues arose. There was moderate-quality evidence
that the Mediterranean diet produced a possible small reduction
in triglyceride levels (MD -0.09 mmol/L, 95% CI -0.16 to -0.01,
I² = 15%) (Analysis 2.12).
Four further trials measured triglyceride levels but did not provide
data in a useable format for meta-analyses. In a study of Mediter-
ranean diet versus low-fat diet in heart and lung transplant recipi-
ents, the serum triglycerides levels declined in both groups over 12
months: Mediterranean diet −0.17 mmol/L (mean −9%, 95%
CI -20 to 4); low-fat diet−0.44 mmol/L (mean−21%, 95% CI -
33 to−7) (Entwistle 2018). In a preliminary report of a trial com-
paring the Mediterranean diet and a low-fat diet in patients with
NAFLD to reduce CVD risk, significant within-group improve-
ments were seen for serum triglycerides in the Mediterranean diet
group but not the low-fat diet group (P < 0.05) (Properzi 2018).
Preliminary results from the CARDIOVEG study comparing the
effects of a Mediterranean diet and vegetarian diet on CVD risk
factors found a significant reduction in triglycerides (-8.9%) only
after the Mediterranean period (Dinu 2017). Another study in
patients with NAFLD reported lipid levels at baseline and follow-
up as normal or altered rather than actual values and variance. The
authors found lower levels of triglycerides in both the intervention
and control groups after six months (Misciagna 2017).
3. Mediterranean dietary intervention versus usual care for
secondary prevention
Two trials (441 participants randomised) measured triglyceride
levels and provided data that could be pooled in a meta-analysis
(Michalsen 2006; The Lyon Diet Heart Study). There was low-
quality evidence that the Mediterranean diet produced little or no
effect on triglyceride levels (MD -0.14 mmol/L, 95% CI -0.38 to
0.10, I² = 0%) (Analysis 3.7).
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
Three studies reported triglyceride levels for this comparison group
with data in a useable format for meta-analyses (Singh 1992;
Singh 2002; Tuttle 2008). Two of the studies have been excluded
in sensitivity analyses from all main analyses due to published
concerns regarding the reliability of the data (Singh 1992; Singh
2002). For all analyses for comparison 4, forest plots are provided
including and excluding these two studies, andwe report in the text
the results of the sensitivity analyses excluding these studies. In the
remaining study, Tuttle 2008, there was very low-quality evidence
of little or no effect of theMediterranean diet on triglyceride levels
(MD 0.46 mmol/L, 95% CI -0.24 to 1.16) (Analysis 4.21).
Blood pressure
1. Mediterranean dietary intervention versus no intervention
or minimal intervention for primary prevention
Two trials (269 participants randomised) measured systolic blood
pressure and reported data that could be used in meta-analyses (
Davis 2017; Esposito 2004). There wasmoderate-quality evidence
of a reduction in systolic blood pressure with the intervention
(MD -2.99 mmHg, 95% CI -3.45 to -2.53, I² = 0%) (Analysis
1.5).
One trial measured systolic blood pressure but did not provide
data in a useable format for meta-analyses (Chasapidou 2014).
Preliminary analysis of an ongoing study reported a change in sys-
tolic blood pressure of 2.6 mmHg between baseline and follow-
up of six months in 181 patients with metabolic disease follow-
ing Mediterranean dietary advice, with a difference between the
intervention and control group who received no advice of -5.1%
(P < 0.05) (Chasapidou 2014).
Two trials (269 participants randomised) measured diastolic blood
pressure and reported data that could be used in meta-analyses (
Davis 2017; Esposito 2004). There wasmoderate-quality evidence
of a reduction in diastolic blood pressure with the intervention
(MD -2.0mmHg, 95%CI -2.29 to -1.71, I² = 0%) (Analysis 1.6).
2. Mediterranean dietary intervention versus another dietary
intervention for primary prevention
Four trials (448 participants randomised) measured systolic blood
pressure and provided data that could be pooled in a meta-analysis
(Athyros 2011; Bajerska 2018; Stradling 2018; Vincent-Baudry
2005). For the PREDIMED trial, blood pressure was analysed
in multivariate analyses and these are reported separately below.
There was low-quality evidence that the Mediterranean diet had
little or no effect on systolic blood pressure levels (MD -1.5
mmHg, 95% CI -3.92 to 0.92, I² = 16%) (Analysis 2.13).
Four trials (448participants randomised)measured diastolic blood
pressure and provided data that could be pooled in a meta-analysis
(Athyros 2011; Bajerska 2018; Stradling 2018; Vincent-Baudry
2005). For the PREDIMED trial, blood pressure was analysed
in multivariate analyses and these are reported separately below.
There was low-quality evidence that the Mediterranean diet had
little or no effect on diastolic blood pressure levels (MD -0.26
mmHg, 95% CI -2.41 to 1.9, I² = 37%) (Analysis 2.14).
The PREDIMED study used multivariate adjusted analyses con-
trolling for centre, age, sex and diabetes, baseline blood pressure
and antihypertensive drugs. Mean differences in systolic blood
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pressure changes (mmHg) in the two intervention groups versus
the control group after a median follow-up of 3.8 years were 0.39
(-0.48 to 1.26) for PREDIMED + extra virgin olive oil (EVOO)
versus control (P=0.38) and - 0.72 (-1.58 to 0.13) for PRED-
IMED + nuts versus control (P = 0.10). Mean differences in di-
astolic blood pressure changes (mmHg) in the two intervention
groups versus the control group after a median follow-up of 3.8
years were -1.53 (-2.01 to -1.04) for PREDIMED + EVOO versus
control (P < 0.001) and -0.65 (-1.15 to -0.15) for PREDIMED +
nuts versus control (P = 0.01).
3. Mediterranean dietary intervention versus usual care for
secondary prevention
One trial (556 participants randomised) measured blood pressure
(The LyonDietHeart Study). There was very low-quality evidence
that the Mediterranean diet produced little or no effect on either
systolic (MD -2.00 mmHg, 95% CI -5.29 to 1.29) (Analysis 3.8)
or diastolic blood pressure (MD -1.00 mmHg, 95% CI -4.29 to
2.29) (Analysis 3.9).
4. Mediterranean dietary intervention versus another dietary
intervention for secondary prevention
Four studies report blood pressure for this comparison group with
data in a useable format for meta-analyses (Singh 1992; Singh
2002; Tuttle 2008; Weber 2012). Two of the studies have been
excluded in sensitivity analyses from all main analyses due to pub-
lished concerns regarding the reliability of the data (Singh 1992;
Singh 2002). For all analyses for comparison 4, forest plots are
provided including and excluding these two studies, and we report
in the text the results of the sensitivity analyses excluding these
studies. In the remaining two studies, Tuttle 2008 and Weber
2012, there was very low-quality evidence of little or no effect
of the Mediterranean diet on systolic blood pressure levels (MD
1.76 mmHg, 95% CI -2.80 to 6.33, I² = 0%) (Analysis 4.23) or
diastolic blood pressure levels (MD 0.98 mmHg, 95% CI -1.97
to 3.93, I² = 0%) (Analysis 4.25).
In a further study and preliminary analysis of the AUSMED trial
the authors report that compared to the low-fat diet, the MedDiet
did not change the blood pressure profile (P > 0.05) (Mayr 2018).
The variables were not measured in a later analysis of the full
cohort.
Type 2 diabetes
One study,which examined the effect of theMediterraneandietary
pattern for primary prevention, reported on incident diabetes (
PREDIMED).
The PREDIMED trial reports on incident diabetes over 4.8 years
of follow-up in an earlier publication (Salas-Salvado 2014), before
the re-analysis of themainpaper (Estruch2018).However, a recent
report states that data for the incidence of type 2 diabetes has
been re-analysed to take account of the clustering and shows very
similar estimates to the original analysis (Anonymous 2018). The
PREDIMED intervention is described as a Mediterranean diet
supplemented with extra-virgin olive oil or tree nuts compared
to a low-fat diet control group. The authors found a statistically
significant reduction in the incidence of type 2 diabetes with the
PREDIMED intervention (HR 0.71, 95% CI 0.52 to 0.96).
Health-related quality of life, adverse effects or costs
None of the trials in any of the four main comparison groups
reported on health-related quality of life or costs.
Adverse effects were reported in only two trials where no adverse
events were noted for either dietary intervention in the PRED-
IMED trial (Ros 2014), and two of 302 CHD patients noted
margarine-related side effects of colitis and diarrhoea in The Lyon
Diet Heart Study.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Mediterranean dietary intervention compared to another dietary intervention for the primary of cardiovascular disease
Patient or population: adults without cardiovascular disease
Setting: community
Intervention: Mediterranean dietary intervent ion
Comparison: another dietary intervent ion
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with another di-
etary intervention
Risk with Mediter-
ranean dietary inter-
vention
CVD mortality
Follow-up: mean 4.8
years
Study populat ion HR 0.81
(0.50 to 1.32)
7447
(1 RCT)
⊕⊕©©
LOW 12
-
12 per 1000 10 per 1000
(6 to 16)
Total mortality
Follow-up: mean 4.8
years
Study populat ion HR 1.00
(0.81 to 1.24)
7447
(1 RCT)
⊕⊕©©
LOW 12
-
47 per 1000 47 per 1000
(38 to 57)
Myocardial infarct ion
Follow-up: mean 4.8
years
Study populat ion HR 0.79
(0.57 to 1.10)
7447
(1 RCT)
⊕⊕©©
LOW 12
-
16 per 1000 12 per 1000
(9 to 17)
Stroke
Follow-up: mean 4.8
years
Study populat ion HR 0.60
(0.45 to 0.80)
7447
(1 RCT)
⊕⊕⊕©
MODERATE 2
-
24 per 1000 14 per 1000
(11 to 19)
Peripheral arterial dis-
ease
Study populat ion HR 0.42
(0.28 to 0.61)
7447
(1 RCT)
⊕⊕⊕©
MODERATE 2
-
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18 per 1000 8 per 1000
(5 to 11)
Total cholesterol
(mmol/ L), change f rom
baseline
Follow-up: range 3
months to 4.8 years
The mean total choles-
terol change f rom base-
line was -0.29 to 0.51
mmol/ L
MD 0.13 mmol/ L lower
(0.3 lower to 0.04
higher)
- 939
(7 RCTs)
⊕⊕©©
LOW 34
-
LDL cholesterol (mmol/
L), change f rom base-
line
Follow-up: range 3
months to 4.8 years
The mean LDL choles-
terol change f rom base-
line ranged f rom -0.18
to 0.27 mmol/ L
MD 0.15 mmol/ L lower
(0.27 lower to 0.02
lower)
- 947
(7 RCTs)
⊕⊕⊕©
MODERATE 3
-
HDL cholesterol
(mmol/ L), change f rom
baseline
Follow-up: range 3
months to 4.8 years
The mean HDL choles-
terol change f rom base-
line ranged f rom -0.02
to 0.16 mmol/ L
MD 0.02 mmol/ L higher
(0.01 lower to 0.04
higher)
- 891
(6 RCTs)
⊕⊕⊕©
MODERATE 3
-
Triglycerides (mmol/ L),
change f rom baseline
Follow-up: range 3
months to 4.8 years
The mean triglycerides
change f rom baseline
ranged f rom -0.44 to 1.
32 mmol/ L
MD 0.09 mmol/ L lower
(0.16 lower to 0.01
lower)
- 939
(7 RCTs)
⊕⊕⊕©
MODERATE 3
-
Systolic blood pressure
(mmHg), change f rom
baseline
Follow-up: range 3
months to 12 months
The mean systolic
blood pressure change
f rom baseline ranged
f rom -10.4 to 6.9 mmHg
MD 1.5 mmHg lower
(3.92 lower to 0.92
higher)
- 448
(4 RCTs)
⊕⊕©©
LOW 13
-
Diastolic blood pres-
sure (mmHg), change
f rom baseline
Follow-up: range 3
months to 12 months
The mean diastolic
blood pressure change
f rom baseline ranged
f rom -8.1 to 5.3 mmHg
MD 0.26 mmHg lower
(2.41 lower to 1.9
higher)
- 448
(4 RCTs)
⊕⊕©©
LOW 13
-
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Adverse events Adverse ef fects were reported by only one RCT -
no adverse events were noted for either dietary
intervent ion in the PREDIMED trial
- 7447
(1 RCT)
⊕⊕⊕©
MODERATE 2
-
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; CVD: cardiovascular disease; HDL: high-density lipoprotein;HR: hazard rat io; LDL: low-density lipoprotein; MD: mean dif ference; RCT: randomised
controlled trial
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by one level for imprecision. Conf idence interval is wide enough to include both an important increase or
decrease in the outcome.
2Downgraded by one level for risk of bias. The only included study was the PREDIMED trial, which was retracted due to
methodological issues with randomisat ion, re-analysed and republished.
3Downgraded by one level for risk of bias. Majority of studies are at unclear risk of select ion bias, attrit ion bias, or both.
4Downgraded by one level for inconsistency. High I2 and forest plots shows dif ferent direct ions of ef fect.
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Mediterranean dietary intervention compared to usual care for secondary prevention of cardiovascular disease
Patient or population: adults with established cardiovascular disease
Setting: community
Intervention: Mediterranean dietary intervent ion
Comparison: usual care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with usual care Risk with Mediter-
ranean dietary inter-
vention
CVD mortality
Follow-up: mean 46
months
Study populat ion RR 0.35
(0.15 to 0.82)
605
(1 RCT)
⊕⊕©©
LOW 1
-
63 per 1000 22 per 1000
(9 to 51)
Total mortality
Follow-up: mean 4
years
Study populat ion RR 0.44
(0.21 to 0.92)
605
(1 RCT)
⊕⊕©©
LOW 1
-
79 per 1000 35 per 1000
(17 to 73)
Total cholesterol
(mmol/ L), change f rom
baseline
Follow-up: range 1 year
to 4 years
The mean total choles-
terol change f rom base-
line ranged f rom -0.22
to -0.31 mmol/ L
MD 0.07 mmol/ L higher
(0.19 lower to 0.33
higher)
- 441
(2 RCTs)
⊕⊕©©
LOW 2
-
LDL cholesterol (mmol/
L), change f rom base-
line
Follow-up: range 1 year
to 4 years
The mean LDL choles-
terol change f rom base-
line ranged f rom -0.26
to -0.41
MD 0.11 higher
(0.09 lower to 0.31
higher)
- 441
(2 RCTs)
⊕⊕©©
LOW 2
-
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HDL cholesterol
(mmol/ L), change f rom
baseline
Follow-up: range 1 year
to 4 years
The mean HDL choles-
terol change f rom base-
line ranged f rom 0 to 0.
15 mmol/ L
MD 0.01 mmol/ L lower
(0.08 lower to 0.07
higher)
- 441
(2 RCTs)
⊕⊕©©
LOW 2
-
Triglycerides (mmol/ L),
change f rom baseline
Follow-up: range 1 year
to 4 years
The mean triglycerides
change f rom baseline
ranged f rom -0.02 to -0.
08 mmol/ L
MD 0.14 mmol/ L lower
(0.38 lower to 0.1
higher)
- 441
(2 RCTs)
⊕⊕©©
LOW 2
-
Systolic blood pressure
(mmHg), change f rom
baseline
Follow-up: 4 years
The mean systolic
blood pressure change
f rom baseline was 9
mmHg
MD 2 mmHg lower
(5.29 lower to 1.29
higher)
- 339
(1 RCT)
⊕©©©
VERY LOW 13
-
Diastolic blood pres-
sure (mmHg), change
f rom baseline
Follow-up: 4 years
The mean diastolic
blood pressure change
f rom baseline was 5
mmHg
MD 1 mmHg lower
(4.29 lower to 2.29
higher)
- 339
(1 RCT)
⊕©©©
VERY LOW 14
-
Adverse events Adverse ef fects were reported in only one RCT.
Two of 302 CHD patients noted margarine-related
side ef fects of colit is and diarrhoea in The Lyon
Diet Heart Study
- 605
(1 RCT)
⊕⊕©©
LOW 1
-
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; CVD: cardiovascular disease; HDL: high-density lipoprotein;LDL: low-density lipoprotein; MD: mean dif ference; RCT: randomised controlled trial; RR:
risk rat io
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect27
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Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by two levels for risk of bias. The only included study had an unclear randomisat ion method and the modif ied
Zelen design may have introduced other biases, although the study was at low risk of bias for allocat ion concealment and
attrit ion.
2Downgraded by two levels for risk of bias as both included studies were at unclear risk of select ion bias or attrit ion bias, or
both, and the majority weight in the meta-analysis was for the study with a modif ied Zelen design.
3Downgraded by one level for imprecision due to small number of part icipants (N < 400).
4Downgraded by two levels for imprecision due to small number of part icipants and wide CI that includes both important
increases and decreases in the outcome.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Mediterranean dietary intervention compared to another dietary intervention for the secondary prevention of cardiovascular disease
Patient or population: adults with established cardiovascular disease
Setting: community
Intervention: Mediterranean dietary intervent ion
Comparison: another dietary intervent ion
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with another di-
etary intervention
Risk with Mediter-
ranean dietary inter-
vention
Total cardiac endpoints
(all-cause and cardiac
deaths, myocardial in-
farct ion, hospital ad-
missions for heart fail-
ure, unstable angina or
stroke, unadjusted)
Follow-up: 2 years
Study populat ion RR 0.98
(0.40 to 2.41)
101
(1 RCT)
⊕©©©
VERY LOW 12
Total cardiac endpoints
was used instead of the
2 individual outcomes
cardiovascular mortal-
ity and total mortality
because this was the
format used in the only
trial report ing this
160 per 1000 157 per 1000
(64 to 386)
To-
tal cholesterol (mmol/
L), change f rom base-
line (sensit ivity analy-
sis without Singh stud-
ies)
See comment See comment - (0 RCTs) - None of the included
studies measured this
outcome when Singh
studies were removed
in sensit ivity analyses
LDL cholesterol (mmol/
L), change f rom base-
line (sensit ivity analy-
sis without Singh stud-
ies)
Follow-up: 2 years
The mean LDL choles-
terol change f rom base-
line was 0.13 mmol/ L
MD 0.08 mmol/ L higher
(0.26 lower to 0.42
higher)
- 71
(1 RCT)
⊕©©©
VERY LOW 12
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HDL choles-
terol (mmol/ L), change
f rom baseline (sensi-
t ivity analysis without
Singh studies)
Follow-up: 2 years
The mean HDL choles-
terol change f rom base-
line was 0.10 mmol/ L
MD 0.05 mmol/ L lower
(0.17 lower to 0.06
higher)
- 71
(1 RCT)
⊕⊕©©
LOW 13
-
Triglycerides (mmol/ L)
, change f rom base-
line (sensit ivity analy-
sis without Singh stud-
ies)
Follow-up: 2 years
The mean triglycerides
change f rom baseline
was -0.63 mmol/ L
MD 0.46 mmol/ L higher
(0.24 lower to 1.16
higher)
- 71
(1 RCT)
⊕©©©
VERY LOW 12
-
Systolic blood pres-
sure (mmHg), change
f rom baseline (sensi-
t ivity analysis without
Singh studies)
Follow-up range: 12
weeks to 2 years
The mean systolic
blood pressure change
f rom baseline ranged
f rom 4 to -9.33 mmHg
MD 1.76 mmHg higher
(2.8 lower to 6.33
higher)
- 150
(2 RCTs)
⊕©©©
VERY LOW 24
-
Diastolic blood pres-
sure (mmHg), change
f rom baseline (sensi-
t ivity analysis without
Singh studies)
Follow-up range: 12
weeks to 2 years
The mean diastolic
blood pressure change
f rom baseline ranged
f rom 1 to -9.23 mmHg
MD 0.98 mmHg higher
(1.97 lower to 3.93
higher)
- 150
(2 RCTs)
⊕©©©
VERY LOW 24
-
Adverse events - - - - - Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; HDL: high-density lipoprotein;LDL: low-density lipoprotein; MD: mean dif ference; RCT: randomised controlled trial; RR: risk rat io
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GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by one level for risk of bias. Only included study had unclear random sequence generat ion and unclear attrit ion.
2Downgraded by two levels for imprecision due to small sample size and wide conf idence interval that crosses the null.
3Downgraded by one level for imprecision due to small sample size. Although CI includes the null, it is reasonably narrow.
4Downgraded by one level for risk of bias. Both studies had unclear randomisat ion method, although allocat ion was concealed.
One study was at low risk of attrit ion bias, the other at unclear risk of attrit ion bias.
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D I S C U S S I O N
The aim of this review was to evaluate the effectiveness of dietary
advice to follow a Mediterranean-style diet or the provision of
foods relevant to the Mediterranean diet for both the primary and
secondary prevention of CVD. As well as clinical endpoints, we
also examined the effects of a Mediterranean-style diet on major
cardiovascular risk factors including blood lipids, blood pressure
and occurrence of type 2 diabetes in both participants with and
without established CVD.
Summary of main results
In this substantive review update, 30 RCTs (49 papers) and seven
ongoing trials met our inclusion criteria. Four pre-specified com-
parison groups were used to analyse the data to address both het-
erogeneity between participants and comparison groups and aid
interpretation of findings. The comparison groups and number of
trials and participants contributing to each are presented below:
1. Comparison 1: Mediterranean dietary intervention versus
no intervention or minimal intervention for primary prevention,
nine trials (1337 participants randomised).
2. Comparison 2: Mediterranean dietary intervention versus
another dietary intervention for primary prevention, 13 trials
(8687 participants randomised, 7747 of whom were from the
PREDIMED trial).
3. Comparison 3: Mediterranean dietary intervention versus
usual care for secondary prevention, two trials (706 participants
randomised).
4. Comparison 4: Mediterranean dietary intervention versus
another dietary intervention for secondary prevention, six trials
(1731 participants randomised, 1406 of whom contributed to
two trials excluded in sensitivity analyses from the main analyses
due to published concerns regarding the reliability of the data)
(Singh 1992; Singh 2002).
Clinical endpoints were measured in only one large primary pre-
vention trial (PREDIMED), and a small trial reporting unadjusted
estimates for stroke in hypertensive patients (Lapetra 2018). The
PREDIMED trial contributed to comparison 2 examining dietary
advice to follow a Mediterranean dietary pattern plus supplemen-
tal extra-virgin olive oil or tree nuts compared to a low-fat diet
for primary prevention of CVD. The trial was conducted in Spain
and randomised 7747 men and women at increased risk of CVD
and observed them over 4.8 years of follow-up. The original re-
port of the PREDIMED trial, Estruch 2013, was retracted and
re-analysed when methodological issues came to light. The recent
publication adjusts for these and the re-analysed data are reported
here (Estruch 2018). The PREDIMED intervention compared to
a low-fat diet shows an effect on composite clinical endpoints (HR
0.70, 95% CI 0.58 to 0.85). The re-analysed paper also reports
clinical endpoints separately where there was low-quality evidence
of little or no effect of the PREDIMED intervention compared
to a low-fat diet on total mortality, CVD mortality or myocardial
infarction, but moderate-quality evidence of a reduction in the
number of strokes was seen with the intervention (HR 0.60, 95%
CI 0.45 to 0.80). Reductions in the numbers of participants expe-
riencing PAD were also observed with the PREDIMED interven-
tion (HR 0.42, 95% CI 0.28 to 0.61, moderate-quality evidence),
but these data are less certain as they were not re-analysed in the
recent paper (Estruch 2018), but come from earlier reports of the
trial.
Clinical endpoints were measured in secondary prevention trials
contributing to comparisons 3 and 4. One trial contributed to
comparison 3 (The Lyon Diet Heart Study). The LyonDiet Heart
Study examined the effect of advice to follow aMediterranean diet
plus supplemental canolamargarine compared to usual care in 605
CHD patients over 46 months and found reductions in adjusted
estimates for a composite endpoint of CVD deaths and non-fatal
myocardial infarction (HR 0.28, 95% CI 0.15 to 0.52), CVD
mortality (HR 0.35, 95% CI 0.15 to 0.82, low-quality evidence)
and total mortality (HR 0.44, 95% CI 0.21 to 0.92, moderate-
quality evidence) with the intervention (The Lyon Diet Heart
Study). For comparison 4, three studies report clinical endpoints
(Singh 1992; Singh 2002; Tuttle 2008). Two of these have been
excluded in sensitivity analyses from all main analyses due to pub-
lished concerns regarding the reliability of the data (Singh 1992;
Singh 2002).One small study from theUS in 101 post myocardial
infarction patients, following aMediterranean diet or low-fat diet,
provided unadjusted estimates for total cardiac endpoints, with
very low-quality evidence showing considerable uncertainly of the
effect size. Two further ongoing trials will report clinical endpoints
in CHD patients randomised to the Mediterranean dietary inter-
vention compared to other dietary interventions (Delgado-Lista
2016; Itsiopoulos 2018), which will add to the evidence base.
CVD risk factors including lipid levels and blood pressure were
reported in all four comparison groups. For comparison 1 there
was low-quality evidence for a possible small reduction in total
cholesterol (-0.16 mmol/L, 95% CI -0.32 to 0.00) and moderate-
quality evidence for a reduction in systolic (-2.99 mmHg, 95%CI
-3.45 to -2.53) and diastolic blood pressure (-2.0 mmHg, 95%CI
-2.29 to -1.71), with low or very low-quality evidence of little or no
effect of the intervention on LDL or HDL cholesterol or triglyc-
erides. For comparison 2 there was moderate-quality evidence of a
possible small reduction in LDL cholesterol (-0.15 mmol/L, 95%
CI -0.27 to -0.02) and triglycerides (-0.09 mmol/L, 95% CI -
0.16 to -0.01) with moderate or low-quality evidence of little or
no effect of the intervention on total or HDL cholesterol or blood
pressure. For comparison 3 there was low-quality evidence of little
or no effect of theMediterranean diet on lipid levels and very low-
quality evidence for little or no effect on blood pressure. Similarly,
for comparison 4 where only two trials contributed to the analyses
there was low or very low-quality evidence of little or no effect of
the intervention on lipid levels or blood pressure.
The largest trial reported on the incidence of type 2 diabetes in
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primary prevention (PREDIMED), where there was a reduction
in the incidence with the PREDIMED intervention (HR 0.71,
95%CI 0.52 to 0.96). Two trials reported on adverse events where
these were absent (Ros 2014) or minor (The Lyon Diet Heart
Study). No trials reported on health-related quality of life or costs.
Overall completeness and applicability of
evidence
In this substantive update we broadened the inclusion criteria of
the original review, which focused only on primary prevention and
no/minimal interventions as comparison groups to the Mediter-
ranean-style diet (New Reference). The expansion in scope was
designed to make the review of relevance to secondary prevention
but also allow comparisons of the Mediterranean diet with other
dietary patterns for cardiovascular health.We have also refined our
definition of the core components of a Mediterranean-style diet
based on extensive review and recent reports of the most likely
active components (Grosso 2017; Martínez-González 2017, see
Types of interventions).We have stratified our analyses by primary
and secondary prevention and by comparison group in an attempt
to address heterogeneity and aid interpretation of findings to make
the review as useful as possible.
There are now a larger number of included trials (30 trials, 12,461
participants randomised), but few report on clinical endpoints,
our primary outcome, and the majority of trials report on CVD
risk factors for primary prevention.
Definitions of the Mediterranean diet differed but all comprised
at least the two core components of a high monounsaturated/sat-
urated fat ratio (use of olive oil as main cooking ingredient and/
or consumption of other traditional foods high in monounsatu-
rated fats such as tree nuts) and high intake of plant-based foods,
including fruits, vegetables and legumes.
Similarly, the dietary comparison groups differed across trials. The
majority of comparison diets were, however, low-fat diets or car-
diac health guidance with notable exceptions of vegetarian diets.
We have not explored the effect of different dietary comparison
groups formally due to an insufficient number of studies to do so.
As noted above there were limited data on clinical endpoints,
our primary outcome. Two studies were excluded from all main
analyses in sensitivity analyses due to published concerns regard-
ing the reliability of the data (Singh 1992; Singh 2002). Only
one trial reported clinical endpoints for primary prevention and
this study experienced methodological issues regarding randomi-
sation with the report subsequently being retracted and re-anal-
ysed (PREDIMED). The findings in secondary prevention are
based on one older trial reporting very large effect estimates using
a modified Zelen design (The Lyon Diet Heart Study). In addi-
tion, both the PREDIMED trial and The Lyon Diet Heart Study
supplied supplemental foods as well as dietary advice to follow a
Mediterranean-style diet so the policy implications of the findings
of these trials are unclear (Appel 2013).
The number of trials reporting primary and secondary outcomes
for secondary prevention was limited, however a number of on-
going trials are exploring the effects of the Mediterranean diet on
clinical endpoints in patients with CVD so these will add to the
evidence base. No effects were seen on CVD risk factors in the
limited number of trials reporting these, but this may be due to
optimal pharmacological treatment where further improvements
in lipid levels and blood pressure may be unlikely, particularly in
more recent trials. We have not explored the effects of medication
on outcomes in secondary prevention due to the low number of
included studies, or in those at high risk in primary prevention,
but we will explore this in future updates.
Adherence to dietary patterns both in the intervention and com-
parison groups will have an impact on their effectiveness. We did
not measure adherence or compliance to the dietary interventions
in this review. Other systematic reviews have shown that a greater
adherence to a Mediterranean-style diet is associated with a signif-
icant improvement in health status and a significant reduction in
overall mortality, as well as in morbidity and mortality from CVD
and othermajor chronic diseases (Sofi 2008; Sofi 2010). In ameta-
analysis of prospective cohort studies, a two-point increase (scale
from 0 to 7-9 points) in adherence to a Mediterranean dietary
pattern was associated with an 8% reduction in all-cause mortality
and a 10% reduction in CVD incidence or mortality (Sofi 2010).
The duration of the intervention and follow-up periods varied
widely across studies, ranging from short-term trials (three to six
months) to long-term interventions (up to five years). Both short-
and long-term health effects of dietary interventions are plausi-
ble in terms of cardiovascular health, given the relatively quick
response of cardiovascular risk factors such as blood lipids and
blood pressure to lifestyle and dietary modifications (AHA 2006;
Appel 1997; Appel 2001; Appel 2006). However, it is likely that
potential beneficial effects of dietary interventions for the preven-
tion of major chronic disease endpoints, such as mortality, CVD
and type 2 diabetes, should represent the outcome of a long-term
process linked to the interplay of dietary patterns with genetic and
environmental factors. In addition, the sustainability of long-term
lifestyle and dietary modifications is challenging. Therefore, the
public health relevance of trials with extremely short-term dietary
interventions or follow-up periods in this context is questionable.
Quality of the evidence
Due to the breadth of the review question, heterogeneity in terms
of participants, interventions and comparators was high and we
have attempted to reduce this by conducting the main analyses
in four comparison groups for primary and secondary prevention
and different comparators, and also explored the heterogeneity of
the interventions in subgroup analyses.
The majority of studies included in this review were at unclear risk
of bias for many of the risk of bias domains so results should be
interpreted cautiously. We noted high risk of bias for differential
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attrition rates between the intervention and control groups in two
trials (Djuric 2009; Vincent-Baudry 2005), and high risk of other
bias in two trials where there are published concerns regarding
the reliability of the data (Singh 1992; Singh 2002). These two
studies have been excluded from the main analyses and GRADE
assessment. The ’Summary of findings’ tables provide GRADE
assessment of overall study quality for each of the four comparison
groups:
For comparison 1, GRADE assessment of the outcomes has led
to trials being downgraded for unclear risk of selection bias or
attrition bias for the majority of studies, inconsistency due to high
heterogeneity where studies were not pooled and imprecision due
to low sample size.
For comparison 2, GRADE assessment of the outcomes has led to
trials being downgraded for unclear risk of selection bias or attri-
tion bias for themajority of studies, imprecision where a wide con-
fidence interval includes both an important increase or decrease in
the outcome, and inconsistency where forest plots show different
levels of effect. The PREDIMED study has been downgraded for
methodological issues regarding randomisation and retraction of
the original report, which was then subsequently re-analysed and
republished.
For comparison 3, GRADE assessment of the outcomes has led
to trials being downgraded for unclear risk of selection bias or
attrition bias or both, and imprecision due to low sample size and
wide confidence intervals that include both an important increase
or decrease in the outcome. The Lyon Diet Heart Study has been
downgraded for having an unclear randomisation method and use
of the modified Zelen method, which may have introduced other
biases.
For comparison 4, GRADE assessment of the outcomes has led
to trials being downgraded for having an unclear method of ran-
domisation and attrition and imprecision.
Potential biases in the review process
We conducted a comprehensive search across major databases for
interventions involving the Mediterranean diet. Two review au-
thors independently selected and assessed trials for inclusion us-
ing pre-specified criteria, extracted data and assessed the quality
of trials to minimise potential biases in the review processes.
There was a high degree of heterogeneity between trials from dif-
ferent sources (participants, nature and duration of intervention,
comparison groups, follow-up, outcome data), which precluded
statistical pooling for some outcomes. We pre-specified four main
comparison groups for analysis to address the likely heterogene-
ity that we would encounter by broadening out the scope of the
review, by primary and secondary prevention and by comparison
groups.
Not all data from all studies were reported in a useable format
to contribute to meta-analyses. We have attempted to contact au-
thors where possible to obtain these data andmany report prelimi-
nary findings in conference proceedings. Data have been reported
narratively where we were unable to pool these.
We took the decision to exclude two trials from the main analyses
and GRADE assessment where concerns have been publicly raised
about the integrity and reliability of the data (Singh 1992; Singh
2002). These two trials reported on 1406 participants and report
clinical endpoints and CVD risk factors relevant to secondary pre-
vention (Comparison 4) so their exclusion limited the findings.
The PREDIMED trial was retracted due to methodological issues
concerning randomisation for two of the 11 study sites, and the in-
clusion of non-randomised second household members, but these
data have been re-analysed adjusting for these and republished.
The new publication has conducted a series of sensitivity analyses
excluding these sites where they have found similar results for clin-
ical endpoints (Estruch 2018). The new publication reports on the
composite clinical outcome, CVD and total mortality, myocardial
infarction and stroke. Other reports of PREDIMED have been
used for CVD risk factors and PAD, which were not reported in
the new publication (Estruch 2018), and therefore have not been
adjusted.
Our decision to restrict this review to interventions that only fo-
cused on the effectiveness of a Mediterranean-style diet per se
avoided the potential confounding effects of other behavioural
interventions on our outcomes, for example, those involving in-
creased exercise or weight loss in the context of multifactorial tri-
als. Our decision to exclude trials in people with diabetes who
are at increased risk for CVD also missed relevant studies, but
interventions for the management of diabetes are covered by the
Cochrane Metabolic and Endocrine Disorders Group and are not
within the remit of the Cochrane Heart Group.
The definition of the Mediterranean dietary pattern is not ho-
mogeneous, and may vary across different geographical and cul-
tural contexts (Helsing 1989; Nestle 1995; Serra-Majem 1993;
Serra-Majem 2006; Willett 1995). Our choice to use a classifi-
cation system rather than include only those studies describing
the intervention as a Mediterranean diet attempted to address this
heterogeneity, and given sufficient studies would allow further
exploration of active components. The components required to
meet our definition of a Mediterranean dietary pattern were based
on previous definitions (Helsing 1989; Nestle 1995; Serra-Majem
1993; Serra-Majem 2006; Willett 1995), and required at least the
following two core components: high monounsaturated/saturated
fat ratio (use of olive oil as main cooking ingredient and/or con-
sumption of other traditional foods high in monounsaturated fats
such as tree nuts) and high intake of plant-based foods, including
fruits, vegetables and legumes. The rationale for this definition is
based on recent work (Grosso 2017; Martínez-González 2017),
which emphasises that the protective effects of the diet appear to
be most attributable to olive oil, fruits, vegetables and legumes.
Agreements and disagreements with other
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studies or reviews
Several recent systematic reviews and overviews of reviews have
reported on the effects of theMediterranean diet on cardiovascular
health.
A recent narrative overview of both prospective observational stud-
ies and RCTs concludes that the Mediterranean diet has some
beneficial effects for CVD prevention but the effects are inconsis-
tent between studies with few studies reported in meta-analyses
and calls for more high-quality trials to address the inconsisten-
cies (Salas-Salvado 2018). This is in line with the findings of the
current review reporting on RCT evidence. An umbrella review
of systematic reviews reports on 13 meta-analyses of observational
studies and 16meta-analyses of RCTs investigating the association
between the adherence to theMediterranean diet and a number of
different health outcomes (Dinu 2018). The authors found robust
evidence for a greater adherence to the Mediterranean diet and a
reduced risk of overall mortality, cardiovascular diseases, coronary
heart disease, myocardial infarction and diabetes with no evidence
for LDL cholesterol levels. Adherence to the Mediterranean diet
was not specifically measured in the current review, which has
been recorded as a potential limitation. With further updates of
this review we will consider exploring the effect of adherence on
outcomes.
A recent systematic review included both primary and secondary
prevention trials and pooled clinical endpoints for these (Liyanage
2016). The trial selection differed from the current review within
the search period for both, in that we excluded trials in type 2
diabetes (Toobert 2003), and did not report on total mortality in a
trial of HIV patients where deaths were associated with AIDS-re-
lated complications (Ng 2011). Sensitivity analyses were similarly
conducted excluding a study with unreliable data (Singh 2002). A
further trial that met our inclusion criteria reporting clinical end-
points was also excluded from their analyses (Tuttle 2008), as well
as another trial with unreliable data (Singh 1992). Pooling their
studies for primary and secondary prevention showed beneficial
effects formajor vascular events (risk ratio (RR) 0.69, 95%CI 0.55
to 0.86) and stroke (RR 0.66, 95% CI 0.48 to 0.92) (Liyanage
2016).
A systematic review comparing the effects of a Mediterranean diet
with low-fat diets on CVD risk factors in those at high risk or
with established disease found favourable but modest effects of the
Mediterranean diet on a wide range of cardiovascular risk factors
and inflammatory markers, such as body weight, systolic and dias-
tolic blood pressure, fasting plasma glucose, total cholesterol and
high-sensitivity C-reactive protein (Nordmann 2011). Other sys-
tematic reviews have pooled together the evidence from both ob-
servational studies and RCTs on the effects of the Mediterranean
dietary pattern on metabolic syndrome and individual cardiovas-
cular risk factors, supporting favourable effects of the Mediter-
ranean diet on cardio-metabolic risk factors (Buckland 2008;
Kastorini 2011). The results of the current review in RCTs show
inconsistencies between studies but wheremeta-analyses were pos-
sible there were small beneficial effects on some CVD risk factors
for primary prevention.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Despite the large number of trials included in the review there
is still uncertainty regarding the effects of a Mediterranean-style
diet on clinical endpoints and cardiovascular disease (CVD) risk
factors for both primary and secondary prevention from current
clinical trial evidence.However, based on supportive observational
evidence, positive findings from early clinical trials and the bio-
logical plausibility of several mechanisms to explain the beneficial
effect of the Mediterranean diet, it has become a popular dietary
pattern.
Indeed, some aspects and components of a Mediterranean-style
diet are already included in scientific and clinical guidelines to
promote healthy eating and prevent cardiovascular disease, such as
the DASH diet (AHA 2006; AHA/ASA 2011; Appel 2006; Locke
2018), the 2015 Dietary Guidelines for Americans, the Healthy
Eating Plate (Locke 2018), and the Eatwell guide (Public Health
England 2018).
Implications for research
There remains uncertainty regarding the effects of a Mediter-
ranean-style diet on clinical endpoints and CVD risk factors for
both primary and secondary prevention. Two trials reporting clin-
ical endpoints for secondary prevention were excluded because of
concerns regarding the reliability of the data, so the available evi-
dence is restricted to one large trial and a small trial reporting un-
adjusted estimates of effect. Several ongoing trials have been iden-
tified, particularly reporting clinical endpoints in secondary pre-
vention, which will add to the evidence base. Evidence for primary
prevention on clinical endpoints is limited to one large trial with
methodological issues (although these have now been addressed
in a recent re-analysis) and a small trial reporting unadjusted ef-
fects for stroke. Further adequately powered primary prevention
trials are needed to confirm findings on clinical endpoints to date.
Many trials reported on CVD risk factors, particularly in primary
prevention, but heterogeneity precluded meta-analyses for some
outcomes. With the accrual of further evidence, the heterogeneity
observed between trials in terms of both the nature and duration
of the intervention, the comparators and the range of participants
recruited can be explored further and its impact on outcomes ex-
amined.
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Athyros 2011
Methods RCT of parallel-group design
Participants 150 men and women with mild hypercholesterolaemia (5.2 to 6.4 mmol/L)
Patients with established CVD, diabetes, metabolic syndrome, those with chronic dis-
eases, malignancies, who are pregnant, on any drug treatment or unwilling to participate
were excluded
All patients had an initial 4-week run-in period where they were advised by trained
dieticians to follow a step 1 hypolipidaemic diet (NCEP). Patients were then randomly
assigned to 3 groups: plant stanol esters (2 g/day spread), a placebo spread and advice to
adhere to a Mediterranean diet
Only the Mediterranean diet and placebo spread groups were analysed in this review:
100 patients randomised; mean age 54.7 years; 49% men
Interventions Patients were encouraged by trained dieticians to adhere to a Mediterranean dietary pat-
tern with efforts to increase adherence and 7-day menu plans with food that incorporated
the salient characteristics of the Mediterranean diet
The placebo group continued with the hypolipidaemic diet throughout the 16-week
intervention period
Outcomes Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, SBP and DBP
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No reported loss to follow-up during the 16-week in-
tervention
Selective reporting (reporting bias) Low risk Reported all outcomes as stated
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Athyros 2011 (Continued)
Other bias Unclear risk Insufficient information to judge
Bajerska 2018
Methods RCT of parallel-group design
Participants 144 centrally obese postmenopausal women recruited in 2014 through advertisements
in Poland
Inclusion criteria: non-smoking, postmenopausal women (with absence of menses of
over 12 months or serum follicle-stimulating hormone > 30 IU/mL) with central obesity
(waist circumference; WC ≥ 80 cm), plus at least one other criterion of the metabolic
syndrome, who wished to lose weight
Exclusion criteria: women with type 2 diabetes; monogenic dyslipidaemia; a history
of cardiovascular disease; use of hypoglycaemic, hypolipidaemic, anti-inflammatory or
weight loss agents, as well as any drug known to influence liver function; with endocrine
disorders or on hormonal replacement therapy. The exclusion criteria also included
significant weight change in the 6 months prior to the current study, intolerance or food
allergy to key components of the intervention diets and excessive alcohol consumption
(> 2 drinks/day)
Mean age 60.5 years
Interventions The 2 supervised dietary intervention arms induced a caloric deficit of ~2.93 MJ/day,
based on individual energy requirements calculated from indirect calorimetry and phys-
ical activity (PA) adjustment
Mediterranean diet group (MED)
Followed a food plan designed on the basis of the Mediterranean dietary recommen-
dations released in 2010 by the Mediterranean Diet Foundation. To build this menu,
typical Mediterranean food products were used providing approximately 37% energy
from total fat, 20% from MUFAs, 9% from PUFAs, 8% from SFAs, 18% from protein
and 45% energy from carbohydrates. Olive oil was used in every meal and 5 to 7 nuts
were served once a day
Central European diet group (CED)
Based on the recommendations of the NCEP and the AHA, and was designed to provide
27% energy from total fat, 10% from MUFAs, 9% from PUFAs, 8% from SFAs, 18%
from protein and 55% energy from carbohydrate, with a special emphasis on high levels
of dietary fibre derived from food items typical of the central European region: cereals
(oatmeal and barley), pulses (peas and beans), vegetables (root vegetables, cruciferous
vegetables) and fruits (apples, plums)
The proportion of soluble to insoluble dietary fibre in the CED was 35% to 65%; in the
MED this was 20% to 80%. Added salt and refined fats, as well as sugar, were excluded
from both diets. 14-day cyclic dietary plans were formulated for both diets. During the
entire 16-week intervention period, study participants picked up packaged main meals
(covering ~35% daily energy requirements) prepared according to dietician’s recipes by
a catering company. Others meals were prepared by the study participants themselves,
according to the prescribed dietary plan, including recipes and written instructions to
facilitate preparation of meals at home. Throughout the intervention, volunteers were
advised to maintain their usual level of PA and keep other lifestyle factors unchanged
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Bajerska 2018 (Continued)
Outcomes Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, SBP, DBP
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer program was used to generate the block
randomisation sequence (block size 4), using body mass
index as the stratification factor
Allocation concealment (selection bias) Unclear risk Randomisation was performed by study staff who had
not been involved in selection of the participants
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were blinded to all laboratory data. All
study personnel (except the dieticians) were blinded to
the dietary allocation of the participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study personnel (except the dieticians) were blinded
to the dietary allocation of the participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5/72 and 9/72 lost to follow-up in MED and CED
groups respectively with reasons provided
Selective reporting (reporting bias) Low risk All outcomes reported as stated
Other bias Unclear risk Insufficient information to judge
Castagnetta 2002
Methods RCT of parallel-group design
Participants Healthy postmenopausal female volunteers aged 44 to 71 years recruited by press cam-
paign from Palermo (Southern Italy)
Inclusion criteria: postmenopausal for at least 2 years, no history of bilateral ovariectomy,
no HRT within the previous year, no history of cancer, no adherence to a vegetarian or
macrobiotic diet, no treatment for diabetes, thyroid disease or chronic bowel disease
230 fulfilled these eligibility criteria and 115 women were enrolled in the study based on
serum testosterone levels equal to or greater than the median population level (0.14 µg/
mL). 58 women were randomised to the intervention group, 55 women to the control
group
Interventions MEDIET project - the intervention group were invited to a weekly cooking course and
to a social dinner with chefs addressing the principles of the traditional Mediterranean
diet. The proposed recipes were based on a traditional Sicilian diet including whole
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Castagnetta 2002 (Continued)
cereals, legumes, seeds, fish, fruits, vegetables, olive oil and red wine. Women were asked
to avoid refined carbohydrates, salt and additional animal fat. The intervention ran for
6 months from January to June 2000, then from 3 months from October to December
2000. Women were instructed to consume the same foods on a daily basis at home
The comparison group followed their usual diet
The follow-up period was at 6 and 12 months
Outcomes Plasma cholesterol
Notes The primary publication (Castagnetta 2002) stated that the comparison group was ad-
vised to increase the consumption of fruits and vegetables as recommended by theWHO.
However, other reports of the study stated that women in the control group followed
their usual diets (Carruba 2006, secondary reference for this study)
No data were provided on cholesterol levels in the paper but simply a statement that they
had reduced. We have contacted the authors several times to request the data to include
in our analyses but, unfortunately, to date this has not been forthcoming
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Block randomisation stratified for baseline parameters
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No ITTanalysis; < 20% loss to follow-up inboth groups
but no reasons provided
Selective reporting (reporting bias) Unclear risk Insufficient information to judge
Other bias Unclear risk Insufficient information to judge
Chasapidou 2014
Methods RCT of parallel-group design
Participants Greek adults with known cardio metabolic diseases recruited from 50 randomly selected
municipalities in Greece
From the preliminary report of 384 participants, 79.9% were obese, 19% had T2DM,
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Chasapidou 2014 (Continued)
55.1% had hyperlipidaemia, 50.6% were hypertensive and 14.6% had established CVD
Interventions The intervention group received a Mediterranean healthy diet personalised in calories
and nutrients according to the patient’s diseases, and was followedmonthly by a dietitian
The control group did not receive any dietary counselling
6 months follow-up
Outcomes LDL cholesterol, SBP
Notes Preliminary results for 384 patients from a total of 8000 estimated to finally participate
in the study, recruited from 50 randomly selectedmunicipalities inGreece (Food4Health
study)
Data are reported narratively in text as no variance is provided for the intervention group
or values for the control group only the percentage difference between groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 17.7% lost to follow-up; unclear if this is balanced be-
tween groups
Selective reporting (reporting bias) Unclear risk Unclear as preliminary report in abstract form but DBP
was missing as was total cholesterol, HDL cholesterol
and triglyceride levels
Other bias Unclear risk Insufficient information to judge
Clements 2017
Methods RCT of parallel-group design
Participants 120 elderly participants aged 65 to 79 years were recruited to the Nu-AGE project via
the Clinical Research and Trials Unit at the University of East Anglia, UK. All were
apparently healthy and free from current or recent (3 months) chronic disease
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Clements 2017 (Continued)
Exclusion criteria: recent changes to medications, type 1 diabetes, using steroids or taking
antibiotics currently or within the previous 2 months
Mean age 70 years; 39% men
Interventions The Nu-AGE project is a multicentre European dietary study specifically addressing the
needs of the elderly. Across 5 countries, 60 participants were randomised to the control
or MED-diet groups, for 1 year
MED-diet group
The participants within the intervention group were provided with dietary advice sheets
and individual dietary advice by members of the study team to achieve the quantitative
requirements for the Nu-AGE dietary intervention:
Whole grains: 6 servings per day (1 serving = 25 g bread, 50 g breakfast cereal)
Fruits: 2 servings per day (1 serving = 1 apple, 1 banana, 8 small plums)
Vegetables and legumes: 330 g per day, once per week 200 g legumes
Dairy and cheese: 500 mL dairy per day (of which 30 g cheese)
Fish and other seafood: 2 times per week; 1 portion = 125 g
Meat and poultry: 4 times per week; 1 portion = 125 g
Nuts: 2 times per week; 20 g portion
Potatoes, pasta and rice: 150 g per day; 80 g (raw weight) whole grain rice or pasta at
least twice a week
Eggs: 2 to 4 times per week
Oil or fat: 20 g oil per day, 30 g margarine per day; maximum of 50 g fat per day. Should
be olive oil and low-fat margarine rich in MUFA and PUFA
Alcohol: maximum of 1 to 2 glasses per day for men and 1 glass per day for women.
Preferably red wine, if not abstain
Fluid: 1.5 litre per day, including milk
Salt: reduce added salt and intake of ready meals (soups, gravy, sauce)
Sugar: limit consumption of sugar and sweetened drinks (replace with fruit or yogurt,
no/reduce sugar in tea or coffee)
This advice was based on the information provided within the 7-day food records col-
lected at baseline. Study participants in theMED-diet group were given extra-virgin olive
oil, whole grain pasta and low-fat margarine rich in MUFA and PUFA freely throughout
the study. The study team distributed these products at baseline and 4 and 8 months,
when the participants attended for appointments
Control group
The control group were provided with a standard healthy living advice leaflet from the
British Dietetic Association and asked to maintain their habitual dietary intake
Follow-up at 1 year
Outcomes Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides
Notes Study focused on effects of diets on dendritic cell function. Lipid levels are shown pre
and post for each group as box and whisker plots in supplementary figure 1. We have
contacted the authors to get the data for these but so far no response. In the report it
states that blood pressure was measured at appointments but data are not shown. The
effects of the dietary interventions on lipid levels have been described narratively in text
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 10/120 participants dropped out of the study with no
reasons given
Selective reporting (reporting bias) Unclear risk Blood pressure data not shown
Other bias Unclear risk States there were no conflicts of interest in relation to
this study
Colquhoun 2000
Methods RCT of parallel-group design
Participants 68 patients with CHD documented by coronary angiography were randomised to a
Mediterranean diet or low-fat diet. All patients were on statin therapy
Interventions Mediterranean diet: 35% to 40% energy from fat with > 50% of fat being monounsat-
urated
Low-fat diet: 20% to 25% energy from fat with 8% to 10% saturated
Follow-up at 3 months
Outcomes Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides
Notes Few details - reported as a conference proceeding
No variance reported so results could not be pooled in meta-analysis
All patients were on statins and lipid levels were the only relevant outcomes for this
review
Risk of bias
Bias Authors’ judgement Support for judgement
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Colquhoun 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details
Selective reporting (reporting bias) Unclear risk No details
Other bias Unclear risk No details
Davis 2017
Methods RCT of parallel-group design
Participants 166 Australian men and women recruited from Adelaide aged greater than 64 years and
free of any cardiovascular, liver, kidney, respiratory or gastrointestinal disease, cognitive
impairment, type 1 or 2 diabetes, malignancy in the past 6 months, major recent head
trauma or a significant psychiatric disorder
Participants with blood pressure above 160/100 mmHg were excluded
Mean age 71 years; 44% men
Interventions The intervention diet was based on a traditional Mediterranean diet, with small adapta-
tions to the Australian food supply. The diet comprised extra-virgin olive oil, vegetables,
fruit, nuts, whole grains, legumes and fish as core foods. It was moderate in red wine
and dairy foods and contained small amounts of red meat. Participants attended the
clinic biweekly to meet with a dietitian to ensure high adherence to the dietary protocol.
Resources were provided that included a recipe book, guidelines for eating out, serving
sizes and the recommended number of servings, and participants also received foods
(olive oil, nuts, legumes, tuna and Greek yogurt) to increase the likelihood of adherence.
The following recommendations were given: abundant use of extra-virgin olive oil (≥ 1
tbsp/day), 5 to 6 servings of vegetables/day,≥ 2 servings of fresh fruit/day, 4 to 6 servings
of whole grain cereals/day, 4 to 6 servings of nuts/week, 3 servings legumes/week, 3
servings of fish (1 oily)/week, less than 1 serving of red meat/week, limit consumption
of discretionary foods to ≤ 3 times/week
The control group were told to consume a regular diet without change (seasonal variation
permitted) and received a voucher to buy regularly consumed foods from supermarkets
Both groups were required to maintain their physical activities and medication and
dietary supplement use throughout the intervention
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6 months intervention and follow-up
Outcomes Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides
Notes The MedDiet for cardiovascular and cognitive health in the elderly (MedLey) study:
primary outcome was cognitive function, CVD risk factors were secondary outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Volunteerswere randomly allocated to either the control
group or the intervention group stratified by gender,
BMI and age by the process of minimisation
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The researcher who administered the cognitive test bat-
tery and assessed and scored cognitive outcomes was
blind to group assignment and will remain blind until
after data analysis to reduce bias. No information re-
garding CVD risk factors
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The researcher who administered the cognitive test bat-
tery and assessed and scored cognitive outcomes was
blind to group assignment and will remain blind until
after data analysis to reduce bias. No information re-
garding CVD risk factors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for withdrawal or missing data were associ-
ated with the assigned treatment in 2 participants only.
Therefore, missing data for participants who were not
included in the final analysis were assumed to bemissing
at random. Overall attrition over 6 months was 17%
Selective reporting (reporting bias) Low risk Report includes all specified outcomes
Other bias Unclear risk Insufficient information to judge
Dinu 2017
Methods Cross-over RCT (3 months each phase)
Participants 117 participants with a low-to-medium cardiovascular risk profile, characterised by being
overweight and by the presence of at least an additional metabolic risk factor, but free
from medications, were included
Mean age 51 years; 15% men
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Dinu 2017 (Continued)
Interventions All the participants were randomly allocated to Mediterranean or vegetarian diets lasting
3 months each, and then crossed over. The 2 diets were isocaloric between them and of
3 different sizes (1400, 1600, 1800 Kcal/day), according to specific energy requirements
3 months follow-up.
Outcomes Total cholesterol, LDL cholesterol, triglycerides
Notes Few details as reported as a conference proceeding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States that an open cross-over designwas used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 99 participants (85%) completed the study.
States that the final analysis was performed in
adherent participants with outliers removed
Selective reporting (reporting bias) Unclear risk Unclear as study is reported as a conference
proceeding only
Other bias Unclear risk Insufficient information to judge
Djuric 2009
Methods RCT of parallel-group design
Participants Healthy, non-obese women aged 25 to 65 years recruited from adverts in community
newsletters, health fairs, flyers and employee newsletters inMichigan, US.Women com-
pleted 7-day food diaries
Eligibility criteria: fat intake was at least 23% of calories with no more than 48% from
MUFA and fruit and vegetable intake was < 5.5 servings per day. This was to reflect
a typical American intake. Women had to have good general health, be current non-
smokers and be in the normal to overweight range (BMI 18 to 30)
Exclusion criteria: chronic diseases such as diabetes, autoimmune disease, hypertension,
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being on medically prescribed diets, taking dietary supplements > 150% RDA, pregnant
or lactating and being treated with therapies or supplements that could obscure the
results
69 women were randomised; mean age 44 years (range 25 to 59) and mean BMI 24 (19
to 30)
Interventions The intervention was a Greek Mediterranean exchange list diet with exchange goals de-
termined by dieticians at baseline and focused on increasing fruit and vegetable intake
and variety and increasing MUFA intake while maintaining the baseline energy intake
and total fat intake. The fruit and vegetable goal was 7 to 9 servings/day depending on
baseline calorie intake and maintaining baseline energy intake was achieved by substi-
tuting fruit and vegetables for other carbohydrates. Variety was achieved using exchange
lists. The fat intake goal was PUFA:SFA:MUFA ratio of 1:2:5. This was achieved by
reducing usual fat intakes by half using low-fat food and then adding in olive oil or other
high MUFA to the diet to keep energy and total fat intake at baseline levels. Participants
were given 3 L of extra-virgin olive oil at baseline and at 3 months. 7-day food records
were taken at baseline, 3 months and 6 months. Counselling by the dieticians occurred
weekly by telephone for the first 3 months and twice weekly thereafter. Face-to-face
counselling occurred at baseline and 3 months. The intervention period was 6 months.
Women were counselled on home eating patterns, restaurant eating, eating at work and
special occasions
The comparison group followed their usual diets. They did not receive counselling, but
were given the National Cancer Institutes Action guide to healthy eating and written
materials on nutritional deficiencies if below 67% RDA
Follow-up was at 6 months after the end of the intervention period
Outcomes Total cholesterol, LDL cholesterol, HDL cholesterol and triacylglycerol
Notes Body weight increased by 0.24 kg in the control group and decreased by 1.21 kg in the
intervention group after the 6-month intervention period
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated. Participants stratified by race and
menopausal status prior to randomisation using a block
design of 6
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
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Incomplete outcome data (attrition bias)
All outcomes
High risk Differential loss to follow-up of 23% in the interven-
tion group compared with 3% in the control group. No
reasons for loss to follow-up reported
Selective reporting (reporting bias) Low risk Reported all outcomes as stated
Other bias Unclear risk Insufficient information to judge
Entwistle 2018
Methods RCT of parallel-group design
Participants Heart and lung transplant recipients who are at a substantially increased risk CVD
Eligible participants were clinically stable, aged ≥16 years, and a minimum 6 months
post-transplant
Exclusion criteria included acute rejection, infection, prevalent cancer, diabetes or
chronic kidney disease (estimated glomerular filtration rate ≤ 30). Patients with any
competing dietary issues (i.e. food allergies and following medically prescribed diets that
conflicted with the interventions) were also excluded
Study participants were identified through hospital records at the transplant outpatient
clinic and recruitment commenced in February 2014 and ended in October 2014. The
study was conducted at the University Hospital of South Manchester, UK
116 patients were assessed for eligibility, 75 were excluded and 41 randomised (20 heart,
21 lung)
Mean age 58; 70% men
Interventions The Assessment of the MEditerraneaN Diet In heart and lung Transplantation
(AMEND-IT) study was a single-centre parallel-randomised study designed to assess the
feasibility and acceptability of 2 dietary interventions, the Mediterranean diet and low-
fat diet among heart and lung transplant recipients
All participants received a printed booklet containing advice about shopping, food prepa-
ration, hygiene, storage, dining out and recipes. Additional advice and support were
provided at 6- and 12-month outpatient visits, and during six 15-minute telephone con-
sultations spaced evenly through the intervention period, when participants could raise
any questions or concerns and when key dietary recommendations (e.g. plant-based diet,
consume minimally processed food) were reinforced. SMS messaging was also used to
remind patients of clinic study requirements. Several 5-hour group education sessions
were conducted for each diet group (with an accompanying family member if desired)
on specified dates outside routine outpatient visits
Mediterranean diet
Received information and encouragement to follow an eating pattern representative of
a traditional Mediterranean diet. The key dietary recommendations were: daily mixed
consumption of a range of vegetables, fruit, whole grains, fish/seafood, raw nuts and
legumes; abundant use of extra-virgin olive oil (a free 5L container of extra-virgin olive
oil was provided to each participant); moderate consumption of dairy products and
red wine; low intake of red and processed meats, of sweets, sweet-baked pastries and
sweetened beverages
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Low-fat diet
Advised to followmodifiedBritishHeart Foundation low-fat guidelines with an emphasis
on consuming mainly plant-based whole foods similar to the Mediterranean diet, with
advice to minimise high-fat foods such as processed meats, commercially baked pastries
and desserts, and vegetable oils and spreads. Advice was given on how to identify and
avoid different types of fat. Each participant received a low-fat recipe book
The main difference between the 2 diets was the intake of oil and fat, which was encour-
aged to a moderate degree in the Mediterranean diet but discouraged in the low-fat diet
12-month follow-up
Outcomes Triglycerides
Notes Data reported narratively in text as variance reported for percentage change frombaseline
only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were stratified according to organ type and
transplant date, and then randomly assigned to either a
Mediterranean diet or a low-fat diet intervention using
a computerised system with random block size and an
equal 1:1 allocation ratio
Allocation concealment (selection bias) Low risk To blind the investigator during recruitment, ran-
domised codes were sent to a third person who then
allocated the randomised interventions to patients per
protocol
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/41 patients lost to follow-up with reasons given
Selective reporting (reporting bias) Low risk All outcomes stated are reported
Other bias Unclear risk Insufficient information to judge
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Methods RCT of parallel-group design
Participants Men and women were recruited from June 2001 to January 2004 among those attending
the outpatient department of theDivision ofMetabolicDiseases at the SecondUniversity
of Naples, Naples, Italy
180 adults (99 men and 81 women); mean age 44.3 years (intervention diet) and 43.5
years (control diet) with metabolic syndrome were enrolled in the study
Inclusion criteria: ≥ 3 of the following: (1) abdominal adiposity (defined as waist cir-
cumference 102 cm (men) or 88 cm (women)); (2) low levels of serum HDL cholesterol
(40 mg/dL (men) or 50 mg/dL (women)); (3) hypertriglyceridaemia (triglycerides level
of ≥ 150 mg/dL); (4) elevated blood pressure (≥ 130/85 mmHg); and (5) impaired
glucose homeostasis (fasting plasma glucose concentration ≥ 110 mg/dL)
Exclusion criteria: CVD, psychiatric problems, a history of alcohol abuse (alcohol con-
sumption 500 g/week in the last year), if they smoked, or if they took any medication
Interventions Intervention diet: 90 participants were given detailed advice about the usefulness of
a Mediterranean-style diet. Through a series of monthly small-group sessions, partici-
pants received education in reducing dietary calories (if needed), personal goal-setting
and self-monitoring using food diaries. Behavioural and psychological counselling was
also offered. Dietary advice was tailored to each participant on the basis of 3-day food
records. The recommended composition of the dietary regimen was carbohydrates, 50%
to 60%; proteins, 15% to 20%; total fat, < 30%; saturated fat, < 10%; and cholesterol
consumption, < 300 mg/day. Participants were advised to consume at least 250 g to 300
g of fruits, 125 g to 150 g of vegetables, 25 g to 50 g of walnuts, 400 g of whole grains
(legumes, rice, maize and wheat) daily and to increase their consumption of olive oil.
Participants were in the programme for 24 months and had monthly sessions with the
nutritionist for the first year and twice monthly sessions for the second year. Compliance
with the programme was assessed by attendance at the meetings and completion of diet
diaries
Control diet: 90 participants were given general oral and written information about
healthy food choices at baseline and at subsequent visits. The general recommendation
for macro-nutrient composition of the diet was similar to that for the intervention group
(carbohydrates, 50% to 60%; proteins, 15% to 20% and total fat, 30%). Participants
had bimonthly sessions with study personnel
Participants in both groups also received guidance on increasing their level of physical
activity, mainly by walking for a minimum of 30 minutes/day but also by swimming or
playing aerobic ball games
Trial was conducted from June 2001 to January 2004. Follow-up period was 2 years
Outcomes Total cholesterol, HDL cholesterol, triglycerides, SBP, DBP
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number sequence
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Allocation concealment (selection bias) Low risk Stored in sealed study folders and held in a central,
secured location until informed consent obtained
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Staff members involved in the intervention had to be
aware of the group assignment; thus, the study was only
partly blinded. Blinding of participants and personnel
for behavioural interventions is difficult and often not
possible, so we have not judged this as at high risk of
bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory staff did not know to which group the par-
ticipants were assigned
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis
Selective reporting (reporting bias) Low risk All outcomes stated are reported
Other bias Unclear risk Insufficient information to judge
Konstantinidou 2010
Methods RCT of parallel-group design
Participants From October 2007 to October 2008, 90 eligible community-dwelling adults (26 men
and 64 women, aged 20 to 50 years) were recruited from primary care centres in Spain.
They were considered healthy on the basis of a physical examination and routine bio-
chemical and haematological laboratory determinations
Exclusion criteria: intake of antioxidant supplements; intake of aceto salicylic acid or any
other drug with established antioxidative properties; high levels of physical activity (3000
kcal/week in leisure-time physical activity); obesity (BMI 30 kg/m2); hypercholestero-
laemia (total cholesterol 8.0 mM or dyslipidaemia therapy); diabetes (glucose 126 mg/
dL or diabetes treatment); hypertension (SBP ≥ 140 mmHg) or (DBP ≥ 90 mmHg),
or both or antihypertensive treatment; multiple allergies; coeliac or other intestinal dis-
eases; any condition that could limit the mobility of the participant, making study visits
impossible; life-threatening illnesses or other diseases or conditions that could worsen
adherence to the measurements or treatments; vegetarianism or a need for other special
diets; and alcoholism or other drug addiction
Interventions Participants were assigned to 1 of 2 interventions or a control group as follows:
1. Traditional Mediterranean diet with virgin olive oil (30 participants)
2. Traditional Mediterranean diet with washed virgin olive oil (30 participants)
The dietician gave personalised advice during a 30-minute session to each participant
following the traditional Mediterranean diets, with recommendations on the desired
frequency of intake of specific foods. Participants were instructed to use olive oil for
cooking and dressing; increase consumption of fruit, vegetables and fish; consume white
meat instead of red or processed meat; prepare homemade sauce with tomato, garlic,
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onion, aromatic herbs and olive oil to dress vegetables, pasta, rice and other dishes; and,
for alcohol drinkers, moderate consumption of red wine
3. Control group (30 participants): participants were advised by a dietician to maintain
their habitual lifestyle
Intervention period and follow-up was 3 months
Outcomes Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, SBP, DBP
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number sequence
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 participant dropped out of the trial
Selective reporting (reporting bias) Low risk All outcomes stated are reported
Other bias Unclear risk Not stated
Lapetra 2018
Methods RCT of parallel-group design
Participants Multicentre trial in primary care in Spain CFAMED - Insuficiencia Cardiaca (Heart
Failure), Fibrilación Auricular (Atrial Fibrillation) and dieta MEDiterránea (MEDiter-
ranean diet)
180 hypertensive patients between 55 and 75 years of age at high CVD risk were ran-
domised to a Mediterranean diet or low-fat diet; 92% men
Exclusion criteria: previous history of CVD (CHD, stroke, HF or AF), BMI > 40, severe
chronic disease with poor prognosis, illegal drug use or chronic alcoholism, physical
limitations, mental or intellectual barriers to participation in the trial, low predicted
likelihood of changing dietary habits, any condition that may affect the development of
the trial
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Interventions Mediterranean-style diet (N = 90)
Low-fat diet according to American Heart Association guidelines (N = 90)
Both groups received dietary advice (individual and group) every 3 months for at least 2
years. Participants attended educational talks about hypertension and healthy eating and
were given a booklet that included essential information from the talks and a seasonal
menu, tailored for each group
2 years follow-up
Outcomes Stroke
Notes Conference proceeding so few details given. Further details taken from trial registration
- ISRCTN27497769
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear - states “simple blind” in abstract (presume this
should read single blind)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear - states “simple blind” in abstract (presume this
should read single blind)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details
Selective reporting (reporting bias) Unclear risk Not all outcomes reported as listed on trial registry but
it was a conference proceeding presenting clinical events
Other bias Unclear risk Insufficient information to judge
Lindman 2004
Methods RCT of parallel-group design (2 x 2 factorial design)
Participants 219 older men with long-standing hypercholesterolaemia were recruited from the Diet
and Omega-3 Intervention trial on atherosclerosis (DOIT) study, Norway
Mean age 69.7 years for both genotypes
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Interventions Men were randomised into 3 intervention groups or the control group as follows:
• Usual care and placebo capsules (control group) (n = 51)
• Dietary advice (’Mediterranean-type’ diet) and placebo capsules (n = 47)
• Usual care and VLC n-3 capsules (n = 51)
• Dietary advice (’Mediterranean-type’ diet) and VLC n-3 capsules (n = 52)
Diet counselling was given individually by a clinical nutritionist based on a food fre-
quency questionnaire. The food frequency questionnaire was also answered by the par-
ticipants at the end of the main study (36 months). Energy content and nutrient com-
position of the diet were calculated from the questionnaires at baseline and 36 months.
Dietary advice was given during 30 to 45 minutes at time of randomisation, and for 30
minutes after 3 months. Participants were supported with a margarine rich in PUFA and
vegetable oils free of cost. Advice was given to increase intake of vegetables, fruit and
fish, and decrease consumption of meat and target energy percents at 27% to 30% fat,
15% to 18% protein and 50% to 55% carbohydrate. To fulfil these goals participants
were recommended to use rapeseed or olive oil for cooking; use leafy vegetables daily;
include fruits, berries and nuts in the diet; eat fish 3 times per week; use wholemeal bread,
skimmed milk and reduced-fat cheese. 2 capsules were taken twice daily corresponding
to 2.4 g VLC n-3 capsules or 2.4 g corn oil (placebo capsules)
Follow-up period was 6 months
Outcomes Triglycerides
Notes Only data from the usual care and placebo capsules (control group) (n = 51) and dietary
advice (’Mediterranean type’ diet) and placebo capsules (n = 47). (The focus of the study
was to investigate the effect of long-term diet and VLC n-3 fatty acids intervention
on plasma coagulation factor VII (FVII), choline-containing phospholipids and triglyc-
erides, especially relating to the R353Q polymorphism of the FVII gene)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
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Selective reporting (reporting bias) Unclear risk Insufficient information to judge
Other bias Unclear risk Insufficient information to judge
Mayr 2018
Methods RCT of parallel-group design
Participants AUSMED Heart Trial - secondary prevention trial in CHD patients recruited from 2
hospitals in Melbourne, Australia between 2014 and 2106
Patients were eligible if they had documented CHD including at least one of the follow-
ing: acute MI, angiographically confirmed angina, revascularisation
Exclusion criteria: malignant tumour, symptomatic chronic heart failure, chronic inflam-
matory disease, chronic kidney disease, decompensated liver disease, pregnancy, breast-
feeding, history of allergy to olive oil or nuts or current participation in another trial
Mean age 62 years; 84% men
Interventions 73 patients were randomised to a Mediterranean diet or low-fat diet. For both diets
advice was tailored to the individual through dieticians using client-centred counselling
and goal setting. Different dieticians advised for the 2 groups to prevent contamination.
Face-to-face meetings with dieticians occurred at baseline, 3 months and 6 months, and
phone calls at weeks 3, 6, 9 and months 4 and 5. The number of contacts and intensity
of the intervention was the same for both diets
Mediterranean diet
Based on a traditional Cretan Mediterranean diet. Modelled a 2-week meal plan incor-
porating key dietary components of a Mediterranean diet with a mix of traditional and
modified recipes considered to be realistic options for multi-ethnic Australians. Target
macronutrient intakes were: 42% total fat (at least 50% MUFA, 25% PUFA), < 10%
SFA, 35% carbohydrates, 15% protein. Patients received a recipe book, shopping lists,
a food pyramid, weekly dietary intake checklists and label reading information. Food
recommendations were: daily intake of extra-virgin olive oil, nuts, fruit and vegetables,
whole grains, regular intake of fish legumes and yogurt and limited intake of red and
processedmeat and sweets and pastries. Hampers were provided at baseline and 3months
to aide adherence (6 L extra-virgin olive oil, 1.2 kg nuts, tinned fish and legumes and
Greek yogurt)
Low-fat diet
Followed the standard diet recommendations for cardiac patients in Australia at the
time (2014). Target recommended macronutrient intakes were: < 30% total fat with
less than 10% saturated fat, 45% to 65% carbohydrate, 15% to 25% protein. Food
recommendations included daily intake of grains and cereals (mostly whole grain 5 to
7 servings per day), fruits (2 servings per day) and vegetables (5 to 6 servings per day)
, protein foods (2 to 3 servings per day) and low-fat dairy food (2 servings per day).
A one week meal plan was provided, resources for label reading, low-fat cooking and
recommended food group serving sizes. To aid compliance patients were provided with
a supermarket voucher at the 3 face-to-face meetings
6 months follow-up
Outcomes Lipid levels, blood pressure
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Notes Lipid levels and blood pressure were not reported in the full paper but only in a prelimi-
nary analysis as a conference proceeding in a subset of the cohort. No data were provided
and the authors findings are reported narratively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation tables were developed by the trial statis-
tician using a computer-generated stratified approach
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 27% loss to follow-up in the intervention group and
17% in the control group over 6 months. Reasons for
dropout provided. Those who dropped out had a higher
dietary inflammatory index and lower intake of fibre at
baseline but were otherwise similar to the completers
Selective reporting (reporting bias) Unclear risk Blood pressure and lipids not reported in the main pa-
per, only in a preliminary analysis
Other bias Unclear risk Insufficient information to judge
Michalsen 2006
Methods RCT of parallel-group design
Participants Patients with established coronary artery disease as verified by coronary angiography
within 3 months. Recruited from 2 hospitals in Germany and the national press
Exclusion criteria: an acute coronary syndrome or coronary artery bypass graft within the
previous 3 months, diabetes mellitus type I, manifest cardiac arrhythmias, heart failure,
life-threatening comorbidity and a BMI > 33
101 patients; mean age 59 years; 77% men
Interventions The study was inspired by the Lyon Diet Heart Study and the Lifestyle Heart Trial,
and aimed to combine the nutritional approach of the traditional Mediterranean diet
with a group-supported comprehensive lifestyle modification program in order to ensure
maximum adherence with the diet in a non-Mediterranean country, Germany
Eligible participants were assigned either to:
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Intervention
A lifestyle modification group with an intensive 100 hour/1-year programme and the
focus on Mediterranean diet. The nutritional therapy did not include any supplements
or free delivered food items, but participants had to adopt the recommended diet strictly
by themselves after intensive instructions and education. The programme began with a
3-day non-residential retreat, followed by weekly 3-hour meetings for 10 weeks. There-
after, 2-hour meetings took place every other week for 9 months. The meetings were
held in groups of 10 to 13 participants. The lifestyle programme addressed diet and stress
management. Participants were extensively informed about the Mediterranean diet by
nutritional information, repetitive group discussions, cooking classes and group meals,
and dietary instructions were tailored to individuals where necessary. The aim of the di-
etary instructions was to provide a diet rich in alinolenic acid (ALA), marine n-3 polyun-
saturated fatty acids (PUFA), monounsaturated fats (MUFA) and phytochemicals, and
low in saturated fats (SFA). The instructions were to consume at least 5 portions of fruits
and vegetables daily, with an emphasis on root and green vegetables with a high content
of ALA, and more than 2 portions of fatty fish per week, to consume preferably whole-
grain bread, pasta and rice, the intake of flaxseed and walnuts was strongly recommended
whereas the intakes of meat and sausage should be limited to three servings per week,
and beef, lamb and pork were to be replaced by poultry, fish or vegetarian dishes. Both
olive oil and canola oil, and, for some dishes, walnut and flaxseed oil, were strongly
recommended. Modest regular alcohol consumption in the form of red wine with the
meals was recommended
Control
Patients in the control group received only written and less detailed information about
the dietary principles of the Mediterranean diet, and some general advice about stress
reduction by means of leaflets that were mailed shortly after randomisation
Follow-up at 1 year
Outcomes Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides
Notes 82% were taking statins at the beginning of the study. During the study, the dose of
statins was non-significantly more reduced in the intervention patients and increased in
control patients
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised assignments weremade centrally by a com-
puter program. Assignments were stratified by age, sex
and status of revascularisation
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/105 patients dropped out with reasons given
Selective reporting (reporting bias) Low risk All outcomes stated are reported
Other bias Unclear risk Insufficient information to judge
Misciagna 2017
Methods RCT of parallel-group design
Participants Participants with non-alcoholic fatty liver disease (NAFLD) were identified during the
NutriEp survey enrolment process (Puglia, Italy). Eligible participants were those with
moderate or severe NAFLD (N = 203)
Exclusion criteria included: overt cardiovascular disease and revascularisation procedures;
stroke; clinical peripheral artery disease; T2DM; more than 20 g/daily of alcohol intake;
severe medical condition that may impair the person participating in a nutritional in-
tervention study; people following a special diet or involved in a programme for weight
loss, or who had experienced recent weight loss and inability to follow a Mediterranean
diet for religious or other reasons
98 participants randomised; 50% men
Interventions Intervention
Low glycaemic index Mediterranean diet (LGIMD). Foods in LGIMD have all a low
glycaemic index (GI) and nomore than 10%of total daily calories coming from saturated
fats. The LGIMD was high in monounsaturated fatty acids from olive oil and contained
also omega 3 polyunsaturated fatty acids, fromboth plant andmarine sources. Adherence
to the LGIMD as measured by Mediterranean Adequacy Index
Control
Italian National Research Institute for Foods and Nutrition (INRAN) guidelines
The recommended diets were provided in brochure format, with graphical explanations
organised according to a traffic light system: with a list of foods that can be consumed
frequently (green foods), sometimes (yellow foods) and never (red foods). The brochure
also contained a dietary record, where participants daily indicated the code of each food
consumed at breakfast, lunch, dinner and during snack time. Monthly follow-up visits
in both groups included a face-to-face interview with the dietician in order to assess the
diet followed by the subject and to give, if needed, personal recommendations to achieve
the “group assigned” goal
6 months follow-up
Outcomes Total cholesterol, HDL cholesterol, triglycerides
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Notes Data provided as number and percentage of participants with normal and altered levels
rather than mean and SD at baseline and follow-up so these cannot be used in meta-
analyses. Findings are reported narratively in text
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned, according to a
computerised random number sequence
Allocation concealment (selection bias) Unclear risk With the exception of the dietitians, investigators and
staff were unaware of the participants’ diet assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States dieticians were aware of group assignment. States
blinding and equipoise were strictly maintained by em-
phasising to the intervention staff and participants that
each diet adhered to healthy principles. Blinding of par-
ticipants and personnel for behavioural interventions is
difficult and often not possible so we have not judged
this as at high risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Staff members who obtained outcome measurements
were not informed about diet assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk The primary analysis was intention-to-treat. 6/50 indi-
viduals were lost in the follow-up in the intervention
group and 2/48 in a control group
Selective reporting (reporting bias) Low risk All outcomes stated are reported
Other bias Unclear risk Insufficient information to judge
Ng 2011
Methods RCT of parallel-group design (pilot study)
Participants 48 patients with HIV were recruited from the Queen Elizabeth Hospital in Hong Kong
(People’s Republic of China)
Inclusion criteria: (1) HIV-positive, (2) 18 years old or above, (3) considered to be
physically well by an experienced nurse specialising in HIV and stable within the context
of their HIV diagnosis with no current illness concerns, (4) not pregnant and (5) had
not previously received dietary advice on lipid lowering
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Interventions Participants in both groups were given both verbal and written instructions regarding the
particular diet that they had been assigned, which they were required to adhere to for a
period of 1 year. The dietitian designed an individualised meal plan for each participant,
taking into account any specific requirements related to their HIV status. Patients were
educated as to the necessary adjustments to their eating habits required to meet the
criteria of their assigned diet group
Modified Mediterranean diet
The Mediterranean diet was based on the basic principle of the low cholesterol diet
with emphasis on avoiding foods rich in saturated fat and cholesterol, modified slightly
to suit the local eating culture. In order to increase the consumption of mono and
polyunsaturated fats, the diet also included one serving per day of 3 items from the
following list:
* 100 g of white meat (fish or chicken) to replace a serving of red meat
* 10 mL of canola, rapeseed or olive oil to be used as cooking oil to replace saturated fats
* 17 g of canola margarine per day in place of butter or other margarine
* 100 g of dried legumes, including soy beans, chick peas and lentils, or 100 g of tofu to
replace meat as a protein source
* 30 g nuts including peanuts, almonds and hazelnuts
* 237 mL of low-fat dairy or soy drink instead of full fat dairy
* 5 servings of fruits and vegetables
Low-fat, low-cholesterol diet
The low-fat and low-cholesterol diet was prescribed according to theNCEP Adult Treat-
ment Panel III guidelines. It involves reducing the intake of saturated fat (< 7% of total
calories) and cholesterol (< 200 mg per day). Up to 10% of calories can be derived from
polyunsaturated fat and up to 20% from monounsaturated fat. Total fat should make
up 25% to 35% of the total calories, carbohydrates 50% to 60% and protein ~15%.
Intake of 20 g to 30 g of fibre per day is encouraged, as are weight reduction and physical
activity
12 months follow-up
Outcomes Total cholesterol, triglycerides
Notes Rationale: HIV and highly active antiretroviral therapies have been associated with
changes in individuals’ lipid profiles and fat distribution (lipodystrophy). This pilot
RCT study was conducted for future larger RCT to evaluate whether lipodystrophy in
HIV patients can be controlled by adopting a low-fat and low-cholesterol diet or the
modified Mediterranean diet. The authors point out that there were several procedural
and methodological issues identified, which must be rectified before a similar large-scale
trial taking place (see other biases below). The standard deviation difference for changes
from baseline in total cholesterol and triglycerides was calculated from P values follow-
ing guidance in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Participants were randomly allocated into
the 2 different diet streams, using com-
puter-generated randomisation. Blinding
was not used in this study
Allocation concealment (selection bias) Unclear risk The dietitian allocated patients into differ-
ent diets according to the next available diet
type on entry into the trial. Although the
dietitian ran the computer-generated ran-
domisation, bias was minimised by hiding
the allocation of diet groups until the par-
ticipant was recruited; the randomised diet
groupwas then revealed to the dietitian and
the participant
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding was not used in this study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding was not used in this study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The data were analysed on the basis of in-
tention-to-treat, including the 12/48 par-
ticipants for whom baseline samples were
available but who dropped out of the study
at later stages. 1/23 patients in the low-fat
diet group dropped out compared to 7/25
following the Mediterranean diet
Selective reporting (reporting bias) Low risk Outcomes reported as stated
Other bias Unclear risk Several difficulties were identified with re-
spect to the procedures utilised, primarily
related to recruitment of participants. De-
spite appearing physically well, as assessed
by experienced HIV nurses and physi-
cians, 4 participants died during the study.
More strict inclusion and exclusion crite-
ria should be set if any similar, large-scale
study were to be undertaken. Similarly, the
reasonably large change in CD4 counts ex-
hibited by our participants suggests that
some were not in a stable phase of their
HIV treatment: given the effect of highly
active antiretroviral treatment on lipid lev-
els, this makes it difficult to draw con-
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clusions as to whether the diet or treat-
ment regime was affecting the level of lipids
measured here. In addition, several partici-
pants were “lost to follow-up”, with thema-
jority of those ceasing participation com-
ing from the Mediterranean diet group.
Some of these participants were known reg-
ularly to miss scheduled appointments at
the clinic, and perhaps greater attention
should be paid to participant attendance at
regular clinical visits when recruiting
PREDIMED
Methods RCT of parallel-group design
Participants PREDIMED is a multicentre trial conducted over 11 sites (169 clinics) in Spain to
examine the effects of the Mediterranean diet supplemented with extra-virgin olive oil
or nuts compared to a low-fat diet in participants at increased risk of CVD
Inclusion criteria: community-dwelling with high risk of CVD but with no CVD at
enrolment, aged 55 to 80 for men and 60 to 80 for women with either T2DM or 3 or
more risk factors (current smoker, HTN, hypercholesterolaemia (LDL > 160 mg/dL or
on hypolipidaemic drugs), HDL < 40 mg/dl, overweight or obesity (BMI > 25), family
history of premature CHD)
Exclusion criteria: previous history of CVD. Any severe chronic illness. Immunodefi-
ciency or HIV status. Illegal drug use or chronic alcoholism. History of allergy to olives
or nuts. Low predicted likelihood of changing dietary habits according to the Prochaska
and DiClemente stages of change model
Recruitment took place between 25 June 2003 and 30 June 2009. 8713 screened for
eligibility, 973 refused to participate, 293 did not meet the inclusion criteria, 7447
participants were randomised 1:1:1 to each of the 3 groups
42% men; mean age 67
Interventions 2 intervention groups followed aMediterranean dietary pattern with supplemental extra-
virgin olive oil or tree nuts, and the control group followed a low-fat diet. Initially the
control group received tailored advice at baseline and a leaflet and yearly follow-up with
trained dieticians, and 3 years into the trial this was amended so the intensity of the low-
fat intervention matched that of theMediterranean diet intervention groups where there
were tailored individual visits to dieticians and group sessions every 3 months. Dur-
ing these sessions behavioural change techniques employed included goal-setting, self-
monitoring, feedback and reinforcement, self-efficacy enhancement, incentives, prob-
lem-solving, relapse prevention and motivational interviewing. Group sessions included
informative talks and discussion with review of dietary goals, menu planning and shop-
ping lists appropriate for each dietary intervention and provision of supplemental extra-
virgin olive oil or nuts or non-food incentives for the control group. Energy restriction
was not specifically advised nor was physical activity promoted in any of the 3 groups
Mediterranean diet groups:
In these 2 groups a 14-item questionnaire of adherence to the Mediterranean diet was
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used in each session and personalised advice given to increase the score. General dietary
advice to follow a Mediterranean diet included the following:
a) Abundant use of olive oil for cooking and dressing dishes
b)Consumptionof≥ 2daily servings of vegetables (at least one of themas fresh vegetables
in a salad)
c) ≥ 2 to 3 daily servings of fresh fruits (including natural juices)
d) ≥ 3 weekly servings of legumes
e) ≥ 3 weekly servings of fish or seafood (at least one serving of fatty fish)
f ) ≥ 1 weekly serving of nuts or seeds
g) Select white meats (poultry without skin or rabbit) instead of red meats or processed
meats
h) Cook regularly (at least twice a week) with tomato, garlic and onion with abundant
olive oil to dress vegetables, pasta, rice and other dishes
i) For usual drinkers, the dietitian’s advice was to use wine as the main source of alcohol
(maximum 300 mL per day)
j) Two main meals per day should be eaten (seated at a table, lasting more than 20
minutes)
Negative recommendations are also given to eliminate or limit the consumption of cream,
butter, margarine, cold meat, pate, duck, carbonated and/or sugared beverages, pastries,
industrial bakery products and desserts, french fries or potato chips
Depending on group allocation, either a 15-litre (4 tablespoons per day) supply of extra-
virgin olive oil (Hojiblanca and Fundación Patrimonio Comunal Olivarero, both from
Spain) or 3-month allowances of nuts consisting of 1350 g (15 g per day) sachets of
walnuts (CaliforniaWalnut Commission, Sacramento, CA), 675 g (7.5 g per day) sachets
of almonds (Borges SA, Reus, Spain) and 675 g (7.5 g per day) sachets of hazelnuts (La
Morella Nuts, Reus, Spain) were provided at each 3-month group session. Quantities
were sufficient for each family unit. The rationale for the 2 Mediterranean diet groups
was as follows: extra-virgin olive oil is a rich source of monounsaturated fatty acids and
a good source of phenolic antioxidants. Walnuts make up half the allowance of nuts
in the other intervention group and are a good source of polyunsaturated fatty acids,
particularly linoleic acid and alpha-linolenic acid, the plant-derived omega-3 fatty acid,
in addition to polyphenols. Almonds and hazelnuts are both rich in monounsaturated
fatty acids and polyphenols. Thus the 2 intervention arms of the study differed in the
intake of 2 foods (extra-virgin olive oil and nuts) and 2 nutrients (monounsaturated fatty
acids and polyunsaturated fatty acids, including alpha-linolenic acid) that are all felt to
be important in cardiovascular prevention and might have differential beneficial effects
Low-fat diet group
The focus in the control group was to reduce all types of fat, with particular emphasis on
recommending the consumption of lean meats, low-fat dairy products, cereals, potatoes,
pasta, rice, fruits and vegetables. The use of olive oil for cooking and dressing and
consumption of nuts and fatty fish were discouraged. A 9-item quantitative score of
compliance with the low-fat control diet was constructed as an instrument for dietitians
to assess and modify the participant’s dietary pattern to upgrade the score. Cooking
instructions were also given to participants in the control group about the preparation
of foods to avoid frying and using instead steaming, broiling, or microwaving
Follow-up was 4.8 years
Outcomes Primary outcome was a composite clinical outcome (CVD deaths, stroke, MI). Other
clinical events included CVDmortality, total mortality, MI, stroke, PAD, T2DM. CVD
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risk factors included blood pressure and lipid levels
Notes The original trial (Estruch 2013) was retracted and re-analysed when methodological
issues concerning randomisation came to light for 2 sites, and the inclusion of non-
randomised second household members. The new publication (Estruch 2018) controls
for these in the analyses and has conducted a series of sensitivity analyses excluding these
sites where they have found similar results for clinical endpoints. The new publication
reports on the composite clinical outcome, CVD and total mortality, MI and stroke.
Other reports of PREDIMED have also been used for CVD risk factors and PAD which
were not reported in themain 2018 paper and therefore have not been adjusted. Data for
the incidence of T2DM has been re-analysed to take account of the clustering and shows
very similar estimates to the original analysis (Correction - Annals Internal Medicine
2018;169(4): 270-2). Data on lipids are reported for 2 study sites rather than all 11
sites, but these were not the 2 sites where methodological issues arose. Follow-up periods
vary for different outcomes - these are 4.8 years for clinical events and incidence of
T2DM and PAD, 4 years for blood pressure and 1 year for lipids. Blood pressure has
been analysed in multivariate analyses in the Toledo paper and is reported narratively
in text. An earlier abstract reports unadjusted values but the addition of these to the
meta-analyses created significant heterogeneity. There is currently no re-analysis of blood
pressure data to take account of the methodological issues with this trial. The trial was
stopped early as clear benefits of the Mediterranean diet over the low-fat diet were seen
for the primary outcome at 4.8 years. Drug treatment regimens were similar for the 3
groups at baseline and continued to be similar throughout the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated random-number sequence pro-
vided randomisation tables for the
11 participating sites. These tables included 4 strata
(men < 70 years of age, men ≥ 70 years of age, women
< 70 years of age and women ≥ 70 years of age) and
were initially generated for 1000 participants (250 per
stratum) for each site
Allocation concealment (selection bias) Unclear risk Randomisation was concealed with sealed envelopes for
the pilot phase of the study but not thereafter
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Patients were informed of their treatment allocation.
Blinding of participants and personnel for behavioural
interventions is difficult and often not possible so we
have not judged this as at high risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary analyses used ITT
Selective reporting (reporting bias) Low risk Outcomes reported as detailed in the protocol
Other bias Unclear risk Insufficient rationale or evidence that an identified
problem will introduce bias (see notes section above)
Properzi 2018
Methods RCT of parallel-group design
Participants 56patientswith non-alcoholic fatty liver disease (NAFLD)who are at increasedCVDrisk
recruited in Australia; 49 participants completed the intervention and 48 were included
in the analysis
Interventions 2 ad libitum isocaloric diets: Mediterranean (MD) versus low-fat (LF)
12-week intervention and follow-up
Outcomes Total cholesterol, triglycerides
Notes Conference proceeding so few details and effects of the 2 diets on lipid levels reported
narratively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States blinded dietary intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States blinded dietary intervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 48/56 analysed
Selective reporting (reporting bias) Unclear risk Conference proceeding reporting preliminary findings
Other bias Unclear risk Insufficient information to judge
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Methods RCT of parallel-group design
Participants Those with definite or possible acute myocardial infarction and unstable angina based
on World Health Organization criteria were assigned to diet A (N = 204) or diet B (N
= 202) within 24 to 48 hours of infarction
Mean age 51 years; 90% men
Interventions In both diets meat, eggs, hydrogenated oils, butter and clarified butter were replaced with
vegetarian meat substitutes and soya bean, sunflower and ground nut oils so as to provide
a prudent diet reflecting the recommendations of theAmericanHeart Association.Group
A patients were also advised to eat fruit, vegetables, pulses, nuts and fish. The goal was
for patients to provide at least 400 g/day of fruits and vegetables. Other health-related
advice, such as stopping smoking, reducing alcohol intake, counselling to reduce mental
stress and on physical activity, was given to both groups. Patients in group A had the
advice regularly reinforced, whereas those in group B were left to usual care after the
initial advice
Outcomes Clinical endpoints at 2 years follow-up (2012 and 2017 papers): total cardiac mortality,
fatal MI, sudden cardiac death, total CVD mortality, total mortality. Total cholesterol,
HDL cholesterol, LDL cholesterol, triglycerides, SBP, DBP at 1 year follow-up (1992
paper)
Notes BMJhas published concerns about research fraud in relation to this study. https://doi.org/
10.1136/bmj.331.7511.281. This study has also been discussed in the expression of
concern published in the Lancet about Singh 2002. Consequently other risk of bias is
rated as high and sensitivity analyses have been performed excluding this study
Several reports of this trial: 2-year follow-up data from the 1992 trial published in 2012
and 2017. 2-year clinical endpoints were used. Blood pressure and lipid levels are reported
at baseline with variance and mean change from baseline with no variance. In all cases
the baseline variance has been used to impute the SD difference for change from baseline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Individually randomised by the dietitian and pharma-
cists and assigned a diet by blindly selecting a pre-coded
sequence of cards designated diet A or diet B from a
stack with an equal number in each
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States the doctor was blind to the assigned diet and the
dietician was not, and that it is a single-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States the doctor was blind to the assigned diet
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data were analysed by intention-to-treat for clinical
endpoints. 27/204 and 43/202 were lost to follow-up
in diet A and B respectively for CVD risk factors
Selective reporting (reporting bias) Unclear risk Several clinical endpoints reported in 1992 paper at 1-
year follow-up not reported in subsequent papers at 2-
year follow-up (2012, 2017)
Other bias High risk BMJ has published concerns about research fraud
in relation to this study. https://doi.org/10.1136/
bmj.331.7511.281. Concerns about Singh 1992 have
also been discussed in the expression of concern pub-
lished in the Lancet about Singh 2002.
Singh 2002
Methods RCT of parallel-group design
Participants Participants with risk factors for coronary artery disease (CAD) were recruited through
advertisements in newspapers and local service clubs in India from 17 centres over
4 years for free medical advice about diagnosis and treatment of their disorders. The
recruitment criterion > 25 years of age and having one or more of the major risk factors
for CAD (hypertension, hypercholesterolaemia, diabetes mellitus, angina pectoris or a
previous myocardial infarction) in the absence or presence of other risk factors. Of 1650
people who responded to advertisements, 1066 volunteered to participate in the trial.
For patients without a documented history, exercise electrocardiography was used to
detect CAD
Exclusion criteria were: absence of major risk factors for CVD, cancer, chronic diarrhoea
or dysentery, a blood urea of more than 6.6 mmol/L, arthritis, dislike of the intervention
diet, refusal of laboratory testing and death before randomisation
66 participants did not meet the inclusion criterion and 1000 participants were ran-
domised; mean age 48.5 years; 90% men
Interventions Participants in both groups were advised to eat food substitutes that would provide
a dietary intake similar to that recommended by the National Cholesterol Education
Program (NCEP) in the step I prudent diet. This diet recommends that less than 30%
of energy comes from total fat, less than 10% from saturated fat, and that less than
300 mg of cholesterol is consumed per day. Additionally, patients in the intervention
group (Indo-Mediterranean diet) were advised to consume at least 400 to 500 g of fruits,
vegetables and nuts per day, (i.e. 250 g to 300 g of fruit, 125 g to 150 g of vegetables,
and 25 g to 50 g of walnuts or almonds). This group were also encouraged to eat 400 g
to 500 g of whole grains, legumes, rice, maize and wheat) daily, as well as mustard seed
or soy bean oil, in 3 to 4 servings per day, which is consistent with recommendations
from the Indian Consensus Group. Patients with diabetes mellitus, angina pectoris, a
history of myocardial infarction or hypertension who visited the physician frequently,
received more frequent dietary advice during the 2 years of follow-up than those who
did not. No details provided regarding the number of contacts for these patients or the
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intervention group as a whole, although food diaries were completed at 4, 8, 12 and 24
weeks, then at 12-week intervals. Measurements were taken at baseline, at 12 weeks, 24
weeks and 2 years
Control patients were given an information sheet on the step I prudent diet at each visit.
Intervention group patients were given a thorough explanation of the usefulness of the
experimental diet, and the types of food that are rich in n-3 fatty-acids. At all meetings,
dieticians provided additional motivation to both groups to adhere to the advice about
diet and exercise. Both groups received the same advice to exercise. Smoking and alcohol
consumption were discouraged, and mental relaxation through yoga, meditation tech-
niques and breathing exercises were encouraged in both groups. Appropriate drugs for
angina pectoris, arrhythmias, raised blood pressure, diabetes and other complications
were provided to both groups
2 years follow-up
Outcomes Non-fatal MI, fatal MI, sudden cardiac death, total cardiac endpoints, total cholesterol,
HDL cholesterol, LDL cholesterol, triglycerides, SBP, DBP
Notes An expression of concern was published about the reliability of this work by
the Lancet journal editor Richard Horton in 2005: https://doi.org/10.1016/S0140-
6736(05)67006-7. Consequently other risk of bias is high and we conducted sensitivity
analyses excluding this study
The majority of participants have confirmed CAD (58% and 59% in the intervention
and comparison groups) so this study has been analysed as a secondary prevention study
No details regarding the number of people assessed at 2 years follow-up for CVD risk
factors. Have taken the number randomised minus those who dropped out and cardiac
and non-cardiac deaths as the N in meta-analyses so 478 for the intervention group and
469 for the comparison group
Singh 2014: same study from the same institution reporting total mortality and weight
loss in a conference proceeding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were assigned to either the intervention or con-
trol group, by selection of a card from a pile of equal
numbers of cards for each group
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States single-blinded study and outcome assessors were
blinded. Blinding of participants and personnel for be-
havioural interventions is difficult and often not possi-
ble so we have not judged this as at high risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk In both groups, clinical data, drug intake, adverse
events, coronary events, hospital admission, blood pres-
sure, blood glucose and blood lipids were recorded by a
physician unaware of patient diet
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Low dropout rate: 9 in the intervention group and 11
in the control group of 1000 patients randomised. All
dropouts occurred within first 12 weeks and no reasons
were provided
Selective reporting (reporting bias) Low risk Reported outcomes as stated
Other bias High risk An expression of concern has been published about the
reliability of the data reported (see notes section above)
Skouroliakou 2017
Methods RCT of parallel-group design
Participants 70 females suffering frombreast cancer with a histological confirmed diagnosis of invasive
breast cancer stage I-IIIA (diagnosed up to 3 months before recruitment) recruited from
a maternity clinic in Athens, Greece
Exclusion criteria:multivitaminor simple vitamin supplementation; a previous or current
history of a second cancer; active infection; other severe coexisting medical conditions;
symptomatic brain metastases; malabsorption; refusal to comply with the nutritional
programme and physical activity recommendations
Interventions Eligible participants were randomly allocated to:
Mediterranean Diet
The intervention groupwere treatedwith a personalised dietary intervention based on the
Mediterranean diet, conducted by 2 trained registered dietitians. The diet was enriched
with olive oil and foods with specific health benefits for breast cancer survivors. Recom-
mendations: (1) 1 tablespoon of flaxseed oil or 4 tablespoons grounded flaxseed per day,
(2) 3 cups of green tea or Greek Mountain Tea per day, (3) seasonal fruits and vegetables
with high antioxidant capacity. They received a personalised dietary programme via e-
mail as well as face-to-face appointments every 15 days for the first 3 months and phone
calls at the end of months 4 and 5 with in-person meetings at the end of the study at 6
months. Specific meals, products, recipes and food portions, educational booklets, food
diaries and individual nutritional advice was provided
Control diet
Received the updated American Cancer Society Guidelines on Nutrition and Physical
Activity for Cancer Prevention and ad libitum diet. Patients were contacted by phone
every 15 days for the first 3 months, then at months 4 and 5 and in-person meetings at
baseline, 3 and 6 months
Recommendations from the American Cancer Society regarding physical activity were
also provided to both groups
6 months follow-up
Outcomes Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides
Notes Breast cancer patients. Rationale for study was that the Mediterranean diet may modify
patients serum antioxidant capacity, body composition and biochemical parameters
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Randomised by odd or even numbers (stated in figure,
nothing in text)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Overall, the withdrawal rate from the study was 35.7%
(25 women) and this was significantly associated with
BMI
Selective reporting (reporting bias) Low risk All outcomes stated are reported
Other bias Unclear risk Insufficient information to judge
Sofi 2018
Methods RCT of cross-over design (cross-over at 3 months)
Participants Clinically healthy participants (18 to 75 years of age) with a low-to-moderate cardiovas-
cular risk profile (< 5% at 10 years according to the European Society of Cardiology)
recruited through advertisements in local media, newspapers, social media and websites
from the Clinical Nutrition Unit of Careggi University Hospital, Florence, Italy, from
March 2014 to June 2015
Eligibility criteria included being overweight (BMI≥ 25) and the simultaneous presence
of ≥ 1 of the following criteria: total cholesterol levels > 190 mg/dL, LDL cholesterol
levels > 115 mg/dL, triglyceride levels > 150 mg/dL and glucose levels > 110 but < 126
mg/dL
Participants were excluded if they were taking medications for any reason, had a serious
illness or an unstable condition, were pregnant or nursing, were participating or had
participated in a weight loss treatment programme in the last 6months, or were following
or had followed a food profile which, to a certain extent, excluded meat, poultry or fish
in the last 6 months
Median age 50 (range 21 to 75); 22% men; 118 participants randomised
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Interventions 2 dietary interventions: Mediterranean diet and lacto-ovo vegetarian diet
Interventions were delivered through face-to-face, individual counselling sessions at the
Clinical Nutrition Unit. Participants were provided with a detailed, 1-week menu plan
as well as tips and information on the food groups that could be included and those that
could not. Both of the diets were low-calorie in nature and acted as dietary interventions
to reduce body weight or the risk parameters for cardiovascular disease. The vegetarian
diet included recipes for preparing meals. Both diets were hypo caloric with respect to
the energy requirements of the participants, but isocaloric between them, and consisted
of 50% to 55% of energy from carbohydrate, 25% to 30% from total fat (≤ 7% of
energy from saturated fat, < 200 mg/day of cholesterol) and 15% to 20% from protein.
The vegetarian diet was characterised by abstinence from the consumption of meat and
meat products, poultry, fish and seafood, and the flesh of any other animal. It included
eggs and dairy products, as well as all the other food groups. The Mediterranean diet
was characterised by the consumption of all the food groups, including meat and meat
products, poultry and fish. There were no substantial differences in the frequency of
servings per week for cereals, fruits and vegetables, potatoes, sweets and olive oil between
the diets. As expected, a higher frequency of consumption, per week, of legumes (5 versus
2.5 servings), nuts (2 versus 1), eggs (2 versus 1), and dairy products (21.5 versus 18.5)
was reported for the vegetarian diet compared to the Mediterranean diet
Follow-up at 3 months
Outcomes Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides
Notes The 2 diets are very similar in terms of the components of theMediterranean diet with the
exception of low consumption of meat and meat products and increased consumption
of fish for the Mediterranean diet
Analysed as a parallel-group design for the first 3-month phase
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used a web-based online randomisation
procedure
Allocation concealment (selection bias) Low risk Used a centralised service and it was not
possible for the investigators to know the
allocation sequence in advance
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States that blinding of participants and di-
eticians is not possible because of obvious
differences between the intervention diets.
Blinding of participants and personnel for
behavioural interventions is difficult and
often not possible so we have not judged
this as at high risk of bias
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial personnel who enrolled participants,
outcome assessors and data analysts were
blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9% and 10% loss to follow-up in the inter-
vention and comparison group respectively
with reasons given
Selective reporting (reporting bias) Low risk Outcomes reported as detailed in the pro-
tocol
Other bias Unclear risk Insufficient information to judge
Stradling 2018
Methods RCT of parallel-group design (pilot)
Participants Adults with stable HIV infection on anti-retroviral treatment for > 6 months and LDL
cholesterol > 3mmol/L from 3 UK centres in the West Midlands were recruited
Exclusion criteria: planning pregnancy in next 6 months; current use of lipid-lowering
agents (any interfering drug or diet); secondary causes of dyslipidaemia (renal or liver
disease, diabetes, hypothyroidism, familial hyperlipidaemia); knownnut allergy; unstable
psychiatric disorder (including eating disorders); current participation in a weight loss
programme or other dietary intervention; and inability to understand printed materials
Interventions 60 patients were randomised to Diet 1: low saturated fat or Diet 2: Mediterranean Port-
folio. Both groups attended 3 individual consultations with the research dietitian, and
received further telephone reinforcement and support during the 6-month intervention
period. This was followed by a 6-month maintenance period, with routine clinic visits
only. The same research dietitian, experienced in HIV nutritional care, provided all con-
sultations
Diet 1: low saturated fat
Focus on reduction of saturated fat to < 10% of energy intake, in line with UK guidelines.
Resources were provided, such as written information, recipes and online videos, covering
various topics including sources of saturated fat, food swaps, food labelling, cooking
methods, cheese facts and margarine types. On completion of the 12-month outcome
measurements, participants in group 1 received the dietary information from Diet 2
(Mediterranean Portfolio)
Diet 2: Mediterranean Portfolio
In addition to the information provided to group 1, participants allocated to Diet 2
received advice and support to adopt the Mediterranean diet supplemented by addi-
tional functional foods with cholesterol-lowering properties. This was embedded within
a motivational interviewing style consultation to include assessing readiness to change,
utilising decisional balance, reflective listening and open-ended questions, to identify
needs, motivators and barriers to changing their diet. The diet was not prescriptive; goals
were negotiated individually with each participant during their first session and reviewed
at each visit. Daily consumption of 57 g tree nuts and 2 g plant stanols was encouraged
81Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stradling 2018 (Continued)
in the form of 2 handfuls of unsalted mixed nuts (almonds, cashew nuts, peanuts, Brazil
nuts, hazelnuts, pecans, walnuts, pistachios, macadamia nuts) and a 50 mL cholesterol-
lowering drink at randomisation and subsequent sessions. Participants were encouraged
to continue with the nuts and stanols, while also aiming to eat 15 g/day soy protein as
soya milk, yogurt or dessert, tofu and meat substitutes, and adopt a Mediterranean-style
diet, with more vegetables and fruit, olive oil and approximately 15 g to 20 g/day soluble
fibre from oats, pearl barley, lentils, beans and flaxseed. Supplies of the functional foods
(nuts, soy protein, plant stanols, oats and pulses) were given to participants to offset the
additional cost of making dietary changes
Follow-up 12 months
Outcomes LDL cholesterol, SBP, DBP
Notes 12-month follow-up data kindly provided by the authors.
ISRCTN32090191. Protocol paper published and conference abstracts with 6-month
follow-up data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A statistician produced a computer-generated al-
location sequence using random block sizes of 2
and 4, stratified by gender and smoking status
Allocation concealment (selection bias) Low risk The research dietitian allocated participants ac-
cording to the diet number concealed in the next
sequentially numbered, opaque, sealed envelope,
relevant for their gender and smoking status
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk As this is a complex intervention, it was not pos-
sible to blind the participants, nor is it possible
to blind the healthcare professionals. The terms
Diet 1 and Diet 2 were used with the aim of
achieving participant blinding to the exact con-
tent of the diet and type of foods included, to
prevent Internet searching of diet titles and po-
tential contamination between groups
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk At 12 months 6/31 and 5/29 missing data for
some outcomes for Diet 1 and Diet 2 respec-
tively. No further details at this stage as the full
paper is not yet published
82Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stradling 2018 (Continued)
Selective reporting (reporting bias) Unclear risk Results reported as conference proceedings only
so cannot be determined
Other bias Unclear risk Insufficient information to judge
The Lyon Diet Heart Study
Methods RCT of parallel-group design.Modified Zelendesign where during hospital stay, patients
were asked to participate in a cohort study with a follow-up of 5 years and to sign a first
informed consent. They were not fully informed about the design of the study, especially
regarding the comparison of 2 diets. Patients assigned to the experimental group were
asked to comply with a Mediterranean-type diet and had to sign a second consent form
Participants Men and women less than 70 years old, who survived a myocardial infarction within 6
months of enrolment were eligible
Exclusion criteria included heart failure (stage III and IV NYHA), hypertension (systolic
> 180 mmHg, diastolic > 110 mmHg) and inability to complete an exercise test due to
recurrent angina, ventricular arrhythmias or atrioventricular block. Among patients who
had coronary angioplasty or bypass, only those who were clinically stable were eligible.
Patients were also excluded if they had any other conditions thought to limit survival or
ability to participate in a long-term trial
605 patients randomised; mean age 53.5; 90% men
Interventions Diet:
Patients in the experimental groupwere advised by the research cardiologist and dietician,
during a 1-hour-long session, to adopt a Mediterranean-type diet: more bread, more
root vegetables and green vegetables, more fish, less meat (beef, lamb and pork to be
replaced with poultry), no day without fruit, and butter and cream to be replaced with
margarine supplied by the study. The patients would not accept olive oil as the only fat,
therefore a rapeseed (canola) oil-based margarine was supplied free for the whole family
to all experimental participants. This margarine had a composition comparable to olive
oil but was higher in linoleic (16-4 versus 8% to 6%) alpha-linolenic acid (4-8 versus
0% to 6%). The oils recommended for salads and food preparation were rapeseed and
olive oils exclusively. Moderate alcohol consumption in the form of wine was allowed at
meals. Advice was tailored to individuals. At each subsequent visit of the experimental
patients, a dietary survey and further counselling were done by the research dietician
Comparison group:
Control patients received no dietary advice apart from that of hospital dieticians or
attending physicians as usual care
After the randomisation visit, patients from both groups were scheduled to be seen 2
months later and then annually at the Research Unit. These visits did not replace their
regular visits to the attendingphysicians, whowere responsible for all aspects of treatment,
including use of medication and of invasive diagnostic and therapeutic procedures
Follow-up at 24 and 46 months
Outcomes CVD mortality, total mortality, composite clinical endpoints CVD death and non-fatal
MI at 46 months. Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides,
SBP, DBP at 24 months
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Notes Clinical events reported in 1999 paper detail extended follow-up (mean 46 months). 2
additional composite clinical endpoints that include additional outcomes not listed as
primary outcomes in our review have not been used. Original 1994 paper reports clinical
events and CVD risk factors at 27 months and 24 months respectively
“An intermediate analysis was proposed by the Scientific Committee to be performed
in March 1993, clinical data being frozen after a minimum follow-up of 1 year for each
patient. Because of a statistically significant result, the decision was made to stop the
trial. The first report was published in June 1994. For ethical, medical, and scientific
reasons, all patients were invited to come to the Research Unit for a final visit, during
which they were fully informed about themain results of the trial. Hence, given the delay
after the clinical status of the 2 groups in March 1993, the decision to invite the patients
to a new assessment, and the time needed to see each patient, an additional follow-up
of ’19 months was available in the 2 groups to perform the final analyses. This offered
the opportunity to evaluate the long-term (mean, 4 years) effect of the diet tested in the
trial and whether the patients continued to comply with it.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single-blinded study. Modified Zelen de-
sign so patients assigned to the intervention
group are fully aware of their assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assignment of patients was not known
by the attending physicians. Mortality and
morbidity outcomes were validated and
classified by an independent committee
that worked only on the blinded data from
hospital files concerning outcomes that in-
volved hospital admission
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses were done based on the intention-
to-treat principle
Selective reporting (reporting bias) Low risk All outcomes reported as stated
Other bias Unclear risk To avoid between-group contamination,
with the approval of the Ethical and Sci-
entific Committees, patients were not fully
informed of the design of the study, espe-
cially of the comparison between 2 diets.
To be included in the study, they had to
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come to the outpatient clinic, 2 weeks af-
ter discharge, and be randomised. Patients
assigned to the experimental group had to
sign a second informed consent in which
they agreed to modify their diets
Tuttle 2008
Methods RCT of parallel-group design
Participants The Heart Institute of Spokane Diet Intervention and Evaluation Trial (THIS-DIET)
was designed to actively compare a conventional heart-healthy low-fat diet with a
Mediterranean-style diet for effects on cardiovascular events and survival after first my-
ocardial infarction. Patients were recruited < 6 weeks after first MIs by referrals from
their attending physicians in the US
Patients were excluded for New York Heart Association class III or IV heart failure,
ventricular arrhythmias requiring medication or a defibrillator, or uncontrolled hyper-
tension
705 patients were screened, 333 did not meet the criteria, 271 refused and 101 were
randomised
Mean age 58; 80% men in the intervention group, 68% in the control group
Interventions Participants were randomised to a Mediterranean-style diet (intervention) or a low-fat
diet (the American Heart Association Step II diet) (control)
The main goals of the low-fat dietary intervention were to reduce saturated fat calories
to ≤ 7% and cholesterol intake to ≤ 200 mg/day.The Mediterranean-style diet shared
these goals, with additional goals of increasing the intake of omega-3 fatty acids (> 0.
75% of calories) and monounsaturates (20% to 25% of calories). The 2 diets recom-
mended the increased intake of fresh fruits and vegetables (≥ 5 servings/day) and whole
grains. The Mediterranean-style diet was distinguished by an emphasis on the increased
consumption of cold-water fish (3 to 5 times/week) and oils from olives, canola and
soybeans. Participants procured and prepared their own meals. Although not a weight-
loss intervention, participants who were overweight or obese were encouraged to reduce
calories to facilitate weight loss. Exercise and smoking cessation were encouraged but
were not specific intervention targets. Participants in both groups received 2 individual
dietary counselling sessions from study dietitians within the first month, followed by
additional individual sessions at months 3, 6, 12, 18 and 24. In separate classes for each
diet conducted by study dietitians, participants attended 6 different group sessions fo-
cused on behavioural modification and practical aspects of their assigned diets, including
recipes, grocery shopping and dining out. After completing 6 classes, participants were
invited but not required to continue attending group sessions
2 years follow-up
Outcomes Composite of endpoints including all-cause and cardiac deaths, MI, hospital admissions
for heart failure, unstable angina or stroke, HDL cholesterol, LDL cholesterol, triglyc-
erides, SBP, DBP
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Notes Both diets were combined and compared to a non-randomised control group as well
as directly compared with one another. Only the randomised comparisons are reported
here
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Sealed envelopes concealing the allocation sequence
were prepared by a research co-ordinator. Assignment
was stratified by diabetes mellitus status using 10-en-
velope blocks. Envelopes were selected in the prepared
order from a locked drawer by a study dietitian to assign
interventions
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States that neither the intervention team nor partici-
pants could be blinded to dietary assignment. Blinding
of participants and personnel for behavioural interven-
tions is difficult and often not possible so we have not
judged this as at high risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The principal investigator was blinded for the purpose
of adjudicating clinical endpoints and adverse events by
the removal of identifiers from records used for review
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Intention-to-treat analyses used for clinical endpoints.
3/51 patients dropped out of the intervention group,
5/50 patients dropped out of the control group. At 2
years 27% and 28% data missing for the intervention
and control group for CVD risk factors
Selective reporting (reporting bias) Low risk Outcomes reported as stated
Other bias Unclear risk Insufficient information to judge
Vincent-Baudry 2005
Methods RCT of parallel-group design
Participants Medi-RIVAGE study conducted in France. Participants recruited from Center for De-
tection and Prevention of Arteriosclerosis at La Timone University Hospital. 232 were
invited and 212 were randomised
Inclusion criteria: at least 1 of the following criteria: fasting plasma cholesterol concen-
tration of 6.5 to 7.7 mmol/L; triacylglycerol concentration of 2.1 to 4.6mmol/L; glucose
concentration of 6.1 to 6.9 mmol/L; SBP and DBP between 140 to 180 and 90 to 105
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mmHg respectively; BMI > 27; smoking; sedentary; or family history of CVD
Participants treated by hypolipaemic or hypoglycaemic drugs were excluded
102 participants were randomised to theMediterranean diet group; mean age 50.8; 42%
men
110 participants were randomised to the low-fat diet group; mean age 51.6; 39.5% men
Interventions The Mediterranean diet recommended nuts, wholemeal bread, cereals and a variety of
raw or cooked, fresh or dried fruit and vegetables and legumes, with up to 35% to 38%
of total energy intake as fat. Olive oil was recommended as the main source of added fat,
and 50% of the energy provided by fat was to come from MUFAs, 25% from PUFAs
and 25% from SFAs. Fish was recommended 4 times/week and red meat only 1 time/
week. The recommended fibre intake was 25 g/day. The suggested red wine intake was
1 to 2 glasses per day. Dairy intake was limited by giving participants a calcium limit of
800 mg/day. The target for carotenoid intake was at 7 mg/day as a marker of fruit and
vegetable intake. Dietary advice was given by physicians and dieticians and participants
received a booklet with nutritional recommendations. In addition, participants were
provided with oat-bran enriched pasta, tomato sauce and olive oil
A commonly prescribed low-fat American Heart Association-type diet was adapted for
the low-fat diet group. Recommendations were to eat more poultry than mammal meat,
to avoid offal and saturated fat-rich animal products, and to eat fish 2 to 3 times/
week. The consumption of raw and cooked fruit and vegetables, low-fat dairy products
and vegetable oils was recommended. Low-fat diet recommendations limited fat intake
to 30% of total energy, with 33% of energy from MUFAs, PUFAs and SFAs. The
recommended fibre intake was 20 g/day and alcohol was to be avoided, especially for
hypertriglyceridaemic participants
Cholesterol was restricted to 200 to 300 mg/day in both diets. To ensure adequate
compliance with dietary recommendations, 3-day food records (at inclusion and after 3
months) and 24-hour unscheduled dietary recalls (once amonth) were used by dieticians.
The physical activity of the participants was recorded on questionnaires and did not
differ at inclusion or at 3 months between the 2 groups
Follow-up was at 3 months
Outcomes Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, SBP, DBP
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Only states randomly assigned
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk 43 participants dropped during 3 months. The char-
acteristics of the dropouts were not significantly differ-
ent from those of the other participants, but there was
differential dropout, with 15.9% in the Mediterranean
diet group and 35.8% in the low-fat diet group
Selective reporting (reporting bias) Low risk All outcomes stated are reported
Other bias Unclear risk Insufficient information to judge
Wardle 2000
Methods RCT of parallel-group design
Participants Participants were adults with mild-to-moderate hypercholesterolaemia with serum
cholesterol levels above 5.2 mmol/L, not current or previous (within 3 months) users of
lipid-lowering medication and with no serious illness
Participants were recruited from dietetic clinics, hospital physicians and general practi-
tioners in London and the South East, UK
117 participants were randomised; mean age 53.5 years; 43.5% men
Interventions The intervention (Mediterranean diet) was delivered in 8 sessions during the 12-week
intervention period using a combination of individual and group sessions with a di-
etician and psychologist. Dietary advice was to increase intake of fruit and vegetables,
and oily fish and to reduce fat to 30% of energy with substitution of predominantly
monounsaturated fat for saturated fat. All participants received individualised advice
to implement dietary changes based on their lifestyle and food preferences and group
support in maintaining changes. Intervention participants were also given free spreading
fats and oils high in monounsaturated fats
The comparison group was a wait-list control. Participants were told it was necessary to
wait for treatment but that they would be seen at 6-week intervals. They were not given
any specific dietary advice but were not discouraged from making changes and some
participants did so
12 weeks follow-up
Outcomes Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides
Notes Focus of the study was the effect of the Mediterranean diet on cognitive function
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details provided but the control group was a wait-
list control
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessment was done by a member of the re-
search team who was blinded (in most cases)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No ITT but details of attrition provided and reasons
Selective reporting (reporting bias) Low risk All of the outcomes stated were reported
Other bias Unclear risk Insufficient information to judge
Weber 2012
Methods RCT of parallel-group design (pilot trial)
Participants Included outpatients who were over 45 years of age with established or previous
atherothrombotic CVD occurring in the past 10 years and who were at high CVD
risk. The patients also had to have at least one of the following risk factors: diabetes
mellitus, hypertension, smoking, dyslipidaemia family coronary artery disease history,
asymptomatic carotid disease or BMI > 25
Exclusion criteria: neurocognitive or psychiatric conditions, pregnant or lactating
women, patients with hepatic impairment or renal insufficiency, and patients with a life
expectancy of less than 6 months (e.g. those with metastatic malignancies)
122 patients randomised; mean age 63 years; 66% men
Interventions Pilot of the BALANCE trial
Patients were randomised in a 1:1:1 ratio to receive one of 3 dietary interventions (A, B
or C)
Group A
Joined the Brazilian Cardioprotective Diet Program, which involves a Brazilian version
of an accessible dietary therapy for cardiovascular diseases and weekly counselling with
dieticians. The main difference between the Brazilian Cardioprotective Diet Program
and the usual dietary therapy (groups B and C) was the consideration of energy density.
The Brazilian Cardioprotective Diet Program helped the patients to avoid high energy
density foods (> 1 kcal/g), thus allowing them to eat more and consume fewer calories.
As they made the right food choices, they felt less restricted, aiding in the improvement
of adherence.
The Brazilian Cardioprotective Diet Program features nutritional recommendations that
are feasible for the Brazilian population, allowing for the easy access and full use of
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foods, in addition to the prioritisation of regional foods that are culturally accepted by
the patients (rice, bean, soy oil, and Brazilian fruits and vegetables). Patients in Group
A attended weekly in-person sessions with dietitians either by phone or in a gourmet
shop. During attendance at the gourmet shop, the patients received tips for eating in
restaurants, instructions on label reading and a list of typical Brazilian recipes that were
adjusted for nutrients and energy densities
Group B
Received the dietary therapy that was proposed by the Brazilian guidelines for cardiovas-
cular diseases and also attended weekly counselling sessions with dietitians. This diet had
the same nutrient profile as that which was presented in Group A but was customised by
the integration of typical Mediterranean foods (e.g. olives, olive oil, chestnuts, walnuts,
almonds, hazelnuts, peanuts and cold water fish). Group B received weekly sessions that
were conducted in person or by telephone
Group C
Received the same dietary intervention as Group B, but the patients were counselled
monthly in person
The nutrient profiles of the 3 diets were based on the Brazilian guidelines for cardio-
vascular disease treatment. The diets contained 50% to 60% of energy from carbohy-
drates, 15% from proteins and 25% to 35% from fats. In addition, 20 g to 30 g/day of
fibre and 2000 mg/day of sodium were recommended. The concentrations of saturated,
monounsaturated and polyunsaturated fatty acids were 7%, 20% and 10%, respectively.
The total dietary energy intake was adjusted only for patients with a baseline BMI >
25 kg/m². The first nutritional session lasted for 60 minutes. The follow-up counselling
sessions lasted for 30 minutes once the teaching and nutrition goals were reviewed. The
phone interviews lasted approximately 15 minutes and included just the time that was
necessary to assess the 24-hour dietary recall
Follow-up 12 weeks
Outcomes SBP, DBP
Notes Used Groups A and B as comparators in this review due to the same number of contacts,
Group B representing the Mediterranean diet and intervention group, Group A the
comparison diet. Change in blood pressure and SD difference were provided in graphs.
Values have been estimated from these to use in meta-analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Allocation concealment was guaranteed by
using sealed and opaque envelopes that were
numbered sequentially
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/42 and 2/41 lost to follow-up in Groups
A and B respectively with reasons provided
Selective reporting (reporting bias) Low risk Outcomes reported as stated
Other bias Unclear risk Insufficient information to judge
AF: Atrial Fibrillation; BMI: body mass index; CVD: cardiovascular disease; DBP: diastolic blood pressure; HDL: high-density
lipoprotein; HF: Heart Failure; HRT: hormone replacement therapy; HTN: Hypertension; IHD: ischaemic heart disease; ITT:
intention-to-treat; LDL: low-density lipoprotein; MI: myocardial infarction; MUFA: monounsaturated fatty acid; PAD: peripheral
arterial disease; PUFA: polyunsaturated fatty acid; RCT: randomised controlled trial; RDA: recommended daily allowance; SBP:
systolic blood pressure; SD: standard deviation; SFA: saturated fatty acid; T2DM: type 2 diabetes mellitus; VLC: very-long-chain;
WHO: World Health Organization
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abedi 2010 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
Azadbakht 2005 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
Berrino 2001 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
Bruno 2018 Intervention included a physical activity element
Burr 2003 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
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Conlin 2000 Follow-up < 12 weeks
CRESSIDA Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
de la Iglesia 2013 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
ENCORE Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
Fuentes 2001 Follow-up < 12 weeks
Jula 2002 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
Lankinen 2014 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
Lanza 2001 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
Lima 2013 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
Lindeberg 2007 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
Mayneris-Perxachs 2014 Sub-study of the PREDIMED trial
Mezzano 2003 Not all participants were randomised
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Papadaki 2008 Not an RCT
Poulsen 2014 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
Sondergaard 2003 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
SYSDIET Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
Thomazella 2011 To maximise adherence, diet allocation was not randomised
Wade 2017 Follow-up period too short at 8 weeks
Weber 2016 Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
The pilot for the BALANCE trial is included in the review Weber 2012 as there is an arm with foods
typical of the traditional Mediterranean diet tested against the new intervention being developed
WHI Intervention did not comprise both core components of:
1. high monounsaturated/saturated fat ratio (use of olive oil as main cooking ingredient and/or consump-
tion of other traditional foods high in monounsaturated fats such as tree nuts);
2. high intake of plant-based foods, including fruits, vegetables and legumes
RCT: randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
Delgado-Lista 2016
Trial name or title CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV
study)
[NCT00924937]
Methods RCT of parallel-group design of 2 dietary interventions
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Participants 1002 patients with CHD from Spain aged 20 to 75 years
Inclusion criteria:
Informed consent
Clinical: unstable coronary disease with documented vessel/myocardial damage, acute myocardial infarction,
revascularisation
Exclusion criteria:
Age < 20 or > 75 years (or life expectancy lower than 5 years)
Patients already planned for revascularisation
Patients submitted to revascularisation in the last 6 months
Grade II-IV heart failure
Left ventricle dysfunction with ejection fraction lower than 35%
Patients unable to follow a protocol
Patients with severe uncontrol of diabetes mellitus, or those with renal insufficiency with plasma creatinine
higher than 2 mg/dl, or cerebral complications of diabetes mellitus
Other chronic diseases: psychiatric diseases, renal insufficiency, chronic hepatopathy, active malignancy,
chronic obstructive pulmonary disease, diseases of the digestive tract, endocrine disorders
Patients participating in other clinical trials (in the enrolment moment or 30 days prior)
Interventions 1) Mediterranean diet, with a minimum 35% of calories as fat (22% MUFA fat, 6% PUFA fat and < 10%
saturated fat), 15% proteins and a maximum of 50% carbohydrates
2) Low-fat high complex carbohydrate diet recommended by the National Cholesterol Education Program
and the AmericanHeart Association, comprising of < 30% total fat (< 10% saturated fat, 12% to 14%MUFA
fat and 6% to 8% PUFA fat), 15% protein and a minimum 55% carbohydrates
The objective was to compare the dietary pattern of the Mediterranean diet food pyramid versus the dietary
pattern recommended by the AmericanHeart Association. Both therapeutic diets should provide awide variety
of foods, including vegetables, fruit, cereals, potatoes, legumes, dairy products, meat and fish. Participants in
both intervention groups receive the same intensive dietary counselling. Dietitians administered personalised
individual interviews at inclusion and every 6 months, and quarterly group education sessions with up to 20
participants per session and separate sessions for each group. These sessions consisted of informative talks
accompanied by written information with detailed descriptions of typical foods for each dietary pattern,
seasonal shopping lists, meal plans and recipes. For those randomised to the Mediterranean diet, on the
basis of the initial assessment of individual scores of adherence using a 14-item questionnaire, dietitians gave
personalised dietary advice with instructions directed to increasing the score, by including, among others, 1)
abundant use of olive oil for cooking and dressing, 2) increased consumption of fruit, vegetables, legumes and
fish, 3) reduction in total meat consumption, with white meat recommended instead of red or processedmeat,
4) preparation of homemade sauces with tomato, garlic, onion and spices with olive oil to dress vegetables,
pasta, rice and other dishes, 5) avoidance of butter, cream, fast food, sweets, pastries and sugar-sweetened
beverages, and 6) in alcohol drinkers, a moderate consumption of red wine. The participants assigned to the
Mediterranean diet were given free extra-virgin olive oil (1 litre/week). The participants randomised to the
low-fat diet received recommendations focused on limiting all types of fat, from both animal and vegetable
sources, and on increasing the intake of complex carbohydrates. The participants also received free food packs
incorporating the main food components of this dietary pattern. No energy restriction was administered, nor
was physical activity promoted specifically by the study team
Follow-up 7 years
Outcomes Primary outcome: combined cardiovascular events (myocardial infarction, revascularisation, ischaemic stroke,
documented peripheral artery disease or cardiovascular death) over 7-year time frame
Pre-specified secondary outcomes are: incidence of intermittent claudication; concentration of LDL choles-
terol; lipid-related atherogenic ratios: total cholesterol/HDL and LDL/HDL; metabolic control of carbohy-
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drates (assessed by glycaemic and insulin responses to tolerance tests to glucose); metabolic control of lipids
and postprandial lipaemia; blood pressure; incidence of malignancy; incidence of type 2 diabetes mellitus;
incidence of metabolic syndrome; arrhythmias; an extended composite of heart events (cardiac death, my-
ocardial infarction, unstable angina, revascularisation, heart failure, heart transplantation and cardiac arrest)
, an extended composite of cardiovascular disease progression (cardiac death, myocardial infarction, unstable
angina, revascularisation, heart failure, heart transplantation, cardiac arrest, stroke and peripheral artery dis-
ease), progression of cognitive decline and changes in gut microbiota
Starting date November 2009
Contact information Francisco Perez Jimenez, Chief of Internal Medicine Unit, Hospital Universitario Reina Sofia de Cordoba,
Spain
Notes Estimated study completion date September 2019. NCT00924937 accessed 7 October 2018
Hardman 2015
Trial name or title The Lifestyle Intervention in Independent Living Aged Care (LIILAC) study [ACTRN12614001133628]
Methods Factorial design, participants individually randomised to one of the following groups:
Group 1: Diet change to reflect a greater adherence to a Mediterranean diet
Group 2: Exercise change to walk up to 30 minutes every second day
Group 3: Combined diet and exercise change
Group 4: Control group with no diet or exercise change
Participants Inclusion criteria: currently living independently or supported accommodation within an aged care facility
in Australia, ability to walk and be ambulatory for at least 30 minutes, free from major physical ailments,
willing to provide blood samples, men and women aged 60 to 90 years
Exclusion criteria: cognitive impairment as defined as a score below 24 on theMiniMental State Examination,
clinical diagnosis of depression, or score of 8 or above on the long form Geriatric Depression Scale, diagnosis
of dementia or Alzheimer’s disease, history of stroke or head trauma, colour blindness
Participants were recruited over a minimum of 15 sites by posters and bulletins for an information event and
opportunity to participate following informed consent
Interventions Diet group: those allocated to the diet change group will be required to score their diet in relation to a
Mediterranean diet sheet and achieve at least an 85% adherence to the diet. Instruction on how to self-
assess the diet sheets and further guidance will be given to participants to inform them of food choices via
a specifically designed Mediterranean Healthier living diet recipe booklet created by a dietician. Participants
will cook for themselves and be issued with recipes and meal ideas. Each person in the diet change group
will be allocated 6 X 750 mL bottles of premium extra-virgin olive oil for the study (allowing for an average
usage of 46 ml/day). An ongoing interaction with the participants will take place at 6 weeks (10 to 20-
minute telephone call) after the initiation of the trial by a member of the research team and then again at
the 3-month (20 to 30-minute face-to-face discussion) intervention and then again at 4.5 months (10 to 20-
minute telephone call) to ensure their adherence to the diet guide and also to ensure their enthusiasm and
participation is maintained
Control group: no intervention
95Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hardman 2015 (Continued)
Outcomes Cognitive function as primary outcomes, CVD risk factors as secondary outcomes (blood pressure and lipid
levels) and quality of life. Follow-up at 6 months and ethical approval for longer term follow-up
Starting date First participant enrolment 21 May 2014
Contact information A/Prof Andrew Pipingas
Head of Neurocognitive Ageing Research, Centre for Human Psychopharmacology (CHP)
Faculty of Health, Arts & Design
Swinburne University of Technology
P.O. Box 218
Hawthorn, Victoria 3122
Australia
Phone: +61 3 9214 5215
Email: apipingas@swin.edu.au
Notes Trial registry shows as completed with last data collection 18 January 2016. 152 recruited from target of 208.
For the current review only 2 arms of the trial are relevant - diet only and the no intervention control group.
ACTRN12614001133628 accessed 7 October 2018
Itsiopoulos 2018
Trial name or title AUSMED: AUStralian MEDiterranean Diet Heart Trial
Methods RCT of parallel-group design
Participants Inclusion criteria: “Eligible patients will be aged ≥ 18 years, English speaking, and within 1 year of acute
presentation of AMI to the recruitment sites, as defined by the Cardiac Society Guidelines: a type 1 MI:
ST-segment elevation MI (STEMI) or non-STEMI presenting with angina pectoris confirmed with elevated
cardiac enzymes (troponin levels) or coronary angiography or balloon angioplasty (with or without stent) as
defined by the third universal definition of MI (UDMI). Patients with type 2 Diabetes will be included.”
Exclusion criteria: “Patients will be excluded if they have active malignancy; symptomatic chronic heart failure
(New York Heart Association Functional Classification II, III, and IV); chronic inflammatory disease (e.g.,
inflammatory bowel disease or rheumatoid arthritis treated with anti-inflammatory or immunomodulating
medications); chronic kidney disease stage 3 or above, decompensated liver disease or taking medications
that cause hepatosteatosis; immunodeficiency or HIV-positive status; body mass index > 40; are currently
breastfeeding, pregnant, or trying to fall pregnant; are currently participating in an intervention trial targeting
CVD, diet, or exercise; or are unable to attend all study appointments. Patients with serious food allergies
will be managed appropriately by the dietitians on the team to ensure allergens are avoided.”
Target recruitment 1032 patients
Interventions Mediterranean diet: “Participants who are randomized to the intervention group (MedDiet) will receive
nutrition assessment and intensive education on the Mediterranean diet. [...] Participants will be asked to
complete a 7-day food diary in household measures during the week before the baseline appointment to
determine habitual diet. Individuals will then be interviewed by an accredited practicing dietitian (APD)
and will receive a 14-day meal plan which incorporates the key principles of the Mediterranean diet and is
consistent with the participant’s cultural and religious dietary requirements. [...] Meal plans will be designed
to meet current energy requirements for weight maintenance and will be consistent with the macronutrient
composition of the Mediterranean diet (15%-20% protein, 35%-40% fat [18%-20% of total energy intake
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as monounsaturated fatty acids], 40%-45% carbohydrate). Food group recommendations will include daily
intake of EVOO, nuts, vegetables, fruit and whole-grain cereals, regular intake of legumes, fish, and yoghurt,
and limited intake of commercial sweets or pastries and red or processed meat. Poultry, eggs, and feta cheese
will be recommended in moderation.”
Low-fat diet: “Participants following the standard care low-fat diet will receive assessment and education
according to the standard protocol that is consistent with the dietetic service of the participating hospitals, that
is, a diet based on the National Heart Foundation Guidelines and the Australian Dietary Guidelines. [...] In
terms of contribution to total energy consumption, target macronutrient intakes will be < 30% total fat, < 7%
saturated fat, 45%-65% carbohydrate, 15%-25% protein, and ≤ 5% alcohol. Food group recommendations
will include daily intake of grains and cereals (mostly whole grains, 5-7 serves per day), vegetables (5-6 serves
per day), fruit (2 serves per day), protein foods (2-3 serves per day) and low-fat dairy foods (2 serves per day)
. [...] The low-fat diet group will have the same number of appointments and support as the intervention
group to control for the level of attention received by both groups.”
Outcomes Primary: cardiovascular events
Secondary: cardiovascular clinical biomarkers, arterial stiffness, immune and inflammatory markers, platelet
activity, body composition, cost-effectiveness
Starting date Enrolment started 1 October 2014. Anticipated last enrolment 1 October 2018
Contact information Prof Catherine Itsiopoulos
Health Sciences Building 1, Allied Health Executive Office, Room 256
Department of Rehabilitation, Nutrition and Sport
School of Allied Health
College of Science, Health and Engineering
La Trobe University
Bundoora VIC 3086
Email: c.itsiopoulos@latrobe.edu.au
Notes ACTRN12616000156482
NCT03053843
Trial name or title PREDIMAR
Methods RCT of parallel-group design
Participants “Inclusion criteria:
• Patients with symptomatic paroxysmal AF (with evidence of more than one symptomatic episode in
the last year and at least one documented episode) upon whom catheter ablation is performed.
• Patients with persistent symptomatic AF upon whom catheter ablation is performed.
Exclusion criteria:
• Serious medical condition that prevents dietary intervention (gastrointestinal disease with intolerance
to fats, advanced malignancy, neurological, psychiatric or severe endocrine disease)
• Any other pathology or medical condition that limits survival to less than one year; Immunodeficiency
or HIV-positive,
• Consumption of illegal drugs,
• Chronic alcoholism or total consumption of alcohol > 80 g/d
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• Body mass index > 40 kg/m2,
• Difficulty or major inconvenience with changing dietary habits, inability to follow a style of
Mediterranean diet, low probability of changing dietary habits according to the models of Prochaska and
Diciemente (Nigg, 1999)
• History of food allergy or hypersensitivity to any component of EVOO
• Participation in a clinical trial carried out with drugs or use of a drug in experimental state during the
year prior to inclusion
• Institutionalised patients for chronic treatment, with lack of autonomy and with inability to perform
the clinical follow-up,
• Impossibility of telephone contact
• Patients with acute infection or inflammatory process (e.g. pneumonia) may be included in the study
three months after the resolution of the infectious symptoms.”
Interventions Intervention: “Mediterranean diet plus extra virgin olive oil. The patients in the intervention group will
receive 1 liter of EVOOper week free of charge and dietary advice on how to follow aMediterranean diet with
contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience
in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED
intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions
with patients about dietary education shall be conducted in telephone form, using the internet and sending
comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations
of typical food in the Mediterranean diet.”
Control: “no specific diet. The control group will be assigned to the usual care and patients assigned to this
group will not receive any special intervention to follow a particular diet, as occurs in the current clinical
practice.”
Outcomes Primary: atrial tachyarrhythmias
Secondary: atrial fibrillation, inflammatory markers, quality of life
Starting date Start: 6 March 2017. Estimated completion: 6 March 2020.
Contact information Teresa Barrio-López
Email: terebarriol@gmail.com
Notes -
NCT03129048
Trial name or title Mediterranean diet, weight loss and cognition in obese older adults
Methods RCT of parallel-group design
Participants “Inclusion criteria:
• Men and women ≥ 55 years of age],
• BMI 30.0-50.0 kg/m2,
• English speaking
• Have access to a phone
• Plan to reside in the Chicago area for the following 14 months
• Minimal levels of cognitive impairment as determined by the Montreal Cognitive Assessment (MoCA)
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< 19.
Exclusion criteria:
• The exclusion criteria ensure that participants can safely participate in the trial.
• renal disease
• autoimmune disorder
• immunodeficiency
• malabsorptive disorder
• gastrointestinal and hepatic diseases
• severe ischemic heart disease
• severe pulmonary disease
• bariatric surgery
• alcohol abuse (> 50 grams/day) or illicit drug abuse
• uncontrolled diabetes based on capillary hemoglobin A1c (HbA1c) > 9.0%
• schizophrenia or bipolar disorder
• cancer treatment within the past 12 months
• weight > 450 lbs. (due to the weight limitation of the DXA scanner)
• diagnosed sleep apnea and regularly using a cpap machine
• currently adhering to a MedDiet, Montreal Cognitive Assessment (MoCA) < 19,(161) -
• currently on a weight-loss diet or actively involved in a formal weight loss program (e.g., Weight
Watchers.)”
Interventions “The MedDiet-A group will learn about and how to adhere to the Mediterranean Diet. Over the course of 8
months, they will receive twenty-two classes 60-minute in length
The MedDiet-WL group will learn about the Mediterranean Diet, how to adhere to is and engage in lifestyle
choices like exercising and eating fewer calories so that they will lose weight. Over the course of 8 months
they will receive 22 classes, each 90 minutes in length
The Typical Diet Control group will be asked to maintain current eating and activity patterns over the course
of the 14 month study.”
MedDiet-A and the Typical Diet Control groups are of interest to this review only
Outcomes Primary: cognitive function
Secondary: “CVD/metabolic risk factors, systemic inflammation, OxStress, and body weight/composition”
Starting date 1 September 2016. Estimated completion date 1 March 2021.
Contact information Dr. Fitzgibbon, Professor Department of Pediatrics, University of Illinois at Chicago
Email: mlf@uic.edu
Notes -
Papamiltiadous 2016
Trial name or title MEDINA:Mediterranean Dietary Intervention Study inNonalcoholic Fatty Liver Disease (NAFLD) patients
Methods RCT of parallel-group design
Participants Inclusion criteria: participants will be included if they are > 18 years, BMI 20 to 40 kg/m2; patients must
have had at least one elevated serum aminotransferase (ALT) level (> 20U/L female, > 30 U/L male) during
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the past 6 months and at screening have a level between > 1.5 and < 5 times upper limit of normal (ULN) in
the absence of another cause of liver disease. Diagnosis of NAFLD upon u/s
Exclusion criteria: participants will be excluded if: they are non-English speaking; refusal or inability to
give informed consent; average weekly alcohol ingestion > 140 g males or females; a current or past history
of cardiovascular, cerebrovascular or peripheral vascular disease; presence of clinically relevant pulmonary,
gastro-intestinal, renal, haematological, neurological, psychiatric, systemic or any acute infectious disease or
signs of acute illness; women who are pregnant or currently breastfeeding; psychosocial or gastrointestinal
(malabsorptive conditions e.g. coeliac disease) contraindications included bulimia nervosa, substance abuse,
clinically significant depression or current psychiatric care. Recent (within 3 months of screening visit) change
in dose/regimen or introduction of vitamin E, vitamin C or high-dose vitamin D, fish oil or probiotics.
Participation in any other clinical study targeting diet and lifestyle factors
Interventions Mediterranean dietary intervention versus standard low-fat moderate carbohydrate diet
An accredited practising dietitian will provide a dietary consultation for intervention patients to follow a
Mediterranean diet protocol or comparator patients to follow a standard protocol (low-fat, Australian Guide
to Healthy Eating and the Heart Foundation’s Guidelines of a low-fat, moderate carbohydrate diet). A food
hamper representing typical Mediterranean diet foods (for example olive oil, nuts, natural Greek yoghurt,
legumes) will be provided to the intervention group and a supermarket voucher will be provided for the
standard group to purchase low-fat, moderate carbohydrate food products to achieve the dietary goals. These
will be provided at baseline, 6 weeks and 12 weeks. Meal plans and recipe books are all provided at baseline to
the relevant diet group. The intervention will be run over a 12-week period with a further 6- and 12-month
follow-up to assess duration of effect and feasibility of sustaining the diet
The dietary intervention and standard diet consultations will be delivered by an dietician through a face-to-
face consultation initially and face-to-face consultations at mid-intervention (6 weeks) and post-intervention
time points. There are regular phone call reviews to check dietary compliance at weeks 2, 4 and 9. A dietitian
will administer the intervention and monitor adherence via food diaries and a food frequency questionnaire,
and plasma fatty acids and urinary hydroxytyrosol will be used as measures for compliance
Outcomes Primary outcome - insulin resistance
Secondary outcomes - hepatic steatosis, liver function tests, inflammatory markers, blood lipid levels, liver
stiffness, anthropometric measures, blood pressure, quality of life, body composition
Starting date 14 April 2015 first participant recruited, anticipated last recruited participant 11 April 2017 but no actual
figure provided when accessed. Recruitment target N = 94
Contact information A/Prof Audrey Tierney
Health Sciences Building 3, Room 438
Discipline of Dietetics and Human Nutrition
Department of Rehabilitation, Nutrition and Sport
School of Allied Health
College of Science, Health and Engineering
La Trobe University
Bundoora
Victoria 3086
Australia
Phone: +61 (0) 3 9479 5253
Fax: +61 (0) 3 9479 5768
Email: a.tierney@latrobe.edu.au
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Notes ACTRN12615001010583 accessed 11 October 2018
Sotos-Prieto 2017
Trial name or title Feeding America’s Bravest: Mediterranean Diet-Based Interventions to Change Firefighters’ Eating Habits
Methods A prospective, cluster-randomised trial, with cross-over of the control group after 1 year to compare aMediter-
ranean diet nutrition intervention (MDNI) versus usual care (control) in career firefighters within the Indi-
anapolis Fire Department (IFD)
Participants Inclusion criteria:
• Those permanently assigned to one of the 45 IFD stations
• With a fire department-provided medical exam in the last 2 years
• At least 18 years of age
• Full duty status at the time of consent
Exclusion criteria:
• Those without a recorded fire department exam in the last 2 years
• Less than 18 years of age
• Restrictions on duty at the time of consent.
Interventions Mediterranean diet intervention: educational materials (online learning) will be provided via the study web-
site; group educational sessions and written materials (brochure with Mediterranean diet recommendations,
shopping list recommendations and sample recipes, specific Mediterranean diet pyramid); videos; educational
sessions; in-person chef-led,Mediterranean cooking demonstrations. Peer-education and support. Discounted
food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous
stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating
firefighters and their families. Email or text message encouragement and reminders during the intervention
Control group: usual care, consisting of existing IFD health and wellness activities, with no investigator-
provided interventions
In phase I, Group 1will receive theMDNI for 12months. Phase II: Group 1 fire houses will cross-over to “self-
sustained continuation,” a less intense, self-directed, maintenance phase for 12 months to examine longer-
term persistence of behaviour change after the active 12-month MDNI. During self-sustained continuation
access to some environmental changes: such as discounted food access, peer education/support and online
learning will remain; however, the stations will not receive investigator-led educational sessions. In Phase II,
Group 2 fire houses will cross-over to receive the full active MDNI for 6 months. The Group 2 MDNI
will test the efficacy of a shorter, but otherwise identical MDNI. It will be followed by a final 6 months of
“self-sustained continuation” (as described above) to examine the shorter MDNI’s effect on persistence of
adherence
Outcomes Primary outcome measures:
Changes in Mediterranean diet scale (time Frame: 6, 12 and 24 months) 12 months change in the MD scores
as well as 12- and 24-month change in group 1; and 6- and 12-month change from baseline to follow-up in
group 2
Secondary outcome measures: changes in BMI (m²/kg) (time frame: 24 months)
Changes in weight (kg) (time frame: 24 months)
Changes in waist circumference (cm) (time frame: 24 months)
Changes in lipids (time frame: 24 months) LDL (mg/dl), HDL (mg/dl), total cholesterol
Changes in inflammatory markers (time frame: 24 months) CRP (mg/L)
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Changes in biomarkers (time frame: 6 months) (tyrosol, hydroxytyrosol and plasma fatty acids)
Starting date October 2016, estimated completion date September 2019
Contact information Harvard TH Chan
School of Public Health
Boston, Massachusetts
United States, 02115
Contact: Stefanos N Kales, MD, MPH 617-665-1580 (skales@hsph.harvard.edu)
Contact: Mercedes Sotos Prieto, PhD 6178608979 (msotosp@hsph.harvard.edu)
Notes NCT02941757
BMI: body mass index; CHD: coronary heart disease; CVD: cardiovascular disease; HDL: high-density lipoprotein; LDL: low-density
lipoprotein; NAFLD: non-alcoholic fatty liver disease; NICE: National Institute for Health and Care Excellence; RCT: randomised
controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Mediterranean dietary intervention versus no intervention or minimal intervention for primary
prevention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total cholesterol (mmol/L),
change from baseline
5 569 Mean Difference (IV, Random, 95% CI) -0.16 [-0.32, 0.00]
2 LDL cholesterol (mmol/L),
change from baseline
4 389 Mean Difference (IV, Random, 95% CI) -0.08 [-0.26, 0.09]
3 HDL cholesterol (mmol/L),
change from baseline
5 569 Mean Difference (IV, Random, 95% CI) 0.02 [-0.04, 0.08]
4 Triglycerides (mmol/L), change
from baseline
4 Mean Difference (IV, Random, 95% CI) Totals not selected
5 Systolic blood pressure (mmHg),
change from baseline
2 269 Mean Difference (IV, Random, 95% CI) -2.99 [-3.45, -2.53]
6 Diastolic blood pressure
(mmHg), change from baseline
2 269 Mean Difference (IV, Random, 95% CI) 0.00 [-2.29, -1.71]
Comparison 2. Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Composite clinical events (CVD
death, stroke, MI)
1 7447 Hazard Ratio (Random, 95% CI) 0.70 [0.58, 0.85]
2 CVD mortality 1 7447 Hazard Ratio (Random, 95% CI) 0.81 [0.50, 1.32]
3 Total mortality 1 7447 Hazard Ratio (Random, 95% CI) 1.00 [0.81, 1.24]
4 Myocardial infarction 1 7447 Hazard Ratio (Random, 95% CI) 0.79 [0.57, 1.10]
5 Stroke 1 7447 Hazard Ratio (Random, 95% CI) 0.60 [0.45, 0.80]
6 Peripheral arterial disease 1 7447 Hazard Ratio (Random, 95% CI) 0.42 [0.28, 0.61]
7 Incidence type 2 diabetes 1 3541 Hazard Ratio (Random, 95% CI) 0.71 [0.52, 0.96]
8 Stroke (unadjusted) 1 180 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.04, 3.14]
9 Total cholesterol (mmol/L),
change from baseline
7 939 Mean Difference (IV, Random, 95% CI) -0.13 [-0.30, 0.04]
10 LDL cholesterol (mmol/L),
change from baseline
7 947 Mean Difference (IV, Random, 95% CI) -0.15 [-0.27, -0.02]
11 HDL cholesterol (mmol/L),
change from baseline
6 891 Mean Difference (IV, Random, 95% CI) 0.02 [-0.01, 0.04]
12 Triglycerides (mmol/L), change
from baseline
7 939 Mean Difference (IV, Random, 95% CI) -0.09 [-0.16, -0.01]
13 Systolic blood pressure
(mmHg), change from baseline
4 448 Mean Difference (IV, Random, 95% CI) -1.50 [-3.92, 0.92]
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14 Diastolic blood pressure
(mmHg), change from baseline
4 448 Mean Difference (IV, Random, 95% CI) -0.26 [-2.41, 1.90]
Comparison 3. Mediterranean dietary intervention versus usual care for secondary prevention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality 1 Risk Ratio (Random, 95% CI) 0.44 [0.21, 0.92]
2 CVD mortality 1 Risk Ratio (Random, 95% CI) 0.35 [0.15, 0.82]
3 CVD death plus non-fatal MI 1 Hazard Ratio (Random, 95% CI) 0.28 [0.15, 0.52]
4 Total cholesterol (mmol/L),
change from baseline
2 441 Mean Difference (IV, Random, 95% CI) 0.07 [-0.19, 0.33]
5 LDL cholesterol (mmol/L),
change from baseline
2 441 Mean Difference (IV, Random, 95% CI) 0.11 [-0.09, 0.31]
6 HDL cholesterol (mmol/L),
change from baseline
2 441 Mean Difference (IV, Random, 95% CI) -0.01 [-0.08, 0.07]
7 Triglycerides (mmol/L), change
from baseline
2 441 Mean Difference (IV, Random, 95% CI) -0.14 [-0.38, 0.10]
8 Systolic blood pressure (mmHg),
change from baseline
1 339 Mean Difference (IV, Random, 95% CI) -2.0 [-5.29, 1.29]
9 Diastolic blood pressure
(mmHg), change from baseline
1 339 Mean Difference (IV, Random, 95% CI) -1.0 [-4.29, 2.29]
Comparison 4. Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Non-fatal MI 1 Risk Ratio (Random, 95% CI) 0.47 [0.28, 0.79]
2 Non-fatal MI (sensitivity analysis
without Singh studies)
0 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
3 Fatal MI 2 Risk Ratio (Random, 95% CI) 0.66 [0.61, 0.71]
4 Fatal MI (sensitivity analysis
without Singh studies)
0 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
5 Sudden cardiac death 2 Risk Ratio (Random, 95% CI) 0.48 [0.37, 0.63]
6 Sudden cardiac death (sensitivity
analysis without Singh studies)
0 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
7 Total cardiac endpoints (fatal
and non-fatal MI, sudden
cardiac death)
2 Risk Ratio (Random, 95% CI) 0.59 [0.44, 0.80]
8 Total cardiac endpoints (fatal
and non-fatal MI, sudden
cardiac death) (sensitivity
analysis without Singh studies)
0 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
9 Total mortality 1 Risk Ratio (Random, 95% CI) 0.59 [0.51, 0.68]
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10 Total mortality (sensitivity
analysis without Singh studies)
0 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
11 CVD mortality 1 Risk Ratio (Random, 95% CI) 0.50 [0.42, 0.60]
12 CVD mortality (sensitivity
analysis without Singh studies)
0 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
13 Total cardiac endpoints
(all-cause and cardiac deaths,
MI, hospital admissions for
heart failure, unstable angina
or stroke, unadjusted)
1 101 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.40, 2.41]
14 Total cholesterol (mmol/L),
change from baseline
2 1283 Mean Difference (IV, Random, 95% CI) -0.50 [-0.61, -0.39]
15 Total cholesterol (mmol/
L), change from baseline
(sensitivity analysis without
Singh studies)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 LDL cholesterol (mmol/L),
change from baseline
3 Mean Difference (IV, Random, 95% CI) Totals not selected
17 LDL cholesterol (mmol/L),
change from baseline
(sensitivity analysis without
Singh studies)
1 71 Mean Difference (IV, Random, 95% CI) 0.08 [-0.26, 0.42]
18 HDL cholesterol (mmol/L),
change from baseline
3 1354 Mean Difference (IV, Random, 95% CI) 0.06 [-0.01, 0.12]
19 HDL cholesterol (mmol/L),
change from baseline
(sensitivity analysis without
Singh studies)
1 71 Mean Difference (IV, Random, 95% CI) -0.05 [-0.17, 0.06]
20 Triglycerides (mmol/L), change
from baseline
3 Mean Difference (IV, Random, 95% CI) Totals not selected
21 Triglycerides (mmol/L), change
from baseline (sensitivity
analysis without Singh studies)
1 71 Mean Difference (IV, Random, 95% CI) 0.46 [-0.24, 1.16]
22 Systolic blood pressure
(mmHg), change from baseline
4 Mean Difference (IV, Random, 95% CI) Totals not selected
23 Systolic blood pressure
(mmHg), change from baseline
(sensitivity analysis without
Singh studies)
2 150 Mean Difference (IV, Random, 95% CI) 1.76 [-2.80, 6.33]
24 Diastolic blood pressure
(mmHg), change from baseline
4 Mean Difference (IV, Random, 95% CI) Totals not selected
25 Diastolic blood pressure
(mmHg), change from baseline
(sensitivity analysis without
Singh studies)
2 150 Mean Difference (IV, Random, 95% CI) 0.98 [-1.97, 3.93]
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Analysis 1.1. Comparison 1 Mediterranean dietary intervention versus no intervention or minimal
intervention for primary prevention, Outcome 1 Total cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Mediterranean dietary intervention versus no intervention or minimal intervention for primary prevention
Outcome: 1 Total cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet
No/minimal
intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Davis 2017 70 -0.11 (0.5) 67 -0.13 (0.4) 25.8 % 0.02 [ -0.13, 0.17 ]
Djuric 2009 27 -0.026 (0.97) 33 -0.1 (0.86) 8.9 % 0.08 [ -0.39, 0.55 ]
Esposito 2004 90 -0.28 (0.155) 90 -0.05 (0.052) 32.7 % -0.23 [ -0.26, -0.19 ]
Konstantinidou 2010 60 -0.125 (0.6) 29 0 (0.6) 17.6 % -0.12 [ -0.39, 0.14 ]
Wardle 2000 53 -0.7 (0.91) 50 -0.2 (0.68) 15.1 % -0.50 [ -0.81, -0.19 ]
Total (95% CI) 300 269 100.0 % -0.16 [ -0.32, 0.00 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 15.05, df = 4 (P = 0.005); I2 =73%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Med diet Favours no/minimal int.
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Analysis 1.2. Comparison 1 Mediterranean dietary intervention versus no intervention or minimal
intervention for primary prevention, Outcome 2 LDL cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Mediterranean dietary intervention versus no intervention or minimal intervention for primary prevention
Outcome: 2 LDL cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet
No/minimal
intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Davis 2017 70 0 (0.4) 67 -0.03 (0.4) 38.3 % 0.03 [ -0.10, 0.16 ]
Djuric 2009 27 -0.052 (0.85) 33 -0.13 (0.69) 14.0 % 0.08 [ -0.32, 0.48 ]
Konstantinidou 2010 60 -0.07 (0.45) 29 0.05 (0.46) 29.8 % -0.12 [ -0.32, 0.08 ]
Wardle 2000 53 -0.6 (0.91) 50 -0.2 (0.81) 17.9 % -0.40 [ -0.73, -0.07 ]
Total (95% CI) 210 179 100.0 % -0.08 [ -0.26, 0.09 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 6.48, df = 3 (P = 0.09); I2 =54%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Med diet Favours no/minimal int.
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Analysis 1.3. Comparison 1 Mediterranean dietary intervention versus no intervention or minimal
intervention for primary prevention, Outcome 3 HDL cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Mediterranean dietary intervention versus no intervention or minimal intervention for primary prevention
Outcome: 3 HDL cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet
No/minimal
intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Davis 2017 70 -0.06 (0.2) 67 -0.06 (0.2) 23.4 % 0.0 [ -0.07, 0.07 ]
Djuric 2009 27 0.026 (0.31) 33 0 (0.37) 8.6 % 0.03 [ -0.15, 0.20 ]
Esposito 2004 90 0.103 (0.052) 90 0.03 (0.026) 33.2 % 0.08 [ 0.06, 0.09 ]
Konstantinidou 2010 60 -0.05 (0.18) 29 -0.05 (0.18) 20.7 % 0.00 [ -0.08, 0.08 ]
Wardle 2000 53 -0.1 (0.34) 50 -0.04 (0.28) 14.0 % -0.06 [ -0.18, 0.06 ]
Total (95% CI) 300 269 100.0 % 0.02 [ -0.04, 0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 13.41, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours no/minimal int. Favours Med diet
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Analysis 1.4. Comparison 1 Mediterranean dietary intervention versus no intervention or minimal
intervention for primary prevention, Outcome 4 Triglycerides (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Mediterranean dietary intervention versus no intervention or minimal intervention for primary prevention
Outcome: 4 Triglycerides (mmol/L), change from baseline
Study or subgroup Mediterranean diet
No/minimal
intervention
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Davis 2017 70 -0.15 (0.3) 67 -0.05 (0.3) -0.10 [ -0.20, 0.00 ]
Djuric 2009 27 0.034 (0.47) 33 0.03 (0.41) 0.0 [ -0.23, 0.23 ]
Esposito 2004 90 -0.203 (0.09) 90 0.01 (0.034) -0.21 [ -0.23, -0.19 ]
Wardle 2000 53 0.3 (0.56) 50 -0.06 (0.53) 0.36 [ 0.15, 0.57 ]
-1 -0.5 0 0.5 1
Favours Med diet Favours no/minimal int.
Analysis 1.5. Comparison 1 Mediterranean dietary intervention versus no intervention or minimal
intervention for primary prevention, Outcome 5 Systolic blood pressure (mmHg), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Mediterranean dietary intervention versus no intervention or minimal intervention for primary prevention
Outcome: 5 Systolic blood pressure (mmHg), change from baseline
Study or subgroup Mediterranean diet
No/minimal
intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Esposito 2004 90 -4 (2) 90 -1 (1) 99.1 % -3.00 [ -3.46, -2.54 ]
Konstantinidou 2010 60 -1.03 (10.8) 29 1.4 (11) 0.9 % -2.43 [ -7.28, 2.42 ]
Total (95% CI) 150 119 100.0 % -2.99 [ -3.45, -2.53 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 12.76 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Med diet Favours no/minimal int.
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Analysis 1.6. Comparison 1 Mediterranean dietary intervention versus no intervention or minimal
intervention for primary prevention, Outcome 6 Diastolic blood pressure (mmHg), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Mediterranean dietary intervention versus no intervention or minimal intervention for primary prevention
Outcome: 6 Diastolic blood pressure (mmHg), change from baseline
Study or subgroup Mediterranean diet
No/minimal
intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Esposito 2004 90 -3 (1) 90 -1 (1) 99.3 % -2.00 [ -2.29, -1.71 ]
Konstantinidou 2010 60 0.17 (7.8) 29 1.7 (8) 0.7 % -1.53 [ -5.05, 1.99 ]
Total (95% CI) 150 119 100.0 % -2.00 [ -2.29, -1.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 13.44 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Med diet Favours no/minimal int.
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Analysis 2.1. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 1 Composite clinical events (CVD death, stroke, MI).
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 1 Composite clinical events (CVD death, stroke, MI)
Study or subgroup Mediterranean diet Another dietary int. log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
PREDIMED (1) 2543 1225 -0.3711 (0.1346) 54.3 % 0.69 [ 0.53, 0.90 ]
PREDIMED (2) 2454 1225 -0.3285 (0.1468) 45.7 % 0.72 [ 0.54, 0.96 ]
Total (95% CI) 4997 2450 100.0 % 0.70 [ 0.58, 0.85 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.54 (P = 0.00039)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Med diet Favours other diet
(1) PREDIMED+EVOO
(2) PREDIMED+nuts
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Analysis 2.2. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 2 CVD mortality.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 2 CVD mortality
Study or subgroup Mediterranean diet Another dietary int. log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
PREDIMED (1) 2454 1225 0.0198 (0.2458) 53.3 % 1.02 [ 0.63, 1.65 ]
PREDIMED (2) 2543 1225 -0.478 (0.2774) 46.7 % 0.62 [ 0.36, 1.07 ]
Total (95% CI) 4997 2450 100.0 % 0.81 [ 0.50, 1.32 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 1.80, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Med diet Favours other diet
(1) PREDIMED+nuts
(2) PREDIMED+EVOO
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Analysis 2.3. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 3 Total mortality.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 3 Total mortality
Study or subgroup Mediterranean diet Another dietary int. log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
PREDIMED (1) 2454 1225 0.1133 (0.1348) 50.2 % 1.12 [ 0.86, 1.46 ]
PREDIMED (2) 2543 1225 -0.1054 (0.1356) 49.8 % 0.90 [ 0.69, 1.17 ]
Total (95% CI) 4997 2450 100.0 % 1.00 [ 0.81, 1.24 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.31, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Med diet Favours other diet
(1) PREDIMED+nuts
(2) PREDIMED+EVOO
113Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.4. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 4 Myocardial infarction.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 4 Myocardial infarction
Study or subgroup Mediterranean diet Another dietary int. log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
PREDIMED (1) 2543 1225 -0.1985 (0.2324) 52.7 % 0.82 [ 0.52, 1.29 ]
PREDIMED (2) 2454 1225 -0.2744 (0.2452) 47.3 % 0.76 [ 0.47, 1.23 ]
Total (95% CI) 4997 2450 100.0 % 0.79 [ 0.57, 1.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Med diet Favours other diet
(1) PREDIMED+EVOO
(2) PREDIMED+nuts
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Analysis 2.5. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 5 Stroke.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 5 Stroke
Study or subgroup Mediterranean diet Another dietary int. log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
PREDIMED (1) 2543 1225 -0.4308 (0.1991) 55.2 % 0.65 [ 0.44, 0.96 ]
PREDIMED (2) 2454 1225 -0.6162 (0.2212) 44.8 % 0.54 [ 0.35, 0.83 ]
Total (95% CI) 4997 2450 100.0 % 0.60 [ 0.45, 0.80 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.47 (P = 0.00052)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Med diet Favours other diet
(1) PREDIMED+EVOO
(2) PREDIMED+nuts
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Analysis 2.6. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 6 Peripheral arterial disease.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 6 Peripheral arterial disease
Study or subgroup Mediterranean diet Another dietary int. log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
PREDIMED (1) 2543 1225 -1.0788 (0.2707) 48.2 % 0.34 [ 0.20, 0.58 ]
PREDIMED (2) 2454 1225 -0.6931 (0.2606) 51.8 % 0.50 [ 0.30, 0.83 ]
Total (95% CI) 4997 2450 100.0 % 0.42 [ 0.28, 0.61 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.05, df = 1 (P = 0.30); I2 =5%
Test for overall effect: Z = 4.56 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Med diet Favours other diet
(1) PREDIMED+EVOO
(2) PREDIMED+nuts
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Analysis 2.7. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 7 Incidence type 2 diabetes.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 7 Incidence type 2 diabetes
Study or subgroup Mediterranean diet Another dietary int. log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
PREDIMED (1) 1154 573 -0.5108 (0.17) 46.9 % 0.60 [ 0.43, 0.84 ]
PREDIMED (2) 1240 574 -0.1985 (0.1509) 53.1 % 0.82 [ 0.61, 1.10 ]
Total (95% CI) 2394 1147 100.0 % 0.71 [ 0.52, 0.96 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 1.89, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Med diet Favours other diet
(1) PREDIMED+EVOO
(2) PREDIMED+nuts
Analysis 2.8. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 8 Stroke (unadjusted).
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 8 Stroke (unadjusted)
Study or subgroup Mediterranean diet Another dietary int. Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lapetra 2018 1/90 3/90 100.0 % 0.33 [ 0.04, 3.14 ]
Total (95% CI) 90 90 100.0 % 0.33 [ 0.04, 3.14 ]
Total events: 1 (Mediterranean diet), 3 (Another dietary int.)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Med diet Favours other diet
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Analysis 2.9. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 9 Total cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 9 Total cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Athyros 2011 50 -0.44 (0.32) 50 -0.1 (0.35) 17.4 % -0.34 [ -0.47, -0.21 ]
Bajerska 2018 67 -0.4 (0.88) 63 -0.29 (0.66) 13.0 % -0.11 [ -0.38, 0.16 ]
Ng 2011 25 0.52 (0.97) 23 0.09 (0.43) 8.8 % 0.43 [ 0.01, 0.85 ]
PREDIMED (1) 78 -0.3 (0.61) 37 -0.12 (0.59) 14.1 % -0.18 [ -0.41, 0.05 ]
PREDIMED (2) 82 -0.35 (0.55) 38 -0.12 (0.59) 14.5 % -0.23 [ -0.45, -0.01 ]
Skouroliakou 2017 26 -0.14 (1.03) 24 0.51 (0.93) 6.4 % -0.65 [ -1.19, -0.11 ]
Sofi 2018 103 0 (0.95) 104 -0.14 (0.93) 13.4 % 0.14 [ -0.12, 0.40 ]
Vincent-Baudry 2005 88 -0.4 (1) 81 -0.3 (0.9) 12.4 % -0.10 [ -0.39, 0.19 ]
Total (95% CI) 519 420 100.0 % -0.13 [ -0.30, 0.04 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 23.41, df = 7 (P = 0.001); I2 =70%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Med diet Favours other diet
(1) PREDIMED+EVOO
(2) PREDIMED+nuts
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Analysis 2.10. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 10 LDL cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 10 LDL cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Athyros 2011 50 -0.38 (0.41) 50 -0.1 (0.41) 19.4 % -0.28 [ -0.44, -0.12 ]
Bajerska 2018 67 -0.24 (0.88) 63 -0.13 (0.55) 13.2 % -0.11 [ -0.36, 0.14 ]
PREDIMED (1) 78 -0.17 (0.57) 37 -0.15 (0.53) 15.6 % -0.02 [ -0.23, 0.19 ]
PREDIMED (2) 82 -0.29 (0.54) 38 -0.15 (0.53) 16.1 % -0.14 [ -0.35, 0.07 ]
Skouroliakou 2017 26 -0.27 (0.87) 24 0.27 (0.73) 6.1 % -0.54 [ -0.98, -0.10 ]
Sofi 2018 103 0.05 (0.89) 104 -0.18 (1.66) 8.3 % 0.23 [ -0.13, 0.59 ]
Stradling 2018 28 -0.03 (0.67) 28 -0.01 (0.65) 8.9 % -0.02 [ -0.37, 0.33 ]
Vincent-Baudry 2005 88 -0.5 (0.9) 81 -0.2 (0.85) 12.5 % -0.30 [ -0.56, -0.04 ]
Total (95% CI) 522 425 100.0 % -0.15 [ -0.27, -0.02 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 12.97, df = 7 (P = 0.07); I2 =46%
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 11 HDL cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 11 HDL cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Athyros 2011 50 0.078 (0.155) 50 0 (0.155) 17.0 % 0.08 [ 0.02, 0.14 ]
Bajerska 2018 67 -0.002 (0.93) 63 0.05 (0.14) 1.2 % -0.05 [ -0.28, 0.17 ]
PREDIMED (1) 82 0.009 (0.104) 38 0.01 (0.108) 37.3 % 0.00 [ -0.04, 0.04 ]
PREDIMED (2) 78 0.012 (0.13) 37 0.01 (0.108) 30.7 % 0.00 [ -0.04, 0.05 ]
Skouroliakou 2017 26 0.21 (0.59) 24 0.16 (0.46) 0.7 % 0.05 [ -0.24, 0.34 ]
Sofi 2018 103 0.01 (0.31) 104 -0.02 (0.28) 9.7 % 0.03 [ -0.05, 0.11 ]
Vincent-Baudry 2005 88 0 (0.4) 81 0 (0.5) 3.3 % 0.0 [ -0.14, 0.14 ]
Total (95% CI) 494 397 100.0 % 0.02 [ -0.01, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.60, df = 6 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 2.12. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 12 Triglycerides (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 12 Triglycerides (mmol/L), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Athyros 2011 50 -0.08 (0.24) 50 -0.01 (0.28) 33.6 % -0.07 [ -0.17, 0.03 ]
Bajerska 2018 67 -0.38 (0.99) 63 -0.44 (0.62) 6.7 % 0.06 [ -0.22, 0.34 ]
Ng 2011 25 -0.01 (0.07) 23 1.32 (3.4) 0.3 % -1.33 [ -2.72, 0.06 ]
PREDIMED (1) 78 -0.12 (0.59) 37 -0.05 (0.57) 10.1 % -0.07 [ -0.29, 0.16 ]
PREDIMED (2) 82 -0.076 (0.46) 38 -0.05 (0.57) 11.7 % -0.02 [ -0.23, 0.18 ]
Skouroliakou 2017 26 -0.15 (0.4) 24 0.12 (0.36) 11.4 % -0.27 [ -0.48, -0.06 ]
Sofi 2018 103 -0.07 (0.56) 104 0.06 (0.57) 19.1 % -0.13 [ -0.28, 0.02 ]
Vincent-Baudry 2005 88 -0.2 (0.95) 81 -0.2 (0.87) 7.1 % 0.0 [ -0.27, 0.27 ]
Total (95% CI) 519 420 100.0 % -0.09 [ -0.16, -0.01 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.20, df = 7 (P = 0.31); I2 =15%
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 13 Systolic blood pressure (mmHg), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 13 Systolic blood pressure (mmHg), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Athyros 2011 50 -5 (7.5) 50 -2 (8.5) 42.6 % -3.00 [ -6.14, 0.14 ]
Bajerska 2018 67 -10.2 (14.6) 63 -10.4 (11.8) 23.8 % 0.20 [ -4.35, 4.75 ]
Stradling 2018 24 1.6 (12.9) 25 6.9 (14) 9.6 % -5.30 [ -12.83, 2.23 ]
Vincent-Baudry 2005 88 -1 (15.1) 81 -2 (14.9) 24.0 % 1.00 [ -3.53, 5.53 ]
Total (95% CI) 229 219 100.0 % -1.50 [ -3.92, 0.92 ]
Heterogeneity: Tau2 = 1.00; Chi2 = 3.56, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Mediterranean dietary intervention versus another dietary intervention for
primary prevention, Outcome 14 Diastolic blood pressure (mmHg), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Mediterranean dietary intervention versus another dietary intervention for primary prevention
Outcome: 14 Diastolic blood pressure (mmHg), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Athyros 2011 50 -2 (5.5) 50 0 (5) 42.1 % -2.00 [ -4.06, 0.06 ]
Bajerska 2018 67 -6.7 (9.8) 63 -8.1 (8.06) 28.6 % 1.40 [ -1.68, 4.48 ]
Stradling 2018 24 3.98 (8.14) 25 5.3 (11.6) 12.2 % -1.32 [ -6.91, 4.27 ]
Vincent-Baudry 2005 88 2 (9.8) 81 0 (18.4) 17.2 % 2.00 [ -2.50, 6.50 ]
Total (95% CI) 229 219 100.0 % -0.26 [ -2.41, 1.90 ]
Heterogeneity: Tau2 = 1.77; Chi2 = 4.74, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Mediterranean dietary intervention versus usual care for secondary prevention,
Outcome 1 Total mortality.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Mediterranean dietary intervention versus usual care for secondary prevention
Outcome: 1 Total mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
The Lyon Diet Heart Study -0.821 (0.3774) 100.0 % 0.44 [ 0.21, 0.92 ]
Total (95% CI) 100.0 % 0.44 [ 0.21, 0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.030)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Mediterranean dietary intervention versus usual care for secondary prevention,
Outcome 2 CVD mortality.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Mediterranean dietary intervention versus usual care for secondary prevention
Outcome: 2 CVD mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
The Lyon Diet Heart Study -1.0498 (0.4323) 100.0 % 0.35 [ 0.15, 0.82 ]
Total (95% CI) 100.0 % 0.35 [ 0.15, 0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Mediterranean dietary intervention versus usual care for secondary prevention,
Outcome 3 CVD death plus non-fatal MI.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Mediterranean dietary intervention versus usual care for secondary prevention
Outcome: 3 CVD death plus non-fatal MI
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
The Lyon Diet Heart Study -1.273 (0.3185) 100.0 % 0.28 [ 0.15, 0.52 ]
Total (95% CI) 100.0 % 0.28 [ 0.15, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.00 (P = 0.000064)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Mediterranean dietary intervention versus usual care for secondary prevention,
Outcome 4 Total cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Mediterranean dietary intervention versus usual care for secondary prevention
Outcome: 4 Total cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Michalsen 2006 49 0.04 (1.15) 53 -0.22 (0.96) 33.7 % 0.26 [ -0.15, 0.67 ]
The Lyon Diet Heart Study 171 -0.33 (1.28) 168 -0.31 (1.25) 66.3 % -0.02 [ -0.29, 0.25 ]
Total (95% CI) 220 221 100.0 % 0.07 [ -0.19, 0.33 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.24, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Mediterranean dietary intervention versus usual care for secondary prevention,
Outcome 5 LDL cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Mediterranean dietary intervention versus usual care for secondary prevention
Outcome: 5 LDL cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Michalsen 2006 49 -0.05 (1.07) 53 -0.26 (0.75) 30.3 % 0.21 [ -0.15, 0.57 ]
The Lyon Diet Heart Study 171 -0.34 (1.13) 168 -0.41 (1.11) 69.7 % 0.07 [ -0.17, 0.31 ]
Total (95% CI) 220 221 100.0 % 0.11 [ -0.09, 0.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Mediterranean dietary intervention versus usual care for secondary prevention,
Outcome 6 HDL cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Mediterranean dietary intervention versus usual care for secondary prevention
Outcome: 6 HDL cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Michalsen 2006 49 0.05 (0.35) 53 0 (0.29) 29.7 % 0.05 [ -0.08, 0.18 ]
The Lyon Diet Heart Study 171 0.12 (0.37) 168 0.15 (0.34) 70.3 % -0.03 [ -0.11, 0.05 ]
Total (95% CI) 220 221 100.0 % -0.01 [ -0.08, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Mediterranean dietary intervention versus usual care for secondary prevention,
Outcome 7 Triglycerides (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Mediterranean dietary intervention versus usual care for secondary prevention
Outcome: 7 Triglycerides (mmol/L), change from baseline
Study or subgroup Mediterranean diet Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Michalsen 2006 49 -0.02 (0.92) 53 0.02 (0.91) 45.6 % -0.04 [ -0.40, 0.32 ]
The Lyon Diet Heart Study 171 -0.3 (1.55) 168 -0.08 (1.51) 54.4 % -0.22 [ -0.55, 0.11 ]
Total (95% CI) 220 221 100.0 % -0.14 [ -0.38, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Mediterranean dietary intervention versus usual care for secondary prevention,
Outcome 8 Systolic blood pressure (mmHg), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Mediterranean dietary intervention versus usual care for secondary prevention
Outcome: 8 Systolic blood pressure (mmHg), change from baseline
Study or subgroup Mediterranean diet Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
The Lyon Diet Heart Study 171 7 (15.4) 168 9 (15.5) 100.0 % -2.00 [ -5.29, 1.29 ]
Total (95% CI) 171 168 100.0 % -2.00 [ -5.29, 1.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Mediterranean dietary intervention versus usual care for secondary prevention,
Outcome 9 Diastolic blood pressure (mmHg), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Mediterranean dietary intervention versus usual care for secondary prevention
Outcome: 9 Diastolic blood pressure (mmHg), change from baseline
Study or subgroup Mediterranean diet Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
The Lyon Diet Heart Study 171 4 (15.4) 168 5 (15.5) 100.0 % -1.00 [ -4.29, 2.29 ]
Total (95% CI) 171 168 100.0 % -1.00 [ -4.29, 2.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Med diet Favours usual care
128Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.1. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 1 Non-fatal MI.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 1 Non-fatal MI
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Singh 2002 -0.755 (0.264) 100.0 % 0.47 [ 0.28, 0.79 ]
Total (95% CI) 100.0 % 0.47 [ 0.28, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0042)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Med diet Favours another diet
Analysis 4.3. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 3 Fatal MI.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 3 Fatal MI
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Singh 1992 -0.4155 (0.0402) 99.0 % 0.66 [ 0.61, 0.71 ]
Singh 2002 -0.4005 (0.393) 1.0 % 0.67 [ 0.31, 1.45 ]
Total (95% CI) 100.0 % 0.66 [ 0.61, 0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 10.39 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 5 Sudden cardiac death.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 5 Sudden cardiac death
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Singh 1992 -0.6931 (0.14) 92.0 % 0.50 [ 0.38, 0.66 ]
Singh 2002 -1.1087 (0.475) 8.0 % 0.33 [ 0.13, 0.84 ]
Total (95% CI) 100.0 % 0.48 [ 0.37, 0.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 5.41 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 7 Total cardiac endpoints (fatal and non-fatal MI, sudden cardiac death).
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 7 Total cardiac endpoints (fatal and non-fatal MI, sudden cardiac death)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Singh 1992 -0.4155 (0.0572) 66.4 % 0.66 [ 0.59, 0.74 ]
Singh 2002 -0.734 (0.191) 33.6 % 0.48 [ 0.33, 0.70 ]
Total (95% CI) 100.0 % 0.59 [ 0.44, 0.80 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 2.55, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 3.47 (P = 0.00051)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 9 Total mortality.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 9 Total mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Singh 1992 -0.5276 (0.0743) 100.0 % 0.59 [ 0.51, 0.68 ]
Total (95% CI) 100.0 % 0.59 [ 0.51, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.10 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.11. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 11 CVD mortality.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 11 CVD mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Singh 1992 -0.6931 (0.089) 100.0 % 0.50 [ 0.42, 0.60 ]
Total (95% CI) 100.0 % 0.50 [ 0.42, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.79 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.13. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 13 Total cardiac endpoints (all-cause and cardiac deaths, MI, hospital
admissions for heart failure, unstable angina or stroke, unadjusted).
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 13 Total cardiac endpoints (all-cause and cardiac deaths, MI, hospital admissions for heart failure, unstable angina or stroke, unadjusted)
Study or subgroup Mediterranean diet Another dietary int. Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Tuttle 2008 8/51 8/50 100.0 % 0.98 [ 0.40, 2.41 ]
Total (95% CI) 51 50 100.0 % 0.98 [ 0.40, 2.41 ]
Total events: 8 (Mediterranean diet), 8 (Another dietary int.)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Med diet Favours another diet
Analysis 4.14. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 14 Total cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 14 Total cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Singh 1992 177 -0.74 (1.19) 159 -0.32 (1.11) 20.3 % -0.42 [ -0.67, -0.17 ]
Singh 2002 478 -0.7 (0.95) 469 -0.18 (1) 79.7 % -0.52 [ -0.64, -0.40 ]
Total (95% CI) 655 628 100.0 % -0.50 [ -0.61, -0.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 8.83 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.16. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 16 LDL cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 16 LDL cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Singh 1992 177 -0.54 (0.73) 159 -0.24 (0.64) -0.30 [ -0.45, -0.15 ]
Singh 2002 478 -0.64 (0.71) 469 -0.15 (0.69) -0.49 [ -0.58, -0.40 ]
Tuttle 2008 37 0.21 (0.71) 34 0.13 (0.74) 0.08 [ -0.26, 0.42 ]
-1 -0.5 0 0.5 1
Favours Med diet Favours another diet
133Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.17. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 17 LDL cholesterol (mmol/L), change from baseline (sensitivity analysis
without Singh studies).
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 17 LDL cholesterol (mmol/L), change from baseline (sensitivity analysis without Singh studies)
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tuttle 2008 37 0.21 (0.71) 34 0.13 (0.74) 100.0 % 0.08 [ -0.26, 0.42 ]
Total (95% CI) 37 34 100.0 % 0.08 [ -0.26, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 4.18. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 18 HDL cholesterol (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 18 HDL cholesterol (mmol/L), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Singh 1992 177 0.07 (0.29) 159 -0.04 (0.25) 35.0 % 0.11 [ 0.05, 0.17 ]
Singh 2002 478 0.03 (0.23) 469 -0.03 (0.19) 46.1 % 0.06 [ 0.03, 0.09 ]
Tuttle 2008 37 0.05 (0.19) 34 0.1 (0.28) 18.9 % -0.05 [ -0.17, 0.06 ]
Total (95% CI) 692 662 100.0 % 0.06 [ -0.01, 0.12 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 6.69, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 1.78 (P = 0.074)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours another diet Favours Med diet
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Analysis 4.19. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 19 HDL cholesterol (mmol/L), change from baseline (sensitivity analysis
without Singh studies).
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 19 HDL cholesterol (mmol/L), change from baseline (sensitivity analysis without Singh studies)
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tuttle 2008 37 0.05 (0.19) 34 0.1 (0.28) 100.0 % -0.05 [ -0.17, 0.06 ]
Total (95% CI) 37 34 100.0 % -0.05 [ -0.17, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours another diet Favours Med diet
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Analysis 4.20. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 20 Triglycerides (mmol/L), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 20 Triglycerides (mmol/L), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Singh 1992 177 -0.29 (0.29) 159 -0.12 (0.26) -0.17 [ -0.23, -0.11 ]
Singh 2002 478 -0.36 (0.37) 469 -0.11 (0.29) -0.25 [ -0.29, -0.21 ]
Tuttle 2008 37 -0.17 (0.78) 34 -0.63 (1.93) 0.46 [ -0.24, 1.16 ]
-1 -0.5 0 0.5 1
Favours Med diet Favours another diet
Analysis 4.21. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 21 Triglycerides (mmol/L), change from baseline (sensitivity analysis without
Singh studies).
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 21 Triglycerides (mmol/L), change from baseline (sensitivity analysis without Singh studies)
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tuttle 2008 37 -0.17 (0.78) 34 -0.63 (1.93) 100.0 % 0.46 [ -0.24, 1.16 ]
Total (95% CI) 37 34 100.0 % 0.46 [ -0.24, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.20)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Med diet Favours another diet
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Analysis 4.22. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 22 Systolic blood pressure (mmHg), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 22 Systolic blood pressure (mmHg), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Singh 1992 177 -13.4 (5.4) 159 -5.2 (7.5) -8.20 [ -9.61, -6.79 ]
Singh 2002 478 -5 (16.5) 469 -2 (16.1) -3.00 [ -5.08, -0.92 ]
Tuttle 2008 37 3 (17) 34 4 (13.7) -1.00 [ -8.16, 6.16 ]
Weber 2012 39 -5.67 (12.1) 40 -9.33 (14.7) 3.66 [ -2.27, 9.59 ]
-10 -5 0 5 10
Favours Med diet Favours another diet
Analysis 4.23. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 23 Systolic blood pressure (mmHg), change from baseline (sensitivity analysis
without Singh studies).
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 23 Systolic blood pressure (mmHg), change from baseline (sensitivity analysis without Singh studies)
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tuttle 2008 37 3 (17) 34 4 (13.7) 40.7 % -1.00 [ -8.16, 6.16 ]
Weber 2012 39 -5.67 (12.1) 40 -9.33 (14.7) 59.3 % 3.66 [ -2.27, 9.59 ]
Total (95% CI) 76 74 100.0 % 1.76 [ -2.80, 6.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Med diet Favours another diet
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Analysis 4.24. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 24 Diastolic blood pressure (mmHg), change from baseline.
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 24 Diastolic blood pressure (mmHg), change from baseline
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Singh 1992 177 -9.3 (2.6) 159 -3.5 (4.2) -5.80 [ -6.56, -5.04 ]
Singh 2002 478 -3 (9.5) 469 -2 (16.1) -1.00 [ -2.69, 0.69 ]
Tuttle 2008 37 1 (10) 34 1 (8) 0.0 [ -4.20, 4.20 ]
Weber 2012 39 -7.3 (7.77) 40 -9.23 (10.8) 1.93 [ -2.21, 6.07 ]
-10 -5 0 5 10
Favours Med diet Favours another diet
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Analysis 4.25. Comparison 4 Mediterranean dietary intervention versus another dietary intervention for
secondary prevention, Outcome 25 Diastolic blood pressure (mmHg), change from baseline (sensitivity
analysis without Singh studies).
Review: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Mediterranean dietary intervention versus another dietary intervention for secondary prevention
Outcome: 25 Diastolic blood pressure (mmHg), change from baseline (sensitivity analysis without Singh studies)
Study or subgroup Mediterranean diet Another dietary int.
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tuttle 2008 37 1 (10) 34 1 (8) 49.3 % 0.0 [ -4.20, 4.20 ]
Weber 2012 39 -7.3 (7.77) 40 -9.23 (10.8) 50.7 % 1.93 [ -2.21, 6.07 ]
Total (95% CI) 76 74 100.0 % 0.98 [ -1.97, 3.93 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Med diet Favours another diet
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL, DARE, HTA and NHS EED
#1 MeSH descriptor: [Fruit] explode all trees
#2 fruit*
#3 MeSH descriptor: [Vegetables] explode all trees
#4 MeSH descriptor: [Vegetable Proteins] this term only
#5 vegetable*
#6 MeSH descriptor: [Fabaceae] explode all trees
#7 fabaceae
#8 bean*
#9 legume*
#10 MeSH descriptor: [Lycopersicon esculentum] this term only
#11 lycopersicon next esculent*
#12 tomato*
#13 solanum next lycopersicum
#14 MeSH descriptor: [Nuts] this term only
#15 nut or nuts
#16 MeSH descriptor: [Bread] this term only
#17 bread*
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#18 MeSH descriptor: [Edible Grain] explode all trees
#19 cereal*
#20 grain*
#21 MeSH descriptor: [Solanum tuberosum] this term only
#22 solanum next tuberosum
#23 potato*
#24 MeSH descriptor: [Seeds] this term only
#25 seed or seeds
#26 olive next oil
#27 MeSH descriptor: [Fatty Acids, Monounsaturated] this term only
#28 monounsaturated next fat*
#29 mono-unsaturated next fat*
#30 MeSH descriptor: [Seafood] explode all trees
#31 MeSH descriptor: [Fish Oils] explode all trees
#32 fish
#33 seafood*
#34 shellfish
#35 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#36 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20
#37 #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30
#38 #31 or #32 or #33 or #34
#39 #35 or #36 or #37 or #38
#40 (high or more or increase* or elevat* or much or rais*) near/6 (intake or consumption or consume or eat* or amount*)
#41 #39 and #40
#42 MeSH descriptor: [Dairy Products] explode all trees
#43 MeSH descriptor: [Milk Proteins] explode all trees
#44 milk*
#45 marg?rine*
#46 butter*
#47 dairy
#48 cheese*
#49 red next meat*
#50 processed next meat*
#51 yog?urt*
#52 red near/4 wine*
#53 #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52
#54 (low or little or medium or moderate or less or decrease* or reduc* or restrict*) near/6 (intake or consumption or consume or eat*
or amount*)
#55 #53 and #54
#56 MeSH descriptor: [Diet, Mediterranean] this term only
#57 mediterranean near/3 diet*
#58 mediterranean near/6 food*
#59 mediterranean near/6 nutrition*
#60 mediterranean near/6 eat*
#61 (diet* or food* or nutrit* or eat*) near/2 (pattern* or habit*)
#62 MeSH descriptor: [Feeding Behavior] this term only
#63 #56 or #57 or #58 or #59 or #60 or #61 or #62
#64 #41 or #55 or #63
#65 MeSH descriptor: [Cardiovascular Diseases] explode all trees
#66 cardio*
#67 cardia*
#68 heart*
#69 coronary*
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#70 angina*
#71 ventric*
#72 myocard*
#73 pericard*
#74 isch?em*
#75 MeSH descriptor: [Stroke] explode all trees
#76 stroke or stokes
#77 cerebrovasc*
#78 apoplexy
#79 brain near/2 accident*
#80 (brain* or cerebral or lacunar) near/2 infarct*
#81 MeSH descriptor: [Hypertension] explode all trees
#82 hypertensi*
#83 peripheral next arter* next disease*
#84 (high or increased or elevated) near/2 (blood next pressure)
#85 MeSH descriptor: [Hyperlipidemias] explode all trees
#86 hyperlipid*
#87 hyperlip?emia*
#88 hypercholesterol*
#89 hypercholester?emia*
#90 hyperlipoprotein?emia*
#91 hypertriglycerid?emia*
#92 emboli*
#93 arrhythmi*
#94 thrombo*
#95 atrial next fibrillat*
#96 tachycardi*
#97 endocardi*
#98 sick next sinus
#99 MeSH descriptor: [Diabetes Mellitus] explode all trees
#100 diabet*
#101 MeSH descriptor: [Hyperglycemia] explode all trees
#102 hyperglycemi*
#103 glucose near/2 intoleran*
#104 MeSH descriptor: [Insulin Resistance] explode all trees
#105 metabolic near/3 syndrome near/3 x
#106 metabolic next cardiovascular next syndrome
#107 dysmetabolic next syndrome next x
#108 insulin next resistan*
#109 MeSH descriptor: [Arteriosclerosis] explode all trees
#110 MeSH descriptor: [Cholesterol] explode all trees
#111 cholesterol
#112 “coronary risk factor*”
#113 MeSH descriptor: [Blood Pressure] this term only
#114 “blood pressure”
#115 #65 or #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74
#116 #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84
#117 #85 or #86 or #87 or #88 or #89 or #90 or #91 or #92 or #93 or #94
#118 #95 or #96 or #97 or #98 or #99 or #100
#119 #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #112 or #113 or #114
#120 #115 or #116 or #117 or #118 or #119
#121 #64 and #120 Publication Year from 2012 to 2018
MEDLINE Ovid
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1. exp Fruit/
2. fruit*.tw.
3. exp Vegetables/
4. Vegetable Proteins/
5. vegetable*.tw.
6. exp Fabaceae/
7. fabaceae.tw.
8. bean*.tw.
9. legume*.tw.
10. Lycopersicon esculentum/
11. lycopersicon esculent*.tw.
12. tomato*.tw.
13. solanum lycopersicum.tw.
14. Nuts/
15. (nut or nuts).tw.
16. Bread/
17. bread*.tw.
18. exp Cereals/
19. cereal*.tw.
20. grain*.tw.
21. Solanum tuberosum/
22. solanum tuberosum.tw.
23. potato*.tw.
24. Seeds/
25. (seed or seeds).tw.
26. olive oil.tw.
27. Fatty Acids, Monounsaturated/
28. monounsaturated fat*.tw.
29. mono-unsaturated fat*.tw.
30. exp Seafood/
31. exp Fish Oils/
32. fish.tw.
33. seafood*.tw.
34. shellfish.tw.
35. or/1-34
36. ((high or more or increase* or elevat* or much or rais*) adj6 (intake or consumption or consume or eat* or amount*)).tw.
37. 35 and 36
38. exp Dairy Products/
39. exp Milk Proteins/
40. milk*.tw.
41. marg?rine*.tw.
42. butter*.tw.
43. dairy.tw.
44. cheese*.tw.
45. red meat*.tw.
46. processed meat*.tw.
47. yog?urt*.tw.
48. red wine*.tw.
49. or/38-48
50. ((low or little or medium or moderate or less or decrease* or reduc* or restrict*) adj6 (intake or consumption or consume or eat*
or amount*)).tw.
51. 49 and 50
52. Diet, Mediterranean/
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53. (mediterranean adj3 diet*).tw.
54. (mediterranean adj6 food*).tw.
55. (mediterranean adj6 nutrition*).tw.
56. (mediterranean adj6 eat*).tw.
57. ((diet* or food* or nutrit* or eat*) adj2 (pattern* or habit*)).tw.
58. Food Habits/
59. or/52-58
60. 37 or 51 or 59
61. exp Cardiovascular Diseases/
62. cardio*.tw.
63. cardia*.tw.
64. heart*.tw.
65. coronary*.tw.
66. angina*.tw.
67. ventric*.tw.
68. myocard*.tw.
69. pericard*.tw.
70. isch?em*.tw.
71. exp Stroke/
72. (stroke or stokes).tw.
73. cerebrovasc*.tw.
74. apoplexy.tw.
75. (brain adj2 accident*).tw.
76. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
77. exp Hypertension/
78. hypertensi*.tw.
79. peripheral arter* disease*.tw.
80. ((high or increased or elevated) adj2 blood pressure).tw.
81. exp Hyperlipidemias/
82. hyperlipid*.tw.
83. hyperlip?emia*.tw.
84. hypercholesterol*.tw.
85. hypercholester?emia*.tw.
86. hyperlipoprotein?emia*.tw.
87. hypertriglycerid?emia*.tw.
88. isch?emi*.tw.
89. emboli*.tw.
90. arrhythmi*.tw.
91. thrombo*.tw.
92. atrial fibrillat*.tw.
93. tachycardi*.tw.
94. endocardi*.tw.
95. (sick adj sinus).tw.
96. exp Diabetes Mellitus/
97. diabet*.tw.
98. exp Hyperglycemia/
99. hyperglycemi*.tw.
100. (glucose adj2 intoleran*).tw.
101. exp Insulin Resistance/
102. (metabolic adj3 syndrome adj3 x).tw.
103. metabolic cardiovascular syndrome.tw.
104. dysmetabolic syndrome x.tw.
105. insulin resistan*.tw.
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106. exp Arteriosclerosis/
107. exp Cholesterol/
108. cholesterol.tw.
109. “coronary risk factor*”.tw.
110. Blood Pressure/
111. blood pressure.tw.
112. or/61-111
113. 60 and 112
114. randomized controlled trial.pt.
115. controlled clinical trial.pt.
116. randomized.ab.
117. placebo.ab.
118. clinical trials as topic.sh.
119. randomly.ab.
120. trial.ti.
121. 114 or 115 or 116 or 117 or 118 or 119 or 120
122. exp animals/ not humans.sh.
123. 121 not 122
124. 113 and 123
125. limit 124 to ed=20121015-20180926
Embase Ovid
1. exp fruit/
2. fruit*.tw.
3. exp vegetable/
4. exp vegetable protein/
5. vegetable*.tw.
6. fabaceae.tw.
7. bean*.tw.
8. legume*.tw.
9. lycopersicon esculent*.tw.
10. tomato*.tw.
11. solanum lycopersicum.tw.
12. exp nut/
13. (nut or nuts).tw.
14. bread*.tw.
15. cereal*.tw.
16. grain*.tw.
17. exp grain/
18. solanum tuberosum.tw.
19. potato*.tw.
20. exp plant seed/
21. (seed or seeds).tw.
22. olive oil/
23. olive oil.tw.
24. monounsaturated fatty acid/
25. monounsaturated fat*.tw.
26. mono-unsaturated fat*.tw.
27. sea food/
28. fish oil/
29. fish meat/
30. fish.tw.
31. seafood*.tw.
32. sea food*.tw.
144Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
33. shellfish.tw.
34. or/1-33
35. ((high or more or increase* or elevat* or much or rais*) adj6 (intake or consumption or consume or eat* or amount*)).tw.
36. 34 and 35
37. exp dairy product/
38. milk*.tw.
39. marg?rine*.tw.
40. butter*.tw.
41. dairy.tw.
42. cheese*.tw.
43. red meat*.tw.
44. processed meat*.tw.
45. exp red meat/
46. yog?urt*.tw.
47. red wine*.tw.
48. or/37-47
49. ((low or little or medium or moderate or less or decrease* or reduc* or restrict*) adj6 (intake or consumption or consume or eat*
or amount*)).tw.
50. 48 and 49
51. Mediterranean diet/
52. (mediterranean adj3 diet*).tw.
53. (mediterranean adj6 food*).tw.
54. (mediterranean adj6 nutrition*).tw.
55. (mediterranean adj6 eat*).tw.
56. ((diet* or food* or nutrit* or eat*) adj2 (pattern* or habit*)).tw.
57. eating habit/
58. or/51-57
59. 36 or 50 or 58
60. exp cardiovascular disease/
61. cardio*.tw.
62. cardia*.tw.
63. heart*.tw.
64. coronary*.tw.
65. angina*.tw.
66. ventric*.tw.
67. myocard*.tw.
68. pericard*.tw.
69. isch?em*.tw.
70. exp cerebrovascular disease/
71. (stroke or stokes).tw.
72. cerebrovasc*.tw.
73. apoplexy.tw.
74. (brain adj2 accident*).tw.
75. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
76. exp hypertension/
77. hypertensi*.tw.
78. peripheral arter* disease*.tw.
79. ((high or increased or elevated) adj2 blood pressure).tw.
80. exp hyperlipidemia/
81. hyperlipid*.tw.
82. hyperlip?emia*.tw.
83. hypercholesterol*.tw.
84. hypercholester?emia*.tw.
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85. hyperlipoprotein?emia*.tw.
86. hypertriglycerid?emia*.tw.
87. emboli*.tw.
88. arrhythmi*.tw.
89. thrombo*.tw.
90. atrial fibrillat*.tw.
91. tachycardi*.tw.
92. endocardi*.tw.
93. (sick adj sinus).tw.
94. exp diabetes mellitus/
95. diabet*.tw.
96. diabet*.tw.
97. diabet*.tw.
98. hyperglycemia/
99. hyperglycemi*.tw.
100. (glucose adj2 intoleran*).tw.
101. insulin resistance/
102. (metabolic adj3 syndrome adj3 x).tw.
103. metabolic cardiovascular syndrome.tw.
104. dysmetabolic syndrome x.tw.
105. insulin resistan*.tw.
106. exp Arteriosclerosis/
107. exp Cholesterol/
108. cholesterol.tw.
109. “coronary risk factor*”.tw.
110. Blood Pressure/
111. blood pressure.tw.
112. or/60-111
113. random$.tw.
114. factorial$.tw.
115. crossover$.tw.
116. cross over$.tw.
117. cross-over$.tw.
118. placebo$.tw.
119. (doubl$ adj blind$).tw.
120. (singl$ adj blind$).tw.
121. assign$.tw.
122. allocat$.tw.
123. volunteer$.tw.
124. crossover procedure/
125. double blind procedure/
126. randomized controlled trial/
127. single blind procedure/
128. 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127
129. (animal/ or nonhuman/) not human/
130. 128 not 129
131. 59 and 112 and 130
132. limit 131 to embase
133. limit 132 to dd= 20121015-20180926
Web of Science
#25 #24 AND #23 Publication date 2012-2018
#24 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
#23 #22 AND #10
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#22 #21 OR #18 OR #15
#21 #20 OR #19
#20 TS= ((diet* or food* or nutrit* or eat*) SAME (pattern* or habit*))
#19 TS=((mediterranean) SAME (diet* or food* or nutrition* or eat*))
#18 #17 AND #16
#17 TS=((low or little or medium or moderate or less or decrease* or reduc* or restrict*) SAME (intake or consumption or consume
or eat* or amount*))
#16 TS=(milk* or marg?rine* or butter* or dairy or cheese* or “red meat*” or “processed meat*” or “red wine*”)
#15 #14 AND #13
#14 TS=((high or more or increase* or elevat* or much or rais*) SAME (intake or consumption or consume or eat* or amount*))
#13 #12 OR #11
#12 TS=(“solamun tuberosum” or potato* or seed or seeds or “olive oil” or “monounsaturated fat*” or “mono-unsaturated fat*” or fish
or seafood* or shellfish)
#11 TS=(fruit* or vegetable* or fabaceae or bean* or legume* or “lycopersicon esculent*” or tomato* or “solanum lycopersicum” or
nut or nuts or bread* or cereal* or grain*)
#10 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#9 TS=(arteriosclerosis or cholesterol or “coronary risk factor*” or “blood pressure”)
#8 TS=diabet*
#7 TS=(hyperlipid* or hyperlip?emia* or hypercholesterol* or hypercholester?emia* or hyperlipoprotein?emia* or hypertriglycerid?
emia*)
#6 TS=(“high blood pressure”)
#5 TS=(hypertensi* or “peripheral arter* disease*”)
#4 TS=(stroke or strokes or cerebrovasc* or cerebral or apoplexy or (brain SAME accident*) or (brain SAME infarct*))
#3 TS=(“artrial fibrillat*” or tachycardi* or endocardi*)
#2 TS=(pericard* or isch?em* or emboli* or arrhythmi* or thrombo*)
WH A T ’ S N E W
Date Event Description
1 March 2019 New search has been performed Evidence is up to date to 26 September 2018.
29 October 2018 New citation required and conclusions have changed Substantive update and expansion in scope. Included pa-
tients with established CVD as well as those from the
general population and at high risk of CVD to examine
the effects of theMediterranean diet on both the primary
and secondary prevention of CVD. Included other diets
as comparators, not just no intervention or minimal in-
tervention. Main analysis now has 4 comparisons to aid
interpretation and reduce heterogeneity:
1. Mediterranean dietary intervention versus no inter-
vention or minimal intervention for primary prevention
2. Mediterranean dietary intervention versus another di-
etary intervention for primary prevention
3. Mediterranean dietary intervention versus usual care
for secondary prevention
4. Mediterranean dietary intervention versus another di-
etary intervention for secondary prevention
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H I S T O R Y
Protocol first published: Issue 4, 2012
Review first published: Issue 8, 2013
Date Event Description
3 July 2014 Amended Minor error in figure corrected
C O N T R I B U T I O N S O F A U T H O R S
All authors of the original review contributed to the protocol development. The expansion of scope for the update was conceived and
led by KR and SS, and KR, LH and SS were authors on the original review. KR, NM, AT, LE, DW, AV and AD screened titles and
abstracts. KR, NM, AT, LE, DW, AV, AD and LH assessed full-text papers for inclusion; KR, NM, AT and AD located full texts
and KR managed collation of studies. KR, LE, DW, AV, AD and LH abstracted data and assessed risk of bias. KR entered data into
RevMan and conducted the analyses. NM and AT led on the GRADE assessment and interpretation with input from KR. KR drafted
the review with input from SS for the introduction and discussion sections. All authors critically read and commented on the final draft
and agreed on it for submission.
D E C L A R A T I O N S O F I N T E R E S T
KR: none known.
AT: none known.
NM: none known.
LE: none known.
DW: none known.
AV: none known.
AD: none known.
LH: none known.
SS: none known.
S O U R C E S O F S U P P O R T
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Internal sources
• Warwick Medical School, University of Warwick, UK.
• Cochrane Heart Group, UK.
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Heart Group.
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, NHS or the Department of Health, UK
External sources
• NIHR Cochrane Programme Grant, UK.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Differences between the previous version of this review (2013) and this update (2018):
1. Authors: altered. The Acknowledgements section recognises authors of the previous version who chose not to participate in this
update.
2. Background: updated.
3. Objectives: altered from “To determine the effectiveness of dietary advice to follow a Mediterranean-style dietary pattern or the
provision of foods relevant to the Mediterranean diet for the primary prevention of CVD” to “To determine the effectiveness of a
Mediterranean-style diet for the primary and secondary prevention of CVD”.
4. Types of participants: we have broadened out the scope of the review to include also patients with established CVD as well as
healthy participants and those at increased risk of CVD so that we can examine the effect of the Mediterranean diet on secondary as
well as primary prevention of CVD.
5. Types of interventions: we have refined the definition of the two core components to be: 1. high monounsaturated/saturated fat
ratio (use of olive oil as main cooking ingredient and/or consumption of other traditional foods high in monounsaturated fats such as
tree nuts); 2. high intake of plant-based foods, including fruits, vegetables and legumes.
6. Types of comparators: we have broadened out the scope of the review to include studies where the comparator is another dietary
intervention as well as no intervention or minimal intervention.
7. Main comparisons: there are now four main comparisons to aid interpretation and address heterogeneity for the different
participant and comparator groups. These are: Mediterranean dietary intervention versus no intervention or minimal intervention for
primary prevention, Mediterranean dietary intervention versus another dietary intervention for primary prevention, Mediterranean
dietary intervention versus usual care for secondary prevention and Mediterranean dietary intervention versus another dietary
intervention for secondary prevention.
8. Sensitivity analyses: we have excluded studies where the reliability of the data has been publicly questioned.
9. GRADE: we created a ’Summary of findings’ table using the five GRADE considerations (study limitations, consistency of
effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to the studies that
contribute data to the meta-analyses for the prespecified outcomes.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Diet, Mediterranean; Cardiovascular Diseases [blood; ∗prevention& control]; Cholesterol [blood]; Cholesterol, LDL [blood]; Primary
Prevention [∗methods]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Humans
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